WORLD GLAUCOMA CONGRESS
Boston, July 8-11, 2009

FINAL PROGRAM

See you at WGC-2011!
Useful telephone numbers

Poster Desk +1 617-954-2594
Registration Desk +1 617-954-2595 / fax: +1 617-954-2601
Faculty Desk +1 617-954-2596
WGC Office +1 617-954-2597
Speaker Ready Room +1 617-954-2598
Hotel Desk +1 617-954-2599
Social Desk +1 617-954-2600

Disclaimer
The Hippocrates Glaucoma Foundation, based upon an agreement with the World Glaucoma Association, organizes the World Glaucoma Congress with the aim of providing education and scientific discourse in the field of glaucoma. The Hippocrates Glaucoma Foundation accepts no responsibility for any products, presentations, opinions, statements or positions expressed by speakers at the congress. Inclusion of material in the scientific program does not constitute an endorsement by The Hippocrates Glaucoma Foundation.

NON-SMOKING POLICY
Please be informed that the World Glaucoma Congress is a non-smoking congress: the congress committee thanks all participants to refrain from smoking in the congress venue.

MOBILE PHONES
We kindly request all participants to keep mobile phones turned off in the congress area and especially in the meeting rooms during the scientific sessions.
# CONTENTS

Welcome by the President ................................................................. IV
Welcome by the Local Organizing Committee .................................. V
Welcome by the Program Committee ............................................... VI
WGC-2009 Committees .................................................................... VII
The World Glaucoma Congress ......................................................... VIII
General Meeting Information ........................................................ IX
CME Credits ................................................................................. XIII
Scientific Program overview (PAAG) ................................................ 1
Scientific Program per day .............................................................. 2
- Wednesday July 8, 2009 ................................................................. 2
- Thursday July 9, 2009 ................................................................. 14
- Friday July 10, 2009 ................................................................. 25
- Saturday July 11, 2009 ............................................................ 38
Scientific Program information ....................................................... 38
- Global Assembly of Glaucoma Societies ..................................... 44
- Scientific Program – Highlights ............................................... 45
Film Festival Program ................................................................. 51
Curricula Vitae
  - Keynote Speakers .................................................................. 53
  - Faculty .................................................................................. 55
Social Program ............................................................................. 110
Excursion Program ..................................................................... 111
World Glaucoma Association ....................................................... 113
WGA Committees ..................................................................... 118
International Glaucoma Review .................................................. 121
WGA Research Awards .............................................................. 122
CME Disclosure ......................................................................... 125
Presenters Index ......................................................................... 139
Welcome by the President of the WGA

Dear Colleagues,

On behalf of The World Glaucoma Association, its Board of Governors and its Organizing Committee, I welcome you to the Third World Glaucoma Congress. This Congress will be a milestone in glaucoma meetings around the globe. The city is Boston. This magnificent setting was chosen based on its beauty, attractiveness and facilities, and the kindness and graciousness of the local hosts. The World Glaucoma Congress is dedicated to all of us: ophthalmologists, members of ocular health teams, vision scientists, industry partners and organizations that combat blindness.

Glaucoma knowledge, like science, has traversed a long road. Its genesis and development has occurred in all civilizations and in all corners of the world. Today, glaucoma is a universal science and this Congress is no exception. More than 75 glaucoma societies will be represented, sharing their experiences, knowledge and creativity. Nothing is more enriching than interpersonal communication, which has been carefully planned for this Congress. Didactic sessions, basic and clinical science sessions, symposia and debates, courses, posters and grand rounds have been organized and planned to exhaustion by the Scientific Committee. This is a great opportunity to advance our glaucoma knowledge, meet colleagues from all continents, and to exchange ideas, practical concepts and friendship. Welcome to Boston!

Remo Susanna Jr
Welcome by the Local Organizing Committee

Dear Colleagues,

Boston is privileged to host the World Glaucoma Congress. On behalf of the Local Organizing Committee, I want to welcome you to one of the oldest cities in the USA and the largest city in New England.

Boston has evolved from a Puritan colony to a vibrant center of higher education, medicine and biotechnology. From Fenway Park to the Back Bay to the North End the city has much to offer. Visitors take note: Red flashing lights above the nearly old John Hancock Building do not signify impending disaster – they simply indicate that the Boston Red Sox baseball game has been postponed due to rain. You will find our citizens are very passionate about their sporting teams!

The Local Organizing Committee has worked closely with the Program Committee for over a year to make this World Glaucoma Congress special. We have recruited local talent for our keynote speakers as well as our entertainers who will greet you during the Gala Evening held at the Boston Public Library. The Boston Public Library is one of the many jewels of Boston and one of the largest libraries in the USA.

The Program Committee has put together a truly outstanding meeting and we trust you will find Boston to be an ideal venue to connect with your colleagues and friends.

Louis R. Pasquale
Dear Colleagues and Friends,

The World Glaucoma Congress 2009 Program Committee welcomes you to Boston!

Together with our colleagues in World Glaucoma Association, the Program Committee has worked hard to develop an innovative and cutting-edge scientific program. The program comprises mixture of various events: didactic sessions on key issues in glaucoma management today, scientific free paper presentations selected by competition from over 700 submitted abstracts, Grand Rounds case management, lunchtime symposia, surgical video presentations, and more than 40 courses on important practical clinical issues given by our best experts, and over 600 scientific posters.

The third WGC is the largest glaucoma meeting ever held. We would like to thank all of our colleagues and friends who helped us along the way, to make this meeting a huge success: WGA Board of Governors, WGA President Remo Susanna, the Executive Vice Presidents, the Local Organizing Committee, Scientific Review Committees collaborating societies, and most of all – our Faculty, speakers, colleagues, participants and audience.

We all wish you a very enjoyable and fruitful four days of learning and fun here in Boston.

Dennis Lam
Jeffrey Liebmann
Choka Melamed
Joel Schuman
WGC-2009 COMMITTEES

Board of Governors:


Organizing Committee:
I. Goldberg, E.L. Greve (co-chair), R.A. Hitchings, D. Lam (program chair), J. Liebmann (program chair), S. Melamed (program chair), J. Schuman (program chair), K. Singh (co-chair), R. Susanna Jr (co-chair), R.N. Weinreb

Local Organizing Committee:
B. Bellows, T. Chen, D. Greenfield (co-chair), T. Hutchinson, C. Mattox, L. Pasquale (co-chair), D. Rhee, B. Shingleton, M. Wand

Program Committee:
D. Lam (co-chair), J. Liebmann (co-chair),


Surgical Subcommittee:
R. Brown (co-chair), A. Crandall (co-chair), D. Lam (co-chair), F. Lerner, C. Melamed, T. Shaarawy, B. Shingleton, K. Singh

Minute Man Statue
THE WORLD GLAUCOMA CONGRESS

Objectives
- To present new developments in Diagnosis and Therapy of Glaucoma to both the glaucoma expert and the general ophthalmologist interested in glaucoma.
- To enhance communication about glaucoma among ophthalmologists from all over the world.
- To enhance exchange of knowledge between the general ophthalmologist and glaucoma experts.
- To maintain high scientific and ethical standards.

Special Features
- Largest glaucoma congress
- Highly appreciated didactic program
- Top-quality glaucoma experts
- Extensive course program at all levels
- Basic and clinical science sessions
- Special topic discussion symposia
- Grants for economically underprivileged colleagues
- Grand rounds (NEW)
- Surgical sessions

The Social Part
- Boston is a beautiful historical city with a green environment
- The WGC Banquet held at the Boston Public Library, one of the largest libraries in the USA
- Farewell Reception at the Hynes Convention Center
In 2007, the organizers of the World Glaucoma Congress and the organizers of the International Glaucoma Symposium decided that it was in the interest of worldwide glaucoma to merge the two meetings into one large glaucoma meeting.

**Venue**
Hynes Convention Center  
900 Boylston Street  
Boston, MA 02115, USA  
www.mccahome.com

**Congress Organizer**
The Hippocrates Glaucoma Foundation  
Jan van Goyenkade 11  
1075 HP Amsterdam, The Netherlands  
T: +31 20 679 34 11  
F: +31 20 673 73 06  
E-mail: info@wgc2009.org

**Housing Bureau**  
(Hotel Accommodation)  
Travel Planners  
381 Park Avenue South  
New York, NY 10016, USA  
T: +1 212 532 1660  
F: +1 212 532 1340  
E-mail: res@tphousing.com

**Best of Boston**  
(Excursion and Partner Program)  
70 Fargo Street  
Boston, MA 02210, USA  
T: +1 781 577 6048  
F: +1 781 487 1097  
Email: www.bestboston.com

**Insurance, Liabilities**
Neither The Hippocrates Glaucoma Foundation, nor the Organizers can be held responsible for any personal injury, loss, damage, accident to private property or additional expenses incurred as a result of delays or changes in air, rail, sea, road, or other services, strikes, sickness, weather, acts of terrorism and any other cause. All participants are encouraged to make their own arrangements for health and travel insurance.

**Program Changes**
The Organizers cannot assume liability for any changes in the program due to external or unforeseen circumstances.

**Technical Exhibition**
An extensive exhibition of pharmaceutical, technical and research products, equipment, books, journals, services, etc. is organized in conjunction with the World Glaucoma Congress. The scientific program will allow participants ample time to visit the exhibits.

The exhibition area, located in Hall D, will be open at the following hours:
- Wednesday, July 8 1.00 p.m.–7.00 p.m.
- Thursday, July 9 8.30 a.m.–6.00 p.m.
- Friday, July 10 8.30 a.m.–6.00 p.m.
- Saturday, July 11 8.30 a.m.–2.00 p.m.

**Currency and banking**
The US dollar (USD) is the unit of currency and is divided into 100 cents. Only major banks exchange foreign currency. ATMs are widespread and credit cards and travelers checks are widely accepted. Travelers checks should be issued in US dollars for maximum convenience. Banking hours are Monday to Friday 9.00 a.m. to 3.00 p.m. There are several ATM’s at the Hynes

IX
Convention Center. All major credit cards are accepted in the majority of hotels, restaurants and shops.

**Climate**
Boston has a continental climate with very changeable weather patterns, such as considerable temperature swings in a matter of days. Summers are usually sunny, hot and humid. In July, the average temperatures are a high of 82°F (28°C) and a low of 65°F (18°C).

**Electricity**
120 volts, 60 Hz. Plugs are mainly the two, flat-pin type, though three-pin plugs are also widely used. Appliances without dual voltage capabilities will require an adapter.

**Shops**
Shops open from 10.00 a.m. to 7.00 p.m. from Monday to Saturday. Most large stores will also open on Sunday, but generally with shorter opening hours.

**Taxes**
Massachusetts has a sales tax of 5% that is applied to the price of goods at checkout. Clothing under $ 175 and food purchased in grocery stores are exempt.

**Time**
Standard time zone: UTC/GMT -5 hours. Daylight saving time: +1 hour. Boston is on EDT (Eastern Daylight Time).

**Tipping**
A 15% tip is expected by taxi drivers, bartenders, hairdressers and waiters, but don’t tip in fast-food or self-service restaurants. In expensive restaurants or for large parties, tip 15-20% of the bill. It is normal to tip staff in hotels. Most services are customarily tipped if the service is good.

**Travel Insurance**
A travel insurance policy to cover theft, loss and medical problems is recommended. The congress organizer will not be held liable for illness, accidents or thefts suffered by participants or accompanying persons during the Congress or their stay in the US before or after the Congress.

**What to Wear**
Business casual attire is appropriate for the congress. Men generally wear slacks and dress shirts or polo shirts, often with a jacket. Women generally wear pantsuits, skirts or slacks and blouses/golf shirts. The dress code for the Welcome Reception is casual attire. The dress code for the Gala Evening at the Boston Public Library is formal attire (black tie optional).

**Public Transport**
Boston’s downtown transportation system, better known as the ‘T’, connects all of Boston and its suburbs by subway, standard rail, bus and commuter boat. The T connects the airport with the convention centers and hotels as well as point-to-point access anywhere in the city. The new Silver Line offers direct public transportation to the new Boston Convention and Exhibition Center from both the airport and downtown Boston via the Seaport World Trade Center. For more information on the T, please visit the Massachusetts Bay Transportation Authority at www.mbta.com.

**Badges**
All participants and accompanying persons will receive a personal badge upon registration. You are kindly requested to wear your name badge when attending any scientific session or social gathering.
Only participants who are wearing their name badge will be admitted to the meeting rooms. You should also wear your badge in the Exhibition area. Please note: accompanying persons and exhibitors will not be admitted to the scientific sessions. Accompanying persons do have free access to the exhibition. Name badges have been color-coded as follows:

- White: WGA Board of Governors
- Red: Faculty
- Blue: Delegates
- Green: Accompanying persons
- Yellow: Exhibitors
- Purple: Press

The charge for replacement of lost badges will be $25.

**Hotel Reservations**
For any enquiries on hotel reservations, please approach the staff of Travel Planners at the hotel reservation desk in the Registration Area, telephone number: +1 617-954-2599.

**Internet Access**
An Internet Corner is available in the Exhibition Area located in Hall D.

**Lunch**
Lunch is available at various catering points throughout the Convention Center at a cost. Lunch boxes will be provided before the plenary lunch symposia and will be available in the center of the Exhibition Area.

**Message Desk**
At the message desk, delegates can leave or collect messages. The desk is located in the Registration Area.

**Program Changes**
Actual program changes will be indicated on the message boards located throughout the congress center. The organizers cannot assume liability for any changes in the program due to external or unforeseen circumstances.

**Registration desk – opening hours:**
Wednesday, July 8 7.00 a.m.–6.00 p.m.
Thursday, July 9 7.00 a.m.–6.00 p.m.
Friday, July 10 7.00 a.m.–6.00 p.m.
Saturday, July 11 8.00 a.m.–4.00 p.m.

**Certificate of Attendance**
Certificates of Attendance will be available at the Registration Desk in the Registration Area as of Friday July 10, 2.00 p.m.

**Lost and Found**
A lost and found is located in the public safety office on the Plaza level of the Hynes Convention Center.

**Car Parking**
There are parking spaces all around the area surrounding the Hynes Convention Center, all within a three-block walk to the Hynes Convention Center. In addition to the garages, there is meter parking around the facility and the adjacent streets. However, these spaces are difficult to obtain.

**Cloakroom and Luggage**
In the cloakroom you can leave your belongings.

**Opening hours:**
Wednesday, July 8 7.00 a.m.–7.00 p.m.
Thursday, July 9 7.00 a.m.–7.00 p.m.
Friday, July 10 7.00 a.m.–7.00 p.m.
Saturday, July 11 7.00 a.m.–6.00 p.m.
**Taxi Service**

Taxis in Boston may be ordered by phone, picked up at authorized taxi stands, or flagged down in the street. Always check that the meter is running. Taxis must usually be paid in cash, although some accept credit cards.

**Telephone numbers:**
- Metro Cab: +1 617-782-5500
- Boston Taxi: +1 617-536-5010
- Top Cab: +1 617-266-4800
- City Cab: +1 617-536-5100
- ITOA: +1 617-426-8276
- Town Taxi: +1 617-536-5000

Trinity Church and John Hancock Tower

XII
Glaucoma, the second leading cause of blindness, is increasing as the population ages worldwide. The 2000 report from the National Eye Institute predicted that the number of diagnosed cases of glaucoma in the United States would increase from 2.2 million to 3.6 million by 2015. Yet more than 50% of cases remain undiagnosed. Glaucoma, macular degeneration, and diabetic retinopathy together will contribute to a predicted increase of almost 70% in the number of legally blind persons worldwide by 2020. Newer diagnostic, therapeutic, and technical options in glaucoma management are being researched by ophthalmologists, optometrists, and vision researchers who are customizing treatments of an increasing number of patients. There have been recent advances in diagnosis, risk factors, medical therapy, and surgical intervention for glaucoma. The extant literature is limited with respect to progression, diagnosis, treatment paradigms, and surgical advances. Educational opportunities that assess the effect of therapy and surgery on optic nerve appearance, visual function, quality of life, and other vision parameters that need to be evaluated over the long term due to the chronic and slowly progressive nature of glaucoma are lacking. The decision to treat glaucoma by drug therapy or interventional surgery has become ever more complex as the number and variety of treatment options has grown. These options have ushered in a trend toward individualized therapy and monitoring based on a variety of actors including efficacy, side effects, cost, ocular comfort, adherence, and risk of visual disability.

The WGC is a 4 day program that will be taught by a group of renowned, worldwide glaucoma specialists and ophthalmic surgeons who have specialized in the epidemiology, diagnosis, treatment, and impact of glaucoma. The course will include extensive didactic lectures, interactive grand rounds, panel discussions, focused courses, and surgical demonstrations designed to share information among researchers and clinicians in a meaningful way that will enhance the care of patients and our understanding of glaucoma pathophysiology. Among the varied topics that will be addressed are research advances, novel diagnostic and treatment modalities, risk factors, risk reduction, and epidemiology, disease progression and current trends in disease management. Case presentation discussions, poster sessions, free paper sessions, and seminars will add to the plethora of learning opportunities. The presence of international colleagues will add to the diversity of opinion and prepare glaucomatologists for future innovation and advances in our field.

General ophthalmologists & glaucoma specialists

At the end of this activity the physician learners will be able to:
• List the risk factors for glaucoma
• Discuss the latest diagnostic tools for identifying patients at risk for glaucoma progression
• Describe the latest medical therapy and surgical interventions available for the treatment of glaucoma
• List the factors to be considered when developing individualized therapy and monitoring for glaucoma patients
• Facilitate communication and knowledge exchange among general ophthalmologists, glaucoma experts, and other professionals from around the world who are active in the field of glaucoma

The New York Eye and Ear Infirmary requires that each teacher/contributor or individual in a position to control the content of a CME activity accredited by the New York Eye & Ear Infirmary disclose the existence of any relevant financial interests or other relationships (eg. paid speaker, employee, paid consultant on a board and/or committee for a commercial company) that would potentially affect the objectivity of activity content. Teachers/Contributors are also asked to make a disclosure that a product is still investigational when an unlabeled use of a commercial product or an investigational use, not yet approved for any purpose, is discussed during an educational activity. The disclosed information in no way presumes to assess the contributor’s qualifications or suitability. The intention is to provide full disclosure of any potential conflict of interest, real or apparent, which is related to a specific educational activity. Individuals who neglect to provide information about relevant financial relationships will be disqualified from serving as a planning committee.
member, teacher, speaker, moderator or author of the educational activity. In addition, such individuals will be prohibited from having control of or the responsibility for the development, management, presentation or evaluation of the CME activity. Full disclosure of faculty and commercial relationships will be presented at the start of each session.

Disclosure Attestation
The contributing faculty and planners for this Congress have attested to the following:
1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
2) that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice and
3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

All CME activities approved for AMA PRA Category 1 Credits™ are valid for recognition by the EACCME.

Accreditation Statement
This continuing medical education activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the New York Eye & Ear Infirmary and The Hippocrates Glaucoma Foundation. The New York Eye & Ear Infirmary is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement
The New York Eye and Ear Infirmary designates this educational activity for a maximum of 24.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All CME activities approved for AMA PRA Category 1 Credit™ are valid for recognition by the EACCME.

How to claim your CME points
A sufficient number of computers are made available to claim your CME credits. Please note you may claim your credits via the WGA website until three months after the closure of the meeting.

Steps to claim your credit points
Step 1 Visit www.worldglaucoma.org and select the CME link on the top left side of the page

Step 2 From the CME home page, select the claim credits tab at the top
Step 3 Enter your personal login code (this is the registration number printed on your congress badge). Click verify to continue
Step 4 Answer the general questions regarding the meeting
Step 5 Click next at the bottom of the page to continue to claim credits > select sessions
Step 6 Evaluate the sessions that you have attended from 1 to 10 (10 is the highest score)
Step 7 Click next at the bottom of the page to view your personal account. The system will automatically save your information after you have left the page
Step 8 To print your CME certificate, please use the print button on the far right side of the table.

For further assistance or more information on CME, we kindly invite you to visit the WGA-IGR booth.

COPE Credits
The following didactic sessions and courses have COPE approval, or have been submitted for COPE approval and it is pending.

Thursday, July 9
○ Diagnosis of Glaucoma: novel diagnostic tools in glaucoma
○ Novel imaging technology advances
○ Glaucoma Progression I
○ Clinical use of risk factor information

Friday, July 10
○ IOP-measurement, IOP-fluctuation, CCT including consensus, refractive surgery
○ Initial treatment for glaucoma: medical vs laser vs surgery
○ Bloodflow including Consensus
○ Glaucoma Progression II

Saturday, July 11
○ New ideas in medical treatment for glaucoma
○ Uveoscleral outflow
○ Improving outcomes in glaucoma; minimize negative impact
○ Genetics and Glaucoma

Total: 14,5 hours
SCIENTIFIC PROGRAM

D = Didactic Sessions
C = Courses
S = Symposia
FP = Free Papers
CR = Case Report
GR = Grand Rounds
GS = Glaucoma Society

For descriptions and outlines, we refer to the separate Abstracts book.

www.worldglaucoma.org
WEDNESDAY JULY 8, 2009

GLAUCOMA SOCIETY SYMPOSIA

8.00–10.00 a.m. Room 302

Symposium organized by the Egyptian Society for the Glaucomas with the African Glaucoma Society Dealing with Glaucoma in Africa

*Chairs:* M. Nassar, A. Ouertani, E. Ancker

Challenging glaucoma in Africa for the next 10 years
A. Ouertani

Assessment of macular anatomical and functional changes in glaucoma patients
A. Sedki, L. Hamouda, K. AbouSedera

Retinal nerve fiber layer evaluation on OCT
F. Wagdi

Correlation structure-function in glaucoma
A. Ouertani

The challenge to prevent glaucoma progression
E. Ancker

Microphacotrabeculectomy in North-African patients
K. Ben Amur

Cyclodiode in the management of refractory glaucoma
A. Abou-el-Enin

Mechanism of neurodegeneration and neuroprotection in glaucoma
M. Nassar

Glaucoma treatment challenges
E. Ancker

FDT vs OCT in early glaucoma north African patients with normal standard automated perimetry
K. Ben Amur

Aphakic glaucoma after congenital cataract surgery
H. Marey, Abd-el-Rahman el-Sebaei, Abd-el-Khleq el-Saadani, M. Nassar

Anterior capsule augmented phacotrabeculectomy
Abd-el-Rahman el-Sebaei, H. Marey, M. Nassar

Organized by The Hippocrates Glaucoma Foundation
WEDNESDAY JULY 8, 2009

8.00–10.00 a.m. Ballroom A

Joint video-symposium of the Argentine and Brazilian Glaucoma Societies, with the Peruvian and Ecuatorial Glaucoma Societies and the sponsorship of the Latin American and Pan-American Glaucoma Societies

Chairs: A. Omi (Brazilian Glaucoma Society), A. Peyret (Argentine Glaucoma Society) (GS04)

New approaches in anti-glaucoma surgery to primary congenital glaucoma (SBrG)
M. Jordão da Silva

Intra-operative glaucoma surgery complication: Supra-choroidal hemorrhage (SBrG)
E. Suzuki

Trabeculectomy’s complications (SPG)
J.A. Dios

Postoperative complication: getting the iris off from the trabeculectomy’s ostium (AsAG)
V. Zanutigh

Choroidal detachment after trabeculectomy (SBrG)
R. Cohen

Bleb repair in late onset Seidel (AsAG)
J. Casiraghi, M. Geria, P. Nahum

How to manage oversized blebs (SLAG)
E. Maul

Transconjuctival use of MMC in late postop needling (AsAG)
J. Lynch

Bleb complications, how to solve them (SLAG)
R. Perez Grossmann

Solving surgical problems by ‘micro-zorro’ (PAGS)
P. Palmberg

Reactivation of failed trabeculectomy after Ahmed GDD implantation (AsAG)
I. Lischinsky

Glaucoma drainage devices after retinal surgery (SBrG)
I. Maynart Tavares

Glaucoma surgery with ‘ExPress’ implant (PAGS)
F. Fantes

Scleral tunnel and Ahmed implants in multioperated patient (SEG)
C. Chacon

www.worldglaucoma.org
WEDNESDAY JULY 8, 2009

8.00–10.00 a.m. Room 304

Symposium organized by the Canadian Glaucoma Society
Current trends on glaucoma management in Canada
Chairs: Y. Buys, M. Nicolela

8.00–8.03  Introduction
           Y. Buys
8.03–8.18  Canadian glaucoma guidelines
           P. Rafuse (GS13)
8.18–8.33  Modern imaging in glaucoma
           M. Nicolela
8.33–8.48  Risk factors for the progression of open-angle glaucoma
           B. Chauhan
8.48–8.55  Risk factors for the presence of open-angle glaucoma and ocular hypertension in Canada
           Y. Buys
8.55–9.10  Visual field progression in glaucoma
           P. Artes
           R. Campbell (GS12)
9.25–9.40  Role of selective versus argon laser trabeculoplasty
           K. Damji
9.40–9.55  An information session for glaucoma patients
           P. Blondeau (GS11)
9.55–10.00 Summary
           M. Nicolela

8.00–10.00 a.m. Room 312

Symposium organized by the Glaucoma Society of India
Glaucoma Management: An Indian Perspective
Chairs: R. George, R. Parikh

Case and Panel discussion:
Panelists: A. Mandal, V. Nangia, S.S. Pandav, R. Ramakrishnan, B. Shantha, R. Sihota, L. Vijaya, P. Vyas
Case presenters: M. Baskaran, T. Dada, R. George, S. Kaushik, R. Parikh, M. Shah (GS02)

Organized by The Hippocrates Glaucoma Foundation
WEDNESDAY JULY 8, 2009

8.00–10.00 a.m. Auditorium

Symposium organized by the European Glaucoma Society
EGS: New Guidelines for Glaucoma: Top Topics
Chairs: C. Migdal, F. Goni, J. Thygesen

Pearls and pitfalls of IOP
C. Migdal
Progression is the key; where we are going with perimetry
F. Goni
Target IOP – where are we now?
J. Thygesen
The combined approach to glaucoma medications
A. Hommer
The cutting edge – glaucoma incisional surgery
T. Shaarawy

8.00–10.00 a.m. Ballroom C

Joint Symposium organized by the Japan and Taiwan Glaucoma Societies
Japan-Taiwan
Roundtable Discussion: Primary angle closure – Asian perspectives
Chairs & Organizers: T. Yamamoto (Japan Glaucoma Society), D.-W.Lu (Taiwan Glaucoma Society)

Has change really occurred? – PAS observation during the last 20 years
T. Yamamoto
The role of pilocarpine in post-LPI angle closure
K.-Y. Wu
Uveal effusion as a mechanism of primary angle closure
H. Sakai
Ultrabiomicroscopic prognostic factors for future PAS formation in primary angle-closure suspect (PAC suspect) eyes
M. Araie
Longitudinal changes of anterior chamber configuration and their associated factors
K. Kashiwagi
Surgical management of angle-closure glaucoma
D.-W. Lu

www.worldglaucoma.org
WEDNESDAY JULY 8, 2009

Lens surgery in PACG
C.J.L. Liu

Angle-closing-mechanism-guided treatment for PAC
Y. Kurimoto

8.00–10.00 a.m. Ballroom B

Symposium organized by the Optometric Glaucoma Society
A New Look at IOP and Tonometry
Chairs: B. Gaddie and T. Lewis

8.00–8.10 Introduction
T. Lewis

8.10–8.25 Fluctuations in IOP
F. Meideros

8.25–8.40 Corneal hysteresis
T. Garway Heath

8.40–8.55 Why 24-hour IOP
J. Liu

8.55–9.10 How 24-hour IOP – Contact lens approach
A. Sit

9.10–9.25 How 24-hour IOP – Adapted DCT
M. Twa

9.25–9.40 Clinical implications and opportunities
Robert N. Weinreb

9.40–9.55 Panel Discussion

8.00–10.00 a.m. Room 310

Symposium organized by the Pan Arab Glaucoma Society

Glaucoma in our world: Glaucoma as a surgical disease
F. Al Sayyad

Epidemiology – The magnitude of the problem in the Arab world
M. Helal

Genetic aspects
M. Bel Meki

Congenital glaucoma in the Arab countries
M. Yaqub (GS01)

Organized by The Hippocrates Glaucoma Foundation
WEDNESDAY JULY 8, 2009

The scope of secondary glaucomas
H. El Hamzawy
Non-penetrating surgery vs trabeculectomy in our region
S. Gohar

8.00–10.00 a.m. Room 210

Symposium organized by the Czech Glaucoma Society
Boston’s Glaucoma Debate
Chairs: I. Liehneova, G. Holló, B. Cvenkel, E. Ruzickova

Welcome and Introduction
View on exfoliation syndrome and glaucoma in 2009
G. Holló
Importance of connective tissue in lamina cribrosa in glaucoma
T. Kubena, K. Kubena
Global indices, GHT and glaucoma changes
J. Hornova (GS17)
Imaging and monitoring of progression: S – OCT
H. Peskova
The impact of the glaucoma medication on the biomechanical properties of the cornea
I. Liehneova (GS05)
Changes in macular thickness after cataract surgery in glaucoma patients receiving prostaglandin analogues – first results of a prospective, longitudinal study
S. Skorkovska, T. Jurecka, K. Skorkovska, E. Zampachova (GS22)
Selective laser trabeculoplasty – efficacy of 270° treatment in primary open-angle glaucoma
P. Vyborny, S. Sicakova (GS23)
Primary angle closure in the Czech Republic – Is laser iridotomy a sufficient method of treatment?
M. Fichtl, J. Betkova, V. Forgacova, E. Ruzickova (GS19)
Cataract surgery in the treatment of angle-closure glaucoma
N. Pavlickova (GS14)
TNF alpha and IL-10 in aqueous humor predict glaucoma surgery outcome
B. Cvenkel

www.worldglaucoma.org
WEDNESDAY JULY 8, 2009

Trabeculectomy with restrictive mattress suture – a safer method for the outpatient glaucoma filtering surgery
M. Fucík (GS20)

Deep nonpenetrating sclerectomy – complications
P. Strnad, J. Svacinova, E. Vlkova

First experience with miniature glaucoma drainage device
M. Prazenicová (GS16)

Treatment of secondary glaucoma by Leksell gamma knife comparison short-term and medium-term results
L. Novacek, P. Vyborný, V. Vladyka, R. Liscák, J. Pasta

Elevated intraocular pressure in thyroid-associated ophthalmopathy
M. Karhanová, K. Maresová, P. Mlčák, Z. Frýsak, M. Herman, J. Rehák (GS15)

Lens particle glaucoma as a consequence of spontaneous rupture of anterior capsule in hypermature cataract – Two case reports

8.00–10.00 a.m. Room 306

Symposium organized by the Israel Glaucoma Group
Chair: R. Nesher, Head of Israel Glaucoma Group

8.00–8.05 Opening remarks
R. Nesher

8.05–8.20 Titanium Laser Trabeculoplasty Vs SLT in open-angle glaucoma, A prospective, randomized, masked study
D. Cotlear, M. Goldenfeld, S. Melamed

8.20–8.35 Do we need to perform gonioscopy during the routine eye exam? A prospective study of the incidence of angle closure in Caucasians. Preliminary results
Y. Barkana

8.35–8.50 Glaucoma detection using machine learning classifiers with OCT, HRT, and GDX measurements
G. Wollstein

8.50–9.05 Revision of cicatricial filtering blebs
M. Zalish

9.05–9.20 Outcome following Ahmed valve implantation in post PKP glaucoma
R. Rachmiel, S. Kurtz

Organized by The Hippocrates Glaucoma Foundation
WEDNESDAY JULY 8, 2009

9.20–9.35 Diabetes mellitus and glaucoma
E. Dahan

9.35–9.50 Detection of glaucomatous retinal nerve fiber layer progression with scanning laser polarimetry and optical coherence tomography
G. Wollstein

9.50–10.05 Injecting autologous blood for a leaking bleb
R. Nesher

8.00–10.00 a.m. Room 311

Symposium organized by the Lithuanian Glaucoma Society

Comprehensive glaucoma management – Evidence-based approach
I. Janulevičienė (GS03)
Age-related eye changes and prostaglandins
L. Kuzmienė
Rare features of Axenfeld-Rieger syndrome
R. Bagdoniene
Exfoliation syndrome among patients scheduled for cataract and glaucoma surgery at Vilnius University Hospital
R. Sirtautiene (GS07)
CCT in pseudexfoliation patients, referred for glaucoma surgery
S. Speičienė (GS08)
The relationship between central corneal thickness, gender, IOP and corneal curvature
S. Galgauskas
Efficacy and safety of fixed glaucoma combination therapy
A. Butkiene (GS06)
Discussion

8.00–10.00 a.m. Room 309

Symposium organized by the Korean Glaucoma Society
Retinal nerve fiber layer evaluation in glaucoma
Chair: G.J. Seong

8.00–8.10 Introduction
J.-I. Moon

8.10–8.20 RNFL evaluation and preperimetric glaucoma:
T.W. Kim

www.worldglaucoma.org
WEDNESDAY JULY 8, 2009

8.20–8.30  Correlation between RNFL photography and OCT
K.H. Park

8.30–8.40  Latest advances in HRT3 analysis of the RNFL
H.T. Wong

8.40–8.50  Current status of scanning laser polarimetry in glaucoma
K.R. Sung

8.50–9.00  Spectral domain OCT
G. Tomita

9.00–9.10  RNFL structure and glaucoma function
C.-Y. Kim

9.10–9.30  Panel discussion

10.00–11.30 a.m. Auditorium

Best of American Glaucoma Society Symposium

10.00–10.08  A comparison of optic disc margin anatomy using clinical photographs and spectral domain optical coherence tomography
C.F. Burgoyne

10.08–10.16  Glaucoma with visual field loss affecting both hemifields increases the risk of disease progression
G. DeMoraes

10.16–10.24  The relationship between intraocular pressure and progressive retinal nerve fiber layer loss in glaucoma
F.A. Medeiros

10.24–10.32  Interventions improve adherence with glaucoma eyedrops
D.S. Friedman

10.32–10.40  Micronutrients in Glaucoma
J.G. Crowston

10.40–10.45  Future implications
R.N. Weinreb

10.45–10.53  Adaptive optics and glaucoma
A. Dubra

10.53–10.58  Future implications
J.M. Liebmann

10.58–11.06  Treatment outcomes and complications in the tube versus trabeculectomy (TVT) study after three years of follow-up
S. Gedde

Organized by The Hippocrates Glaucoma Foundation
WEDNESDAY JULY 8, 2009

11.06–11.14 The association of primary open-angle glaucoma and mortality: A meta-analysis of observational studies
L.R. Pasquale

11.14–11.30 Discussion

11.30 a.m.–12.00 p.m. BREAK AND VISIT TO THE EXHIBITION

PLENARY LUNCH SYMPOSIUM

12.00–1.00 a.m. Auditorium

Advances and unmet needs in glaucoma management
Chairs: E. Greve, J. Schuman, K. Singh

Global glaucoma burden in the 21st century
T. Shaarawy
Barriers to compliance with glaucoma therapy
D. Friedman
Future directions in assessment of optic nerve structure
G. Wollstein
Advances and limitations in assessing functional change
S. Miglor
Glaucoma surgery: What comes next?
F. Grehn

This symposium is supported by an educational grant from Pfizer

1.00–1.30 p.m. BREAK AND VISIT TO THE EXHIBITION

1.30–2.30 p.m. Auditorium

Global Assembly

Opening and Welcome
Remo Susanna Jr
Introduction of new Glaucoma Societies since WGC–2007
Tarek Shaarawy

www.worldglaucoma.org
WEDNESDAY JULY 8, 2009

World Glaucoma Association: The History
Erik Greve

International Glaucoma Review
Robert N. Weinreb

World Glaucoma Day
Robert Ritch, George Lambrou

Consensus & Promulgation
Robert N. Weinreb

The World Glaucoma Association in 2009 and Beyond
Kuldev Singh

2.30–3.00 p.m. BREAK AND VISIT TO THE EXHIBITION

3.00–5.30 p.m. Auditorium

Opening Session

Welcome by the Founding Executive Vice President, World Glaucoma Association
Erik Greve

Welcome, President of the World Glaucoma Association
Remo Susanna Jr

Welcome, Executive Vice President of the World Glaucoma Association
Kuldev Singh

Welcome, President of the American Glaucoma Society
Theodore Krupin

Local Organizing Committee Welcome
Louis Pasquale

Program Committee Welcome
Dennis Lam

Board of Governors Welcome
Ivan Goldberg

Glaucoma Consensus
Robert Weinreb

World Glaucoma Day
Robert Ritch, Ivan Goldberg

International Glaucoma Review
Robert Weinreb

Organized by The Hippocrates Glaucoma Foundation
WEDNESDAY JULY 8, 2009

Introduction Robert Langer
Joel Schuman
Keynote Speech
Robert Langer
WGA Science Awards
Erik Greve
WGA Recognition Awards
Kuldev Singh
Introduction of Robert Merton
Paul Cotran
Keynote Speech
Robert Merton
Closing by President of the World Glaucoma Association
Remo Susanna Jr

5.30–7.00 p.m. WELCOME RECEPTION IN THE EXHIBITION AREA
THURSDAY JULY 9, 2009

8.00–11.30 a.m. Room 210

WGC Film Festival
Please see page 51 for the list of video’s to be shown.

8.00–11.30 DIDACTIC MORNING SESSIONS

8.00–9.30 a.m. Auditorium

D01 Novel diagnostic targets in Glaucoma, including Angle-closure Glaucoma and Structure and Function Consensus

Chairs: H.G. Lemij, P. Sample

8.00–8.07 D01-01 The value of consensus and levels of evidence in diagnostic practice
P. Sample

8.07–8.14 D01-02 Functional measures of glaucoma
E.M. Blumenthal

8.14–8.21 D01-03 Structural measures of glaucoma
M.S. Kook

8.21–8.28 D01-04 The relationship of structure and function in glaucoma
M.T. Nicolela

8.28–8.35 D01-05 Epidemiology and classification of angle closure glaucoma
E.M. Hoffmann

8.35–8.42 D01-06 Detection of primary angle closure and angle-closure glaucoma
D. Friedman

8.42–8.49 D01-07 The genetics of glaucoma
S. Chakrabarthi

8.49–8.56 D01-08 Diagnosis of glaucoma: Consensus
H.G. Lemij

8.00–9.30 a.m. Ballroom A

D02 Novel imaging technology advances

Chairs: C.K.S. Leung, J. Schuman

8.00–8.07 D02-01 Longitudinal evaluation of retinal ganglion cell damage with blue-light confocal scanning laser ophthalmoscope
C.K.S. Leung

Organized by The Hippocrates Glaucoma Foundation
### THURSDAY JULY 9, 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.07–8.14</td>
<td>D02-02</td>
<td>Novel glaucoma imaging diagnostics</td>
<td>J. Schuman</td>
</tr>
<tr>
<td>8.14–8.21</td>
<td>D02-03</td>
<td>Advances in imaging neuroprotection in vivo</td>
<td>M.F. Cordeiro</td>
</tr>
<tr>
<td>8.21–8.28</td>
<td>D02-04</td>
<td>Optophysiology: Functional imaging of the retina with OCT</td>
<td>W. Drexler</td>
</tr>
<tr>
<td>8.28–8.35</td>
<td>D02-05</td>
<td>Ultrahigh speed and resolution optical coherence tomography</td>
<td>J. Fujimoto</td>
</tr>
<tr>
<td>8.35–8.42</td>
<td>D02-06</td>
<td>Detecting glaucoma progression with OCT, CSLO and SLP – today and tomorrow</td>
<td>D.S. Greenfield</td>
</tr>
</tbody>
</table>

#### 8.00–9.30 a.m. Ballroom B

**D03 Translational Science**  
*Chairs: K.R.G. Martin, R.N. Weinreb*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00–8.07</td>
<td>D03-01</td>
<td>Introduction</td>
<td>K.R.G. Martin</td>
</tr>
<tr>
<td>8.07–8.14</td>
<td>D03-02</td>
<td>Identifying pressure responding genes in the human trabecular meshwork</td>
<td>T. Borras</td>
</tr>
<tr>
<td>8.14–8.21</td>
<td>D03-03</td>
<td>Structural and functional testing</td>
<td>J.G. Crowston</td>
</tr>
<tr>
<td>8.21–8.28</td>
<td>D03-04</td>
<td>Mechanisms of uveoscleral outflow regulation</td>
<td>J. Lindsey</td>
</tr>
<tr>
<td>8.28–8.35</td>
<td>D03-05</td>
<td>Glaucoma models. Of Mice and Men</td>
<td>H. Quigley</td>
</tr>
<tr>
<td>8.35–8.42</td>
<td>D03-06</td>
<td>Measurement of aqueous dynamics in humans</td>
<td>A. Sit</td>
</tr>
<tr>
<td>8.42–8.49</td>
<td>D03-07</td>
<td>Challenges: Rewiring the eye to the brain in glaucoma</td>
<td>Y. Yücel</td>
</tr>
<tr>
<td>8.49–8.56</td>
<td>D03-08</td>
<td>Conclusions</td>
<td>R.N. Weinreb</td>
</tr>
</tbody>
</table>

**9.30–10.00 a.m. BREAK AND VISIT TO THE EXHIBITION**
THURSDAY JULY 9, 2009

10.00–11.30 a.m. Auditorium

D04 Glaucoma Progression I
Chairs: D. Garway Heath, J.M. Liebmann

10.00–10.10 D04-03 How many participants with primary optic disc endpoints develop visual field loss?
M.A. Kass

10.10–10.20 D04-04 Beta-zone parapapillary atrophy, disc hemorrhage, and visual field progression
C.G.V de Moraes

10.20–10.30 D04-05 Evaluation of glaucoma progression by measuring the rate of change of retinal nerve fiber layer thickness
C.K.S. Leung

D04.1 Structure and functional parameters that predict progression
Chairs: J.M. Liebmann, A. Heijl

10.30–10.37 D04.1-03 GDx, OCT
D.S. Greenfield

10.37–10.44 D04.1-04 Selective tests of function (FDT, SWAP) that predict progression
C.A. Johnson

10.44–10.51 D04.1-05 Disc hemorrhage
K. Sugiyama

10.51–10.58 D04.1-06 HRT
L. Zangwill

D04.2 Detecting and establishing rates of glaucoma functional progression: Debate
Chair: A. Heijl, J.M. Liebmann

10.58–11.30 Debate: Event vs trend analysis for detection of VF progression
D. Garway Heath, B. Bengtsson

Organized by The Hippocrates Glaucoma Foundation
THURSDAY JULY 9, 2009

10.00–10.45 a.m. Ballroom A

D05 Epidemiology and screening
Chairs: D.S. Friedman, R. Wilson

10.00–10.07 D05-01 Which populations should be screened for POAG
D.S. Friedman

10.07–10.14 D05-02 Fundamental issues related to screening for disease
R. Wilson

10.14–10.21 D05-03 Where do we stand with angle-closure glaucoma screening?
A. Azuara Blanco

10.21–10.28 D05-04 What will screening for glaucoma look like in 10 years?
P.R. Healey

10.28–10.35 D05-05 Should populations with high rates of PXF be screened more frequently?
F. Topouzis

10.45–11.30 a.m. Ballroom A

D06 Clinical use of risk factor information
Chairs: A.L. Coleman, T. Yamamoto

10.45–10.55 D06.1 Cerebrospinal fluid pressure in glaucoma
R. Ren

10.55–11.05 D06.2 24h Diurnal ocular perfusion pressure in primary open-angle glaucoma
V.P. Costa

11.05–11.10 D06-03 Central corneal thickness as a risk factor of glaucoma
J. Brandt

11.10–11.15 D06-04 Risk factors found in randomized clinical trials
S.L.M. Mansberger

11.15–11.20 D06-05 Long-term IOP fluctuation as a risk factor of glaucoma
S. Miglior

11.20–11.25 D06-06 Vascular risk factors for glaucoma (excluding systemic hypertension)
S. Susanna Jr

11.25–11.30 D06-07 Risk factors for primary angle closure
P. RojanaPongpun

www.worldglaucoma.org
THURSDAY JULY 9, 2009

10.00–11.30 a.m. Ballroom B

D07 New ideas
Chairs: J. Ge, J. Morgan

10.00–10.07 D07-02 Pre-apoptotic retinal ganglion cell degeneration in glaucoma
J. Morgan

10.07–10.14 D07-03 Establishment of new glaucoma model
M. Aihara

10.14–10.21 D07-05 Decreased cerebral blood flow in human glaucoma
R. Duncan

10.21–10.28 D07-06 Compartmentalized RGC damage
S. John

10.28–10.35 D07-07 Impact of longitudinal change in the anterior chamber depth in glaucoma
K. Kashiwagi

10.35–10.42 D07-08 Cellular interactions in retinal cell survival
J. Sahel

10.42–10.49 D07-09 New insights into retinal ganglion cell oxygenization
G. Tezel

11.30–11.45 a.m. BREAK

PLENARY LUNCH SYMPOSIUM

11.45 a.m.–12.45 p.m. Auditorium

Glaucoma 2010: IOP and beyond
Chairs: D. Lam, J. Liebmann, R. Susanna Jr

11.45–12.04 Natural history of glaucomatous disease
J. Crowston

12.04–12.13 IOP as a risk factor for glaucoma progression
H. Quigley

12.13–12.22 Optimizing strategies for IOP control
C. Migdal

Organized by The Hippocrates Glaucoma Foundation
THURSDAY JULY 9, 2009

12.22–12.31  Neuronal mechanisms of glaucomatous disease
K. Martin

12.31–12.40  Neuroprotection: When to expect a breakthrough
N. Gupta

12.45–2.00 p.m. BREAK AND VISIT TO THE EXHIBITION

2.00–3.00 p.m. PARALLEL SYMPOSIA

2.00–3.00 p.m. Auditorium

S01 Early detection
Chairs: H.G. Lemij, N. Pfeiffer

Ancestry differences in the spatial distribution of visual field damage observed in healthy eyes in the African descent and glaucoma evaluation study (adages) (S01.1)
L. Racette

Screening for glaucoma and the problem of false-positives and avoiding them
D. Garway Heath

Functional tests for early detection
Ch. A. Johnson

Structure-function relationships, suggesting a potential role for early structural measurements
F. Medeiros

2.00–3.00 p.m. Ballroom A

S02 Glaucoma & Myopia
Chairs: K. Singh, J.C. Tsai

Introduction
Optic nerve head characteristics of young myopic adults
S. Lin

Refractive error, axial dimensions and primary open-angle glaucoma
T. Aung

www.worldglaucoma.org
THURSDAY JULY 9, 2009

Diagnostic and therapeutic dilemmas in myopes with glaucoma
J. Tsai
Glaucoma surgery in high myopes
P. Palmberg
Discussion

2.00–3.00 p.m. Ballroom B

S03 Global economic recession – How can health economics help us
Chairs: G. Schwartz, A. Tuulonen

Why is it important to consider economic issues in glaucoma care
A. Tuulonen
Main principles of health economics for clinicians. How to evaluate economic studies
S. Kymes
Discussant
S.A. Obstbaum
Cost and care issues in developing world
R. Thomas

2.00–3.00 p.m. Ballroom C

S04 Exfoliation syndrome and exfoliative glaucoma
Chairs: A.G. Konstas, R. Ritch

Treatment of exfoliative glaucoma
A.G. Konstas
Ocular and systemic findings
R. Ritch
Cataract surgery in exfoliation syndrome
G.P. Condon
The LOXL1 gene and its potential clinical relevance
F. Jonasson
Pathobiology of exfoliation syndrome
U. Schlötzer-Schrehardt

Organized by The Hippocrates Glaucoma Foundation
THURSDAY JULY 9, 2009

2.00–3.00 p.m. Room 302

S05 Update on Consensus Reports
Chair: R.N. Weinreb

Structure and function in the management of glaucoma
F. Medeiros

Intraocular pressure
A. Sit

Screening of OAG and ACG
P. Healey

Surgery of open-angle glaucoma
T. Wells

3.00–3.30 p.m. BREAK AND VISIT TO THE EXHIBITION

3.30–4.50 p.m. FREE PAPER SESSION

3.30–4.50 p.m. Room 203

Free Paper Session – Basic Science

3.30–3.40 FPBS1 – Detection of longitudinal change in experimental glaucoma using three dimensional (3-D) spectral domain optical coherence tomography (SD-OCT) optic nerve head (ONH) volumes
N.G. Strouthidis

3.40–3.50 FPBS2 – Lamina cribrosa and peripapillary sclera histomorphometry in normal and advanced glaucomatous Chinese eyes with normal and elongated axial length
R. Ren

3.50–4.00 FPBS3 – Hydrodynamic and morphological characteristics after Y27632 treatment in bovine, monkey and human eyes
Z. Lu

4.00–4.10 FPBS4 – Genomic (epigenetic) DNA methylation in patients with open-angle glaucoma
A.G.M. Jünemann

www.worldglaucoma.org
THURSDAY JULY 9, 2009

4.10–4.20 FPBS5 – New insights into aqueous humor outflow from the laser-induced glaucoma monkey model
H. Gong

4.20–4.30 FPBS6 – A glucocorticoid-inducible MMP1 gene therapy vector lowers IOP in a sheep model of steroid-induced ocular hypertension
T. Borras

4.30–4.40 FPBS7 – Search for secondary genetic factors for pseudoexfoliation glaucoma
B. Fan

4.40–4.50 FPBS8 – Decreased cerebral blood flow in human glaucoma
O. Duncan

3.30–4.30 p.m. PARALLEL COURSES

3.30–4.30 p.m. Room 202

CO-01 Glaucoma epidemiology. Prevalence and diagnosis
D.S. Friedman (chair), P. Healey (chair), M. Araie, H. Quigley

3.30–4.30 p.m. Room 210

CO-03 Electrophysiology and glaucoma diagnosis
S. Graham (chair), V. Porciatti (chair), C. Bowd, B.A. Fortune

3.30–4.30 p.m. Room 302

CO-04 Congenital and infantile glaucoma
P. Khaw (chair), A.K. Mandal (chair), J. Brandt, Ch.L. Ho, E. Maul

3.30–4.30 p.m. Room 304

CO-05 Delivering GL in the developing world
F. Gomez Goyeneche (chair), L.W. Herndon Jr (chair), K. Ben Amor, G. Gazzard

Organized by The Hippocrates Glaucoma Foundation
THURSDAY JULY 9, 2009

3.30–4.30 p.m. Room 306

CO-06 Laser for OAG

3.30–4.30 p.m. Room 309

CO-07 Glaucoma surgery – basics
F. El-Sayyad (chair), R. Ramakrishnan (chair), L.B. Cantor, Y. Kuwayama, C. Mattox, C. Migdal, R. Bellows

3.30–4.30 p.m. Room 310

CO-08 Glaucoma biostatistics
L. Rossetti (chair), N. Congdon, W.J. Feuer, S.L.M. Mansberger

4.30–4.45 p.m. BREAK AND VISIT TO THE EXHIBITION

4.45–5.45 p.m. PARALLEL COURSES

4.45–5.45 p.m. Room 202

CO-09 Clinical trials & evidence-based glaucoma
A.L. Coleman (chair), K. Singh (chair), S. Miglior, R. Parikh, R. Wilson

4.45–5.45 p.m. Room 203

CO-10 New tonometry, CCT
J. Brandt (chair), L. Pillunat (chair), R.L. Fellman, J. Liu, A. Sit, E. Leuenberger

4.45–5.45 p.m. Room 302

CO-11 Optic disc photography
J.B. Jonas (chair), M.T. Nicolela (chair), A. Tomidokoro
THURSDAY JULY 9, 2009

4.45–5.45 p.m. Room 304

CO-12 Guidelines on diagnosis and treatment of ACG  
W. Nolan (chair), T. Aung, M. He, N. Wang, T.-H. Wang, J. Zhao

4.45–5.45 p.m. Room 306

CO-13 Laser for ACG  
P. RojanaPongpun (chair), C. Tham (chair), M.B.A. Agulto, J. Thygesen

4.45–5.45 p.m. Room 309

CO-14 Optimizing trabeculectomy outcome  
K. Barton (chair), F. Grehn (chair), Ch. Baudouin, P. Khaw, D.W Lu, L. Wang

4.45–5.45 p.m. Room 310

CO-15 Filtering surgery: implants  
J. Freedman (chair), G. Baerveldt, E. Dahan, A. Molteno, M. Sherwood, G. Trope

4.45–5.45 p.m. Room 210

CO-16 Glaucoma patient organization (how to organize, interact with GPO)  
S.R. Christensen (chair), G.N. Lambrou (chair), B. Lindsell (chair), I. Goldberg, R. Ritch, D.J. Wright

Organized by The Hippocrates Glaucoma Foundation
FRIDAY JULY 10, 2009

8.30–10.00 a.m. Auditorium

GRAND ROUNDS
Chairs: D.L. Epstein, R. Thomas
Panel: F. Lerner, C. Migdal, I. Goldberg, W. Alward

GR01 A 77-year-old man with blurry vision and pain
P.B. Gross
GR02 Glaucoma with sclero-keratitis: Whether to touch the sleeping lion
S. Tejwani
GR03 Ugh syndrome with sulcus-fixated IOL
G. Murthy
GR04 Bilateral acute angle-closure glaucoma following Topiramate therapy for migraine prophylaxis
R. Venkatesh
GR05 Clues, yet clueless!
S. Kaushik

8.30 a.m.–12.00 p.m. Room 210

WGC Film Festival
Please see page 51 for the list of video’s to be shown.

8.30 a.m.–12.00 p.m. DIDACTIC MORNING SESSIONS

8.30–9.15 a.m. Ballroom A

D08 IOP, fluctuation, CCT, refractive surgery, consensus
Chairs: J. Brandt, M. Irkec

8.30–8.36 D08.1 Intraocular pressure fluctuation and associated risk factors in eyes with angle closure
R.S. Kumar
8.36–8.43 D08-01 World Glaucoma Association IOP Consensus
J. Brandt
8.43–8.50 D08-02 Short-term IOP fluctuation (diurnal)
M. Irkec
FRIDAY JULY 10, 2009

8.50–8.57  D08-03  Central corneal thickness
L.W. Herndon, Jr

8.57–9.04  D08-05  Tonometry in the refractive surgery patient
T. Samuelson

9.15–10.00 a.m. Ballroom A

D09 Initial treatment for glaucoma: medical vs laser vs surgery
Chairs: R. Fechtner, G.L. Skuta, R. Susanna Jr

9.15–9.18  D09-01  Introduction
R. Susanna Jr

9.18–9.25  D09-02  Randomized clinical trials – Designs
F.J. Goni

9.25–9.32  D09-03  Why medical treatment first?
D.E. Grigera

9.32–9.39  D09-04  Why laser surgery first?
T. Realini

9.39–9.46  D09-05  Why incisional surgery first?
G. Skuta

9.46–9.53  D09-06  Is cost a consideration?
R. Fechtner

9.53–10.00  D09-07  Discussion & Summary
R. Susanna Jr

8.30–10.00 a.m. Ballroom B

D10 Surgical management ACG incl. consensus
Chairs: D. Lam, J. Thygesen

8.30–8.37  D10.1  Increased iris thickness, curvature and volume are risk factors for angle closure
N. Ramli

8.37–8.44  D10.2  Phacoemulsification versus combined phaco-trabeculectomy in chronic angle closure glaucoma with cataract – prognostic factors for intraocular pressure control
C.Y. Tham

Organized by The Hippocrates Glaucoma Foundation
FRIDAY JULY 10, 2009

8.44–8.51  D10.3  Schlemm’s canal cross-sectional area increases at collector channel junctions
    E. Kagemann

8.51–8.58  D10-03  Prophylactic laser iridotomy for narrow angle
    T. Aung

8.58–9.05  D10-04  Glaucoma drainage devices (GDD) – any role in ACG?
    P.T.K. Chew

9.05–9.12  D10-05  An integrated evidence-based management approach in ACG
    D.S. Friedman

9.12–9.19  D10-06  Alternate treatments (AC paracentesis and corneal indentation) in acute ACG
    D. Lam

9.19–9.26  D10-07  Filtration surgery in ACG
    P. Palmberg

9.26–9.33  D10-08  Pre-operative assessment in ACG
    L. Sakata

9.33–9.40  D10-09  Goniosynechialysis (GSL)
    H. Tanihara

9.40–9.47  D10-10  Lens extraction in ACG
    C. Tham

9.47–9.54  D10-11  An overview of surgical options in ACG
    J. Thygesen

10.00–10.30 a.m. BREAK AND VISIT TO THE EXHIBITION

10.30 a.m.–12.00 p.m. Auditorium

D11 Emerging surgery
    Chairs: S. Melamed, P. Netland

10.30–10.37  D11.1  MMC-deep sclerectomy with implant versus MMC-trabeculectomy in adults affected by advanced open-angle glaucoma: a 24-month randomized controlled trial
    R. Carassa

10.37–10.44  D11-03  Update on glaucoma drainage implants: Standard for secondary surgery
    V.P. Costa

10.44–10.51  D11-04  Ex-PRESS implant under scleral flap
    L.W. Herndon, Jr

www.worldglaucoma.org
World Glaucoma Congress, July 8-11, 2009

**FRIDAY JULY 10, 2009**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.51–10.58</td>
<td>D11-05</td>
<td>Ophthalmic microcatheter and canaloplasty</td>
<td>R.A. Lewis</td>
</tr>
<tr>
<td>11.58–11.05</td>
<td>D11-06</td>
<td>Trabectome</td>
<td>S. Mosaed</td>
</tr>
<tr>
<td>11.05–11.12</td>
<td>D11-07</td>
<td>Gold micro shunt</td>
<td>M. Nardi</td>
</tr>
<tr>
<td>11.12–11.19</td>
<td>D11-08</td>
<td>Modified Trabeculectomy: Standard for primary surgery</td>
<td>P. Palmberg</td>
</tr>
<tr>
<td>11.19–11.26</td>
<td>D11-09</td>
<td>Non-penetrating surgery</td>
<td>T. Shaarawy</td>
</tr>
<tr>
<td>11.26–11.33</td>
<td>D11-10</td>
<td>I-Stent</td>
<td>D. Spiegel</td>
</tr>
</tbody>
</table>

**10.30–11.15 a.m. Ballroom A**

**D12 Laser treatment for OAG**

*Chairs: I. Goldberg, L.J. Katz*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30–10.37</td>
<td>D12.1</td>
<td>Argon laser trabeculoplasty in early manifest glaucoma trial</td>
<td>D. Peters</td>
</tr>
<tr>
<td>10.37–10.44</td>
<td>D12-01</td>
<td>Laser trabeculoplasty: Which wavelength should be used?</td>
<td>I. Goldberg</td>
</tr>
<tr>
<td>10.44–10.51</td>
<td>D12-02</td>
<td>The glaucoma treatment paradigm: where does laser trabeculoplasty fit?</td>
<td>L.J. Katz</td>
</tr>
<tr>
<td>10.51–10.58</td>
<td>D12-03</td>
<td>From the bedside to the bench and back again. Predicting and improving the outcomes of SLT glaucoma therapy</td>
<td>J. Alvarado</td>
</tr>
<tr>
<td>10.58–11.05</td>
<td>D12-04</td>
<td>Technique modifications and repeatability</td>
<td>T. Wells</td>
</tr>
<tr>
<td>11.05–11.12</td>
<td>D12-05</td>
<td>SLT in PXF glaucoma</td>
<td>O. Geyer</td>
</tr>
</tbody>
</table>

Organized by The Hippocrates Glaucoma Foundation
FRIDAY JULY 10, 2009

11.15 a.m.–12.00 p.m. Ballroom A

D13 Results of the recent Blood Flow in Glaucoma Consensus Report  
Chairs: R.N. Weinreb, A. Harris  
Panel: R.N. Weinreb, A. Harris, J. Jonas, M. Araie, J. Crowston, L. Pasquale

11.15–11.30 D13-03 Anatomy and physiology of the blood supply to the eye  
J. Jonas  
Discussion

11.30–11.45 D13-06 Clinical methods of OBF  
A. Harris  
Discussion

11.45–12.00 D13-04 Clinical relevance of OBF and impact of medication  
M. Araie  
Discussion

10.30–11.15 a.m. Ballroom B

D14 Glaucoma Progression II: Detecting and establishing rates of glaucoma structural progression  
Chairs: R.A. Hitchings, J.M. Liebmann

10.30–10.37 D14-03 Optic disc photography and clinical examination  
D.S. Greenfield

10.37–10.44 D14-04 HRT structure change and rate  
B. Chauhan

10.44–10.51 D14-05 GDx RNFL structure change and rate  
H.G. Lemij

10.51–10.58 D14-06 OCT RNFL structure change and rate  
F. Medeiros

10.58–11.15 Panel discussion: Combined structure-function assessment in clinical practice

11.15 a.m.–12.00 p.m. Ballroom B

D15 Clinician Scientist Symposium  
Chair: P.R. Healey

11.15–11.22 D15-02 Molecular mechanisms of intraocular pressure regulation  
M. Aihara

www.worldglaucoma.org
FRIDAY JULY 10, 2009

11.22–11.29 D15-03 Genetics
J. Craig

11.29–11.36 D15-04 Aging and mitochondrial dysfunction in glaucoma
J.G. Crowston

11.36–11.43 D15-05 Genetic study based on twins
M. He

11.43–11.50 D15-06 Molecular/gene therapies
K.R.G. Martin

11.50–11.57 D15-07 Gene therapy in Leber Amaurosis- preliminary results from a clinical trial
A. Viswanathan

12.00–12.15 p.m. BREAK AND VISIT TO THE EXHIBITION

PLENARY LUNCH SYMPOSIUM

12.15–1.15 p.m. Auditorium
Hot topics in glaucoma care
Chairs: M. Araie, S. Melamed, R.N. Weinreb

Is early glaucoma diagnosis beneficial?
N. Pfeiffer

Does early glaucoma treatment improve prognosis?
I. Goldberg

The prevalence of ocular surface disease in glaucoma patients
R. Fechtner

The impact of glaucoma therapy on ocular tissues
C. Baudouin

Therapeutic strategies to reduce ocular side effects with glaucoma therapy
M. Kahook

This symposium has been made possible by an educational grant from Alcon

1.15–2.30 p.m. BREAK AND VISIT TO THE EXHIBITION

Organized by The Hippocrates Glaucoma Foundation

30
FRIDAY JULY 10, 2009

2.30–3.30 p.m. PARALLEL SYMPOSIA

2.30–3.30 p.m. Ballroom A

S06 Glaucoma disability
Chairs: R. Varma, A. Viswanathan
Presenters: A.L. Coleman, H.D. Jampel, G. Spaeth

Driving cessation and driving limitation in glaucoma: The Salisbury Eye Evaluation Project (S06.1)
Y. Ramula

2.30–3.30 p.m. Ballroom B

S07 Low-pressure glaucoma
Chairs: T. Krupin, K. Sugiyama

Introduction: Changing definition of open-angle glaucoma
T. Krupin
Differential diagnosis; evaluation nonglaucoma diseases
D.S. Greenfield
Pathogenesis and systemic evaluation
P. Tanna
IOP-lowering treatment
J.M. Liebmann
Treatment beyond IOP reduction
T. Krupin

2.30–3.30 p.m. Ballroom C

S08 Glaucoma management non-industrialized world
Chairs: R. Thomas, N. Wang
Panel: N. Congdon, E. Maul, T. Shaarawy

Introduction
R. Thomas
Training
J. Standefer

www.worldglaucoma.org
FRIDAY JULY 10, 2009

Role of NGO’s in glaucoma care
K. Ben Amor
Is the pattern of disease different?
N. Congdon
Diagnosis: Should the approach be different?
E. Maul
Out of Africa
T. Shaarawy
Treatment: Should the approach be different?
R. Sihota
Solutions and Conclusion
N. Wang

2.30–3.30 p.m. Room 302

S09 Integrative eye care for glaucoma
Chairs: R. Ritch, L. Ventura

Curcumin as an anti-inflammatory in glaucoma
R. Ritch
Psychoneuroimmunology and glaucoma
L. Ventura
Lymphocytes and glaucoma
M. Schwartz
Wolfberry and glaucoma
K.F. So
Cytokines and glaucoma
C. Zhang
Immune-regulatory pathways relevant to glaucoma
M. Wax

2.30–3.30 p.m. Room 304

S10 Innovative approaches for protecting the retinal ganglion cells
Chairs: H. Quigley, H. Verbin-Levkovitch
Panel: P. Kaufman, L. Levin, G. Tezel, J. Lindsey

Altering the sclera to treat glaucoma
H. Quigley

Organized by The Hippocrates Glaucoma Foundation
FRIDAY JULY 10, 2009

Stem cell therapy for glaucoma – dreams and reality
H. Verbin-Levkovitch

Preventing axonal degeneration in glaucoma – barriers and hopes
K.R.G. Martin

Axonal regeneration – the key to therapeutic advancement
S. Thanos

The mitochondria in glaucoma – how to protect them from elevated IOP
C. Grosskreutz

2.30–3.30 p.m. Room 306

S11 Meeting the challenge of preventing blindness from Open-Angle Glaucoma in people of African heritage
Chairs: E.J. Higginbotham, L. Pasquale

Race versus ethnicity versus ancestry: Does it matter?
E.J. Higginbotham

Case presentation
C. Okeke

The epidemiology of open-angle glaucoma in people of African descent
R. Bourne

Managing glaucoma on the African continent
A. Ashaye

What do randomized clinical trials tell us about managing glaucoma in people of African origin?
D.S. Friedman

Challenges finding the genes for POAG in people of African origin.
M. Hauser

Synopsis of the problem and future strategies
R. Wilson

3.30–4.00 p.m. BREAK AND VISIT TO THE EXHIBITION
FRIDAY JULY 10, 2009

4.00–5.20 p.m. FREE PAPER SESSION

4.00–5.10 p.m. Room 202

Free paper Session – Clinical Science

4.00–4.10  
**FPCS1** – Comparison of stereo disc photos and alternation flicker using a novel matching technology for detecting glaucomatous changes in the optic disc  
M. Radcliffe

4.10–4.20  
**FPCS2** – Re-training on the assessment of optic nerve head photographs for the glaucoma diagnosis  
S. Andersson

4.20–4.30  
**FPCS3** – Optic disc morphology using HRT versus clinical examination  
C. Loon

4.30–4.40  
**FPCS4** – Pre-perimetric detection of glaucoma: a blue-on-yellow multifocal VEP study  
H. Arvind

4.40–4.50  
**FPCS5** – Prevalence of glaucoma and ocular hypertension in a rural adult Chinese population: The Handan Eye Study  
Y.B. Liang

4.50–5.00  
**FPCS6** – Changes in mean deviation in people with glaucoma – A decision analytic model from the CIGTS, OHTS, and AGIS trials (COA changes in MD model)  
S.M. Kymes

5.00–5.10  
**FPCS7** – Structure-function relationship between spectral-domain optical coherence tomography (SD-OCT) parameters and pattern electroretinogram (PERG) recordings in glaucomatous eyes  
G. Vizzeri

5.10–5.20  
**FPCS8** – (D17.01) Computerized imaging and measurement of episcleral venous pressure  
A. Sit

Organized by The Hippocrates Glaucoma Foundation
4.00–6.15 p.m. PARALLEL COURSES

4.00–5.00 p.m. Room 203

CO-17 GL Health economics
S. Kymes (chair), R. George

4.00–5.00 p.m. Room 210

CO-18 How to detect progression and use it to manage glaucoma
B. Chauhan (chair), A. Heijl, (chair), D. Garway Heath, B.E. Prum, L. Zangwill, A. Boehm

4.00–5.00 p.m. Room 302

CO-19 Advanced optic nerve imaging (HRT, GDX, OCT)
C.K.S. Leung (chair), J. Schuman (chair), R. Burk, M. Fingeret, H.G. Lemij, G. Wollstein

4.00–5.00 p.m. Room 304

CO-20 Secondary angle-closure glaucoma: diagnosis and management
G. Gazzard (chair), L. Vijaya (chair), S. Asawaphureekorn, K. Park, H. Sakai

4.00–5.00 p.m. Room 306

CO-21 Principles of medical therapy in glaucoma practice
R. Fechtner (chair), S. Miglior (chair), M. Aquino, N. Aquino, Y. Lachkar, G. Skuta, H. Tanihara, J. Thygesen

4.00–5.00 p.m. Room 309

CO-22 Filtering surgery: penetrating / nonpenetrating / implants
D.K. Heuer (chair), R. Carassa, S.K. Fang, P. Netland, T. Shaarawy

4.00–5.00 p.m. Room 310

CO-23 Pediatric glaucoma surgery
A.K. Mandal (chair), D. Walton (chair), T.C. Chen, Ch.L. Ho, P. Khaw

www.worldglaucoma.org
FRIDAY JULY 10, 2009

4.00–5.00 p.m. Room 311

CO-24 Electronic Medical Records
M. Lim (chair), C. Mattox (chair), J. Schuman

5.00–5.15 p.m. BREAK AND VISIT TO THE EXHIBITION

5.15–6.15 p.m. Room 202

CO-25 Experimental models in glaucoma
S. John (chair), F. Grus (chair), M. Honjo, M.B. Wax, L. Wheeler

5.15–6.15 p.m. Room 203

CO-26 Gonioscopy and imaging for chamber angle evaluation
T. Dada (chair), P.T.K. Chew, C.K.S. Leung, C. Hartleben, G. Marchini

5.15–6.15 p.m. Room 210

CO-27 Assessment of bloodflow in glaucoma
M. Araie (chair), A. Harris (chair), G. Michelson, L. Schmetterer, L. Kagemann, A. Tomidokoro

5.15–6.15 p.m. Room 302

CO-28 Maximum medical therapy
M. Diestelhorst (chair), G. Holló (chair), A. Brooks, S. Gandolfi, A. Hommer, G. Schwartz

5.15–6.15 p.m. Room 304

CO-29 Neuroprotection and apoptosis of retinal ganglion cells related to glaucoma
N. Gupta (chair), K. Martin (chair), M.F. Cordeiro, M. Schwartz, J. Tsai

Organized by The Hippocrates Glaucoma Foundation
FRIDAY JULY 10, 2009

5.15–6.15 p.m. Room 306

CO-30 Decision-making after failed trabeculectomy  
R. Carassa (chair), S.J. Gedde (chair), K. Barton, Y.M. Buys, K. Ishida, D.S. Minckler

5.15–6.15 p.m. Room 309

CO-31 Cyclophotocoagulation – why, when and how?  
P. Bloom (chair), S. Lin (chair), F.S. Mikelberg, B. Shields, R. Susanna Jr

5.15–6.15 p.m. Room 310

CO-32 Anti-VEGf therapy for glaucoma  
E. Blumenthal (chair), J.B. Jonas (chair), M. Kahook, J.R. Piltz-Seymour, T. Wong

7.00–11.00 p.m. WGC BANQUET IN THE BOSTON PUBLIC LIBRARY
SATURDAY JULY 11, 2009

8.30 a.m.–12.00 p.m. Room 210

WGC Film Festival
Please see page 51 for the list of video’s to be shown.

8.30 a.m.–12.00 p.m. DIDACTIC MORNING SESSIONS

8.30–10.00 a.m. Auditorium

D16 Video Session Glaucoma Surgery
Chairs: A.S. Crandall, D. Lam

8.30–8.38 D16-03 Gold shunt
I. Ahmed

8.38–8.46 D16-04 Eye pass
R.H. Brown

8.46–8.54 D16-05 Trabectome
G.P. Condon

8.54–9.02 D16-06 Angle closure goniosynechiae
N. Congdon

9.02–9.10 D16-07 ExPress shunt
L.W. Herndon, Jr

9.10–9.18 D16-08 Trab closure
P. Khaw

9.18–9.26 D16-09 Trap flap and punch or cut of trab
D. Rhee

9.26–9.34 D16-10 Glaucos shunt
T. Samuelson

9.34–9.42 D16-11 Canaloplasty
M. Tetz

9.42–9.50 D16-12 ALPI, paracentesis, and corneal indentation for APAC
D. Lam

Organized by The Hippocrates Glaucoma Foundation
SATURDAY JULY 11, 2009

8.30–10.00 a.m. Ballroom A

D17 Uveoscleral outflow
Chairs: A. Sit, E. Tamm

8.30–8.40 D17-01 Measurement of uveoscleral outflow in humans A. Sit
8.40–8.47 D17-02 Morphology of the uveoscleral pathway E. Tamm
8.47–8.54 D17-03 Animal models of uveoscleral outflow J. Lindsey
8.54–9.01 D17-04 Is uveoscleral outflow altered in glaucoma? C. Toris
9.08–9.15 D17-05 Future therapy for uveoscleral outflow L. Wheeler
9.15–9.22 D17-07 Evidence of a uveolymphatic outflow pathway in the eye N. Gupta

8.30 a.m.–10.00 a.m. Ballroom B

D18 New ideas in medical treatment
Chairs: M. Araie, P.L. Kaufman

8.30–8.39 D18-02 Topical instillation: Is it possible to cause local pharmacologic effects in the ipsilateral posterior fundus of an eye by local penetration? M. Araie
8.39–8.48 D18-03 Update on cytoskeletal approaches to glaucoma therapy P.L. Kaufman
8.48–8.57 D18-04 The calcium hypothesis of glaucomatous neurodegeneration D. Calkins
8.57–9.06 D18-05 The use of antibiotics in glaucoma S. John
9.06–9.15 D18-07 Considerations for treatments directed at ganglion cell survival R. Nickells

www.worldglaucoma.org
SATURDAY JULY 11, 2009

10.00–10.30 a.m. BREAK AND VISIT TO THE EXHIBITION

10.30 a.m.–12.00 p.m. Auditorium

**D19 WGA-ASCRS Video session Glaucoma & Cataract**  
*Chairs: R.H. Brown, T. Shaarawy, B. Shingleton*

- **10.30–10.40 D19-01**  
  *Conquering angle closure with cataract surgery ± goniosynechialysis*  
  *R.H. Brown*

- **10.40–10.50 D19-02**  
  *Phako-deep sclerectomy*  
  *T. Shaarawy*

- **10.50–11.00 D19-03**  
  *Late IOL dislocation: The real deal*  
  *G.P. Condon*

- **11.00–11.10 D19-04**  
  *Weak zonules, small pupils, and other cataract challenges in glaucoma patients*  
  *A.S. Crandall*

- **11.10–11.20 D19-05**  
  *IOP fluctuations post cataract and postglaucoma surgery*  
  *A.G. Konstas*

- **11.20–11.30 D19-06**  
  *Combined surgery*  
  *T. Samuelson*

- **11.30–11.40 D19-07**  
  *Pseudoexfoliation: Tips for successful cataract surgery*  
  *B. Shingleton*

- **11.40–11.50 D19-08**  
  *Phako surgery for CACG cases*  
  *D. Lam*

10.30–11.15 a.m. Ballroom A

**D20 Improving outcomes in GL minimize negative impact**  
*Chairs: F. Grehn, H. Quigley*

- **10.30–10.37 D20-01**  
  *Avoiding surgical complications: How to achieve the best long-term filtering bleb*  
  *F. Grehn*

- **10.37–10.44 D20-02**  
  *Like adding another drop, and it’s (almost) free: Improving adherence*  
  *H. Quigley*

Organized by The Hippocrates Glaucoma Foundation
SATURDAY JULY 11, 2009

10.44–10.51  D20-03  Is chamber angle imaging predictive of future angle closure?
D.E. Grigera

10.51–10.58  D20-04  Avoiding surgical complications: How to minimize tube-shunt problems
R. Parrish

10.58–11.05  D20-05  The impact of glaucoma on quality of life: Driving, reading, mobility
P. Ramulu

11.05–11.12  D20-06  After the iridotomy, how to improve angle closure outcomes
R. Sihota

11.15 a.m.–12.00 p.m. Ballroom A

D21 Genetics
Chairs: S. Chakrabarthis, J. Wiggs

11.15–11.25  D21.1  The role of the nitric oxide synthase 3 gene in primary open-angle glaucoma. A population-based assessment incorporating environmental exposure data
L.R. Pasquale

11.25–11.32  D21-01  CYP1B1 haplotypes in POAG and PACG
S. Chakrabarthis

11.32–11.39  D21-02  Genetic risk factors for pseudoexfoliation
J. Wiggs

11.39–11.46  D21-03  Update on POAG genes
R.R. Allingham

11.46–11.53  D21-04  Familial cavitary optic disk anomalies
W. Alward

11.53–12.00  D21-05  Genes contributing to low-tension glaucoma
C. Pang

12.00–12.07  D21-06  Clinics and genetics of the myocilin ASN480LYS glaucoma mutation in a family of andean descent
R. Perez Grossman

10.30 a.m.–12:00 p.m. Ballroom B

D22 Aqueous Drainage Devices
Chairs: K. Barton, K. Singh

10.30–10.37  D22-03  How I choose a drainage device
V.P. Costa

www.worldglaucoma.org
World Glaucoma Congress, July 8-11, 2009

SATURDAY JULY 11, 2009

10.37–10.44 D22-04 Update on the Tube vs Trabeculectomy Study
S.J. Gedde

10.44–10.51 D22-05 Indications for glaucoma drainage device implantation
B.T. Hutchinson

10.51–10.58 D22-06 Complications of drainage device implantation
P. Netland

12.00–1.30 p.m. LUNCH AND VISIT TO THE EXHIBITION

1.30–2.30 p.m. PARALLEL COURSES

1.30–2.30 p.m. Room 202

CO33 Understanding the genetic basis of glaucoma: Its role in clinical practice
W. Alward (chair), J. Wiggs (chair), R.R. Allingham, S. Chakrabarti, J. Craig, D. Mackey, C. Pang, S. Bhattacharija

1.30–2.30 p.m. Room 203

CO34 Advances in psychophysical testing for glaucoma patients
R. Harwerth (chair), Ch.A. Johnson (chair), M. Fingeret, J.G. Flanagan, A. Iwase, R.L. Stamper

1.30–2.30 p.m. Room 210

CO35 Stereoscopic optic disc viewing: Top-ten pitfalls in identifying glaucoma damage and progression
A. Zalta

1.30–2.30 p.m. Room 302

CO36 Management of glaucoma in presence of other ocular disease
M. Helal (chair), R. Mills (chair), G. Tomita, A.D. Beck, J.A.A. Giaconia, M. Irkec, B. Mani

Organized by The Hippocrates Glaucoma Foundation
### SATURDAY JULY 11, 2009

**1.30–2.30 p.m. Room 306**

**CO38 Filtering surgery: Novel techniques**  
I. Ahmed (chair), F. Lerner (chair), F. El-Sayyad, S.D. Vold

**1.30–2.30 p.m. Room 309**

**CO39 Managing cataract and glaucoma**  
D. Lam (chair), B. Shingleton (chair), A.S. Crandall, M. Sherwood

### 2.45–3.45 p.m. CLOSING SYMPOSIUM

- **3.00–3.10**  
  What I learned from OHTS  
  M. Kass

- **3.10–3.20**  
  What I learned from EMGT  
  A. Heijl

- **3.20–3.50**  
  Poster recognitions

- **3.50–4.00**  
  The future of the World Glaucoma Association  
  R. Susanna Jr

### 4.00–5.00 p.m. FAREWELL RECEPTION AT THE HYNES CONVENTION CENTER
GLOBAL ASSEMBLY

The WGA unites 75 Glaucoma Societies. The larger regions are represented by the regional Glaucoma Societies in the General Assembly (e.g., the European Glaucoma Society represents the national Glaucoma Societies in Europe). The Global Assembly of Glaucoma Societies is organized every two years at the occasion of the World Glaucoma Congress. Representatives of all national and regional Glaucoma Societies (see page 113) get together during this major event to discuss topics of interest at a global glaucoma level. The Global Assembly is a unique occasion for representatives of the world Glaucoma Societies to meet each other. Since 2007, 11 additional Glaucoma Societies/Groups/Sections have joined the WGA.

Highlights from the Global Assembly agenda:

○ Introduction of new Glaucoma Societies since WGC-2007
○ The World Glaucoma Association in 2009
○ International Glaucoma Research
○ Glaucoma Societies
○ Glaucoma Patient Organizations
○ World Glaucoma Day
○ Consensus & Promulgation

Organized by The Hippocrates Glaucoma Foundation
SCIENTIFIC PROGRAM – HIGHLIGHTS

This meeting
After the highly successful World Glaucoma Congress in Vienna, 2005 and Singapore 2007, some adaptations were made to the program, largely based on the request from the faculty and participants. The Scientific Program is based upon the following principles:

- Excellent surgical sessions
- More video surgical activity
- Grand Rounds
- Glaucoma Patient Organization Course: how to organize/interact with GPO

Symposia and Debates on hot issues
These one-hour sessions have been introduced to cover the need for representation of various viewpoints on these issues and to provide the audience with an idea what future developments can be expected. The parallel Symposia and Debates present a large choice of topics in order to satisfy the divergent needs and interest of the audience.

Target Groups
The WGC targets the Glaucoma Specialist as well as the General Ophthalmologist and Optometrist who after all takes care of most of the glaucoma patients.

Guidance through the program
The WGC participants will find a majority of parallel sessions and a few solo sessions. The solo sessions are:

- Opening
- Plenary Lunch Symposia
- Closing

Opening Session and Lectures
The Opening Session will present a perspective of the position of Boston in the world and the Global WGA Award.

www.worldglaucoma.org

45
Didactic Sessions

The lectures of the Didactic Morning Sessions are a selection of topics highlighted by the world’s glaucoma experts, that form a continuum with the courses and parallel symposia. Many of the topics introduced in the didactic lectures will come back in courses where extensive interaction will be possible.

Consensus updates

The WGA proudly presents the result of its Consensus Meetings. Five topics have been published in books (by Kugler Publications, Amsterdam):

○ 2003: Structure and Function
○ 2005: Surgery Open-Angle Glaucoma
○ 2006: Angle-Closure Glaucoma
○ 2007: IOP
○ 2008: Screening
○ 2009: Blood Flow (available at WGC-2009)

Updates of these Consensus Meetings will be presented at the WGC in Sessions D13 on Bloodflow.

Guidelines on Reporting and Publishing of Results of Glaucoma Surgery

After the Consensus Meeting on Surgery of Primary Open-Angle Glaucoma, the need was felt to unify the way in which surgical results are presented in reports and publications. Only through a unified reporting strategy, it will be possible to compare results of different studies. A special global WGA subcommittee worked with great energy on this issue and they will present the results at this WGC during Session D13.

Plenary Lunch Symposia

The WGC Platinum sponsors of the World Glaucoma Congress have been given the opportunity to organize a plenary midday symposium. This symposium will be part of the Scientific Program and as such will fall under the full responsibility of the Program Committee.

The 11 Symposia on Thursday and Friday were especially created for this meeting. There aim is to provide in one hour the various viewpoints on hot issues. The participants should leave the Symposia and Debates with a fair impression of the dominant line of thought on these issues. As there will be 11 parallel Symposia on Thursday and Friday, there will be something of interest for each participant. The symposia are planned for all participants.

The Courses have the usual course format with ample possibilities for discussion. This will allow participants to attend six of the courses of their choice during the congress including several popular courses.

Posters

Posters are an excellent and important way of providing scientific information. The WGA is making an effort to provide high visibility for the posters. The posters will be on from Wednesday, July 8, noon until Saturday, July 11, 1.00 p.m.

Poster Mounting and Removing

Posters should be mounted on Wednesday, July 8, between 8.00 a.m. and noon. Assistance and material for mounting the
Posters will be available from 8.00 a.m. at the Poster desk in the Poster area. Posters should be removed after 1.00 p.m. and before 3.00 p.m. on Saturday, July 11. Posters that have not been taken down by the author(s) will be removed and destroyed by the Congress Organizer.

**Poster Recognitions**
During the Closing Ceremony, the Poster Committee will announce the three best posters which will receive the World Glaucoma Congress Poster Recognition.

**Special Attention Flags**
Apart from the selection of posters for Recognition, the Poster Committee will give special attention flags to posters that have caught the special attention of the members of the Poster Committee, other than those selected for the poster session.

**Glaucoma Society Posters**
In 2007, all Glaucoma Societies were asked to present a poster about their society. This year, the Program Committee asked Glaucoma Societies to create a follow-up to the highly successful Glaucoma Society poster presentation during the WGC in 2007. These Glaucoma Society Posters describe the major achievements of the Glaucoma Society between July 2007 and July 2009 including meetings, best research, awards, publication, scientific interaction with other WGA member societies, and promulgation.

**Discussions and Interactive Questions**
The WGC will have the following types of discussions:
- Panel discussions during Surgical Grand Rounds and Surgical Videos
- During courses
- During debates

In addition to the discussions there will be frequent interactive questions (IQA) during most of the sessions, in order to give the participants the opportunity to express their opinion on several issues discussed at the WGC.

**Language**
English.

**Quality of Evidence; Global WGA Guidelines on Reporting and Publishing, and on Quality and Quantity of Glaucoma Meetings**
From the beginning, the WGA has emphasized the importance of scientific quality of its presentations and discussions. It has therefore published two reports that deal with these quality aspects: Global WGA Guidelines on Reporting and Publishing, and Global WGA Guidelines on Quality and Quantity of Glaucoma Meetings. The WGC will be an exercise in maintaining these ambitious levels. For reports see www.worldglaucoma.org. For Quality of Evidence, the WGC has adapted the Minckler – AAO Quality of Evidence levels:

**Level I:** (Interventional) Evidence obtained from at least one properly done, well-designed, randomized, controlled trial or meta-analyses of high-quality, randomized, controlled trials. (Observational) Evidence obtained from well-done population-based prevalence or incidence studies.
Level II: (Interventional) Evidence obtained from well-done, non-randomized, comparative trials or well-done, systematic literature reviews summarizing primarily level II publications. (Observational) Evidence obtained from high quality case-control and cohort studies.

Level III: (Interventional or Observational) Evidence obtained from non-comparative case series, case reports, and expert or consensus opinion.

○ The overall level of evidence rating cannot exceed that of the individual studies reviewed. All literature assessed is assumed to be peer reviewed.

Glossary Case-control study
An observational (non-interventional, usually retrospective) study that begins by identifying individuals with a disease (cases) for comparison to individuals without a disease (controls or reference group), in which analysis proceeds from effect to cause.

Case report
Usually a retrospective report of a single interventional or observational case experience, often with clinical-pathological correlation.

Case series
Case series include those studies describing more than one consecutive or nonconsecutive cases, studied retrospectively or prospectively, usually with regard to the outcome of an intervention for its efficacy, safety, and complications. Non comparative case series generally have no control group included, but the outcome may be compared to that in the literature.

Cohort study
An observational study that begins by identifying individuals with (study group) and without (control group) a factor being investigated to observe over time with regard to disease outcome; study and control groups may be concurrent or nonconcurrent, but must be derived from the same well defined cohort; almost always prospective with regard to data collection. Almost always longitudinal in that a particular group of patients is followed forward from a point in time. May or may not be population based.

Comparative study
A study including two or more defined groups, compared to each other, to make a judgment about the influence of some factor or treatment.

Cross-sectional study
An observational study that identifies individuals with and without the condition or exposure being studied at the same time (synonymous with prevalence study). May or may not be population-based.

Interventional study
A study that includes an attempt to alter the course of disease by medical or surgical or other therapy.

Observational study
A study without intervention or attempt to alter the natural course of disease or physical condition.

Organized by The Hippocrates Glaucoma Foundation
Audio Visual Support / Speaker Ready Room
The Speaker Ready Room will be open on the following days and hours:

- Wednesday, July 8: 7.00 a.m.–6.00 p.m.
- Thursday, July 9: 7.00 a.m.–6.00 p.m.
- Friday, July 10: 7.00 a.m.–6.00 p.m.
- Saturday, July 11: 8.00 a.m.–4.00 p.m.

Equipment to enable a final check to be made for your presentation is available in the Speaker Ready Room.

Power Point presentations: we strongly advise you to bring your presentation to the Speaker Ready Room AT LEAST 3 HOURS BEFORE the start of your lecture.
Please note that there are no facilities to use laptops in the session rooms.

Travel Grants
The WGA has granted close to 60 travel grants, which include waiving of the registration fee, to glaucoma clinician scientists under forty years of age who have demonstrated a special interest in glaucoma.

Continuing Medical Education Meeting Evaluation
It is essential for assessing the quality of the WGC that participants take time to complete the evaluation forms. Every participant can have an impact on the planning for the next WGC. The WGA has purposely created this elaborate evaluation system in order to provide the participants with an even better congress in two years. Your input is highly appreciated.

Relationship with Glaucoma Industry Members
The WGA has deliberately chosen for a close contact with Glaucoma Industries. It is realized that Glaucoma Industry is an important force in the world of glaucoma, both in research as well as in education. The WGA aims to improve science and care of glaucoma in cooperation with its Glaucoma Industry Members. In joint committees the WGA has established rules for the relationship with industry:
- WGA Code of Practice
- WGA Guidelines on Reporting and Publishing
- WGA Guidelines of Quality and Quantity of Glaucoma Meetings

These guidelines follow the trend in specialist-industry relationship as expressed in the scientific literature, while focusing on the special aspects related to the WGA organization.

Industry Involvement Excerpt from Global WGA Guidelines on Quality and Quantity of Glaucoma Meetings
1. The WGA encourages appropriate interactions between glaucoma specialists and glaucoma industry. It encourages partnership with glaucoma industry in conducting meetings of the highest scientific quality while fostering quality professional relationships.
2. All presentations on new industry
scientific findings should be within the official scientific program of the meeting and as such reviewed by the scientific program committee.

3. Proposals for lectures or a group of lectures made by industry will be treated as any other proposal to the scientific program committee. Such proposals should be purely scientific and balanced, i.e., not promotional. The opportunity to propose topic and speaker does not imply a right to have them on the program. There will be competition with other proposals for the program. They will not be called industry sponsored symposia.

4. It was also agreed that industry opportunities for scientific presentations would be either within the official scientific program and under the full responsibility of the scientific program committee as mentioned above, for outside the scientific program and under the responsibility of industry. Other options are not recommended. It is the duty of the (co-)chair(s) of Industry Sponsored Symposia to ensure that material presented by speakers, panelists or discussants is either evidence based or has consensus and that regional differences are recognized (statements regarding care in country A may have limited validity for country B). One co-chair of the Symposium will be appointed by the Program Committee (as for all other sessions) in concert with the sponsor. The chairs of all sessions represent the best thinking of the WGA. The audience may place a higher value on presentations scientifically scrutinized than presentations with a commercially sponsored flavor. Even when so-called sponsored symposia are organized under industry responsibility, such symposia should still have a high quality level, as neither the Program Committee nor the individual sponsor will benefit from mediocre, clearly promotional symposia. Regarding sponsored symposia, parties agreed that competing events should be avoided for the major symposia. For organizational reasons industry sponsored symposia may be scheduled in concert with the Program Committee.

5. Appropriate scientific agenda scheduling will be part of the task of the program committee.

6. A checklist for essential requirements for abstracts will be used.

7. Rejection of abstracts will be based on the list of ‘Reasons for Rejection’.
Film Festival Show Dates: Thursday July 9, Friday July 10 and Saturday July 11
Venue: Room 210

8.30–8.38 and 10.00–10.08
VS01 Is the angle open or closed? A video guide to modern gonioscopy (8 minutes)
L. Liu

8.39–8.46 and 10.09–10.16
VS02 Excimer laser trabeculostomy (ELT) (6.33 minutes)
M. Berlin

8.47–8.55 and 10.17–10.25
Third Prize
VS03 Substantial reduction of intraocular pressure by a modified 360-degree trabeculotomy in adult primary and secondary open-angle glaucoma (7.59 minutes)
S. Chin

8.56–9.04 and 10.26–10.34
VS04 Management of an advanced case of congenital glaucoma with trabeculotomy with trabeculectomy with mitomycin c (7.58 minutes)
S. Dubey

9.05–9.13 and 10.35–10.43
VS05 Comprehensive approach to glaucoma implants in keratoprosthesis (7.55 minutes)
V. Thasarat

9.14–9.22 and 10.44–10.52
First Prize
VS06 Revisiting needling for failed blebs (7.39 minutes)
D. Lam

www.worldglaucoma.org
World Glaucoma Congress, July 8-11, 2009

9.23–9.25 and 10.53–10.55
VS07  Ab internal tube trimming in Ahmed valve implant (1.58 minutes)
       J. Jimenez-Roman

9.26–9.34 and 10.56–1.04
Second Prize
VS08  New technique of phaco surgery in a small pupil (8.09 minutes)
       B.S. Fyodorov

9.35–9.43 and 11.05–11.13
VS09  Training to tackle glaucoma in developing world – the Shaolin Temple approach (7.26 minutes)
       M. Kumar

9.44–9.51 and 11.14–11.21
VS10  Combating glaucoma blindness – reaching the undetected (6.21 minutes)
       M. Kumar

Organized by The Hippocrates Glaucoma Foundation

52
Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). He has written approximately 1,050 articles. He also has approximately 750 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history.

He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995–2002 and as its Chairman from 1999 - 2002.

Dr. Langer has received over 170 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers and the 2008 Millennium Prize, the world’s largest technology prize. He is the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008), the Prince of Asturias Award for Technical and Scientific Research (2008) and the University of California – San Francisco Medal (2009). In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine.” In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction. Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover Magazine (2002) named him as one of the 20 most important people in this area. Forbes Magazine (2002) selected Dr. Langer as one of the 15 innovators world wide who will reinvent our future. Time Magazine and CNN (2001) named him as one of the 100 most important people in America and one of the 18 top people in science or medicine in America.
(America’s Best). Parade Magazine (2004) selected Dr. Langer as one of 6 ‘Heroes whose research may save your life’. Dr. Langer has received honorary doctorates from the Mt. Sinai School of Medicine, Yale University, the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), the University of Liverpool (England), the University of Nottingham (England), Albany Medical College, the Pennsylvania State University, Northwestern University and Uppsala University (Sweden). He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

Robert C. Merton

Robert C. Merton is the John and Natty McArthur University Professor at the Harvard Business School. He is past President of the American Finance Association, a member of the National Academy of Sciences, and a fellow of the American Academy of Arts and Sciences. In 1993, he received the inaugural Financial Engineer of the Year Award from the International Association of Financial Engineers. In 1997, Professor Merton received the Alfred Nobel Memorial Prize in Economic Sciences with Myron Scholes for a new method to price derivative securities. A former senior advisor to Salomon Inc. and J.P. Morgan and a co-founder and principal of Long-Term Capital Management, Professor Merton is currently the developer of SmartNest, a pension management system that addresses deficiencies associated with traditional defined-benefit and defined-contribution plans. He serves as Chairman of Daedalus Software, Inc., a Cambridge based bio-informatics Company with transplant and research bio-bank software applications. Professor Merton is also a board member, Vical, Inc., which researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Professor Merton holds a B.S. in Engineering Mathematics from Columbia University, an M.S. in Applied Mathematics from California Institute of Technology and a Ph.D. in Economics from Massachusetts Institute of Technology. He holds honorary degrees from the University of Chicago, Claremont Graduate University, and seven foreign universities. [http://www.people.hbs.edu/rmerton/]

Organized by The Hippocrates Glaucoma Foundation
Manuel B. Agulto, MD
Affiliation: Director, Institute of Ophthalmology, University of the Philippines, Manila, Philippines.
Research interest: Glaucoma.

Ike Ahmed, MD, FRCSC
Affiliation: Professor, University of Toronto, Toronto, Ontario, Canada. Fellowship Director, Glaucoma and Anterior Segment Surgery (GAASS) Fellowship, University of Toronto, Research Fellowship Director, University of Toronto, Department of Ophthalmology and Vision Sciences.

Makoto Aihara, MD, PhD
Affiliation: Assistant Professor in Department of Ophthalmology, University of Tokyo, Japan
Areas of Interest: In basic glaucoma research animal glaucoma model especially in mouse, mechanism of IOP especially related to prostaglandins, and neuroprotection. To apply mouse eyes for glaucoma, our group has sent out basic information as to IOP including diurnal variation, aqueous humor dynamics, IOP reduction by drugs. Now pharmacological research is conducted using various transgenic mice. Also, various neuroprotective agents are investigated using in vivo rodent models and in vitro purified RGC and Muller cell culture under various stresses. My goal is to clarify the mechanism of IOP and IOP reduction, and to develop new neuroprotective drugs and ocular hypotensive drugs. My clinical research interests are medical and surgical therapy, especially about trabeculectomy and bleb formation.

Jorge Alvarado, MD
Affiliation: Professor of Ophthalmology, University of California San Francisco (UCSF). Dr. Alvarado received his undergraduate, medical school, specialty, and sub-specialty training at the University of California, in Berkeley and San Francisco. Over 30 years ago, he became the first full-time glaucoma specialist at UCSF.
Areas of Interest: Pathogenesis of glaucoma; Primary Open Angle glaucoma; congenital glaucoma; pigmentary glaucoma; steroid glaucoma; aqueous outflow; cultured endothelial cells of the trabecular meshwork and Schlemm’s canal; macrophage/monocyte regulation of aqueous outflow; cellular/molecular regulation of aqueous outflow; glaucoma surgery; aqueous outflow regulation by adrenergic agents; Viral etiology of the Irido-corneal endothelial (ICE) syndrome; phenotype, genotype correlation in congenital glaucoma; Ahmed valve; argon and selective laser trabeculoplasty; endoscopic cyclophotocoagulation; cytokine secretion by endothelial cells of aqueous outflow pathway; regulation of intercellular junction assembly/disassembly by cytokines and monocytes. Cell-to-cell signaling and the cellular and molecular basis for the regulation of aqueous outflow in the eye. This cell signaling mechanism is of great potential for the development of novel glaucoma therapies.

Wallace Alward, MD
Affiliation: Frederick C. Blodi Chair in Ophthalmology; Professor and Vice-Chairman; Director, Glaucoma Service; University of Iowa Carver College of Medicine.
Areas of Interest: The molecular genetics of glaucoma; Pigmentary glaucoma; Normal tension glaucoma; Axenfeld-Rieger syndrome; Gonioscopy.

www.worldglaucoma.org
Leadership positions: Director, American Board of Ophthalmology; Head, Membership Committee, Glaucoma Research Society; Editorial Board, International Glaucoma Review.


Mario Aquino, MD, DPBO

Leading positions: Founding Member of the Philippine Board of Ophthalmology, Founder and Emeritus President, Philippine Glaucoma Society, Founding Member Philippine Implant & Refractive Surgery, Member, Philippine Medical Association, Founding Member, Southeast Asia Glaucoma Interest Group (SEAGIG), Chairman: Examination Committee, Philippine Board of Ophthalmology, Member, Editorial Board, Asian Journal of Ophthalmology, Diplomat: Philippine Board of Ophthalmology, Member: Philippine Academy of Ophthalmology, Member: Vitreo-Retinal Society of the Philippines, Member, Philippine Society of Cataract & Refractive Surgery, International Member: American Academy of Ophthalmology, Director: Mabuhay Deseret Foundation.

Special Honors: Most Outstanding Educator, Philippine Academy of Ophthalmology.

Norman Aquino, MD
Affiliation: Clinical Associate Professor, Department of Ophthalmology, University of the Philippines, Philippine General Hospital; Assistant Chief at the University of the Philippines-Philippine General Hospital.

Areas of interest: Glaucoma including visual field testing, imaging, treatment modalities of refractive glaucoma, pediatric glaucoma, and glaucoma education and training.

Leadership positions: Immediate-Past President of the Philippine Glaucoma Society. He is also an examiner of the Philippine Board of Ophthalmology. He was a founding member of the Philippine Glaucoma Society, and was a member of the Executive Council of the Philippine Academy of Ophthalmology. He is also Clinical Instructor at the Ateneo de Manila University School of Medicine and Public Health. Dr. Aquino currently serves as Chief of the Glaucoma Service at the American Eye Center and the Cardinal Santos Medical Center, and as Dr. Aquino continues to serve as invited speaker and resource person in many local and regional meetings and scientific fora.

Makoto Araie, MD, PhD
Affiliation: Professor and Chairman, Department of Ophthalmology, The University of Tokyo Graduate School of Medicine.

Areas of Interest: Glaucoma, Normal-tension glaucoma, Ocular blood flow, Ocular pharmacokinetics, Neuroprotection.

Special Honors: Suda Prize from Japan Glaucoma Society, 1992; Alcon Research Institute’s Award; 1993; Japanese Ophthalmological Society; Council Award, 1994.

Publications: More than three hundred papers in peer reviewed international journals.


Somkiat Asawaphureekorn, MD MSc (Clinical Epidemiology)
Affiliation: Assistant Professor, Chief of Glaucoma Unit, Department of Ophthalmology, Siriraj Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Areas of Interest: Diagnosis and treatment of angle closure glau-
George Baerveldt, MD, FFFCS (SA)

Mr. Keith Barton, MD FRCP FRCS FRCOphth
Affiliation: Glaucoma Service Director & Consultant Ophthalmologist, Moorfields Eye Hospital, London. Honorary Senior Lecturer, Department of Epidemiology, Institute of Ophthalmology, University College London. For further information please see: www.keithbarton.co.uk/about.htm. Areas of Interest: Surgical management of glaucoma. Pathogenesis and management of uveitic glaucoma.

Christophe Baudouin, MD, PhD (France)
Affiliation: Professor of Ophthalmology since 1995, Head of the Department of Ophthalmology, Ambroise Paré Hospital, APHP, University of Versailles, and Head of the Department III of Quinze-Vingts National Ophthalmology Hospital, Paris. Director of Ocular Immunotoxicology Unit, Vision Institute, INSERM UMRS968, University Paris 6, Paris. Areas of Interest: Dry eye, ocular allergy, toxic side-effects induced by topical treatments, especially in glaucoma. Leadership positions: Editor-in-chief of the French Journal of Ophthalmology, President of the Ophthalmological Society of Paris and member of eight international societies.

Allen Dale Beck, MD
Affiliation: Redmond Professor of Ophthalmology, Emory University School of Medicine, Atlanta, GA. Areas of Interest: Diagnosis and management of pediatric glaucoma, with a focus on new surgical techniques. Clinical trials in glaucoma/ocular hypertension and medication.

www.worldglaucoma.org

coma, Glaucoma imaging, Evidence-based Ophthalmology.

Tin Aung, FRCSEd, FRCOphth, PhD
Affiliation: Senior Consultant and Head, Glaucoma Service, Singapore National Eye Centre; Deputy Director, Singapore Eye Research Institute. Associate Professor, Department of Ophthalmology, National University of Singapore. Areas of Interest: Angle Closure Glaucoma, Ophthalmic Genetics, Anterior Segment Imaging, Glaucoma Epidemiology. Leadership positions: Associate EVP, World Glaucoma Association, President, Singapore Society of Ophthalmology.

Augusto Azuara Blanco, PhD, FRCSEd (Ed)
Affiliation: Consultant Ophthalmologist, Aberdeen Royal Infirmary, and Honorary Senior Lecturer, University of Aberdeen (UK). Research interest: Glaucoma and Cornea. Health services research, diagnostic techniques, randomised controlled trials, glaucoma surgery, patient-reported outcomes, health economics, ocular surface, angle-closure glaucoma. Leadership Positions: Consultant Ophthalmic Surgeon, Aberdeen Royal Infirmary; Honorary Senior Lecturer, University of Aberdeen; Member of the Editorial Board of the British Journal of BJO, EYE, Journal of Glaucoma, European Journal of Ophthalmology, International Glaucoma Review, and the Society for Clinical Ophthalmology; Member of the scientific committee of the Royal College of Ophthalmologists; Member of the scientific committee of the International Glaucoma Association; Trustee of the charity ‘Fighting for Sight-Aberdeen’; Examiner for the Royal College of Surgeons of Edinburgh, since 2004; Member of Steering Committee of the World Glaucoma Association (WGA); Member of the Committee for Global Research and Screening of the World Glaucoma Association (WGA) since 2008; Previous co-chair (2004-2006) of the Committee for Glaucoma Society Organisation of the World Glaucoma Association; Member of the task force for the publication of the EGS guidelines for glaucoma, 3rd edition (2008); Reviewer of public-funded grants for six different funding bodies. Special Honours: Fellowship of the Royal College of Surgeons of Edinburgh (awarded without examination). – Recipient of the 2008 American Academy of Ophthalmology Achievement Award.
adherence. Past Principal Investigator for AGIS and OHTS. Currently co-investigator for I-SIGHT, National Eye Institute 1 RO1 EY016997-01. Interactive Study to Increase Glaucoma Adherence to Treatment (I-SIGHT). A prospective, randomized, controlled clinical trial evaluating the effects of an automated, interactive telephone intervention strategy on glaucoma patient compliance compared to usual care. Medical monitor for Infant Aphakia Treatment Study (IATS). The primary aim of IATS is to determine whether infants with a unilateral congenital cataract are more likely to develop better vision following cataract extraction surgery if (1) they undergo the primary implantation of an intraocular lens or if (2) they are treated primarily with a contact lens. Secondary aims are to determine the occurrence of postoperative complications and measurements of parental stress in both groups. Leadership positions: 1999-2002: Advanced Glaucoma Intervention Study (AGIS) Steering Committee. 2006-date: American Glaucoma Society Patient Care Committee. Practice Guidelines Subcommittee. 2008-date: Editor, Board of JAPOS. 1994-2001: Emory Glaucoma Fellowship Director. 1999-date: Emory Glaucoma Section Director. Special Honors: 1989: Alpha Omega Alpha Medical Society. 1999: Clinical Teaching Award, Emory Ophthalmology Residents. 2002: Clinical Teaching Award, Emory Ophthalmology Residents. 2002: American Academy of Ophthalmology Achievement Award.

Khaled Ben Amor, MD

Boel Bengtsson, PhD
Affiliation: Associate Professor, Department of Clinical Sciences, Ophthalmology, Lund University, Malmö University Hospital, Malmö, Sweden. Areas of Interest: Glaucoma diagnostics and particular perimetry. Epidemiology. Clinical trials. Glaucoma diagnostics: Development of perimetric test programs (SITA), and interpretation tools, e.g. glaucoma change probability maps and indices (VFI) for calculation of functional rate of progression. Explore machine learning classifiers for the diagnosis of glaucoma using perimetry and Optical Coherence Tomography. Evaluation of diagnostic ability of different glaucoma diagnostic devices measuring both functional and structural parameters. Epidemiology: Effects of population screening for glaucoma on development of visual impairment. Clinical Trials: Study effect of IOP-reducing treatment on development.

Philip Bloom, FRCS, FRCOphth
Affiliation: Consultant Ophthalmic Surgeon, Western Eye & Hillingdon Hospitals. Honorary Professor of Ophthalmology, Middlesex University. Honorary Senior Lecturer, Imperial College School of Medicine. Areas of Interest: Trans-scleral and endoscopic cyclophotocoagulation. Combined cataract and glaucoma surgery. Spectacle independence following cataract surgery, including multifocal lens implantation, toric IOLs and incisional refractive surgery. Leadership positions: Service Director and Lead Clinician, Western Eye Hospital. Chief of Glaucoma Services, Hillingdon Hospital. Course Leader, Post-Graduate Diploma in Ophthalmology, Middlesex University. Surgical Tutor & Micorsurgical Skills Faculty Member, Royal College of Ophthalmologists. Continuing Professional Development (CPD) representative (North Thames), Royal College of Ophthalmologists. Past Vice President, Ophthalmology section, Royal Society of Medicine. Hillingdon Hospital Past Postgraduate Clinical Tutor in Ophthalmology, Royal College of Ophthalmologists. Pastoral Tutor, Imperial College School of Medicine. Special Honors: Keeler Scholarship (Royal College of Ophthalmologists) 1994-5. Muthusamy Gold Medal (Royal College of Surgeons, Edinburgh) 1990.

Dr. Eytan Z. Blumenthal
Affiliation: Head, Glaucoma Service, Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel. Areas of Interest: Glaucoma and cataract surgery. Glaucoma diagnosis and imaging. Technology development and evaluation. Research and development of ophthalmic technology. Volk Blumenthal suturelysis lens: used for post-trabeculectomy suturelysis. Katena Blumenthal con-
candidate genes with good potential to reduce intraocular pressure. Her goals are to be able to provide the molecular basis onto which new efficient and safer gene/drugs for glaucoma could be developed.

Leadership positions: Member of NIH study section, member of the scientific advisory board of the Glaucoma Foundation and of the editorial board of Molecular Vision. She has organized national and international symposia including Gene Therapy and Glaucoma at the ICER since 2000, APAO conference 2009 and co-organizer of the annual GF ‘Think Tanks’ since 2001. She has been invited to be part of the scientist’s ‘Washington Advisory Group’ in June 2009.


Rupert Bourne, MD
Affiliation: Professor of Ophthalmology, Vision & Eye Research Institute, Anglia Ruskin University, Cambridge, UK. Consultant Ophthalmic Surgeon at Moorfields Eye Hospital, Hinchinbrooke Hospital and Addenbrookes Hospital, Cambridge.


Terete Borrás, PhD
Affiliation: Professor of Ophthalmology, School of Medicine, Department of Ophthalmology, University of North Carolina at Chapel Hill.
Areas of interest: Dr. Borrás is an ocular molecular biologist with an interest in gene therapy. She received her Master degree in Biology from the University of Madrid, Spain and her Doctorate in Molecular Biology under a collaborative program of the University of Madrid and Purdue University, Indiana. Her area of research at the National Eye Institute (NIH) involved regulation of gene expression. Currently, her research is focused on the search for alternative, long-term treatments of glaucoma. She has pioneered new strategies for delivering genes to the human trabecular meshwork and identified several
James Brandt, MD
Affiliation: Professor & Director, Glaucoma Service, Department of Ophthalmology & Vision Science, University of California, Davis.
Research Interests: Pachymetry and tonometry techniques and their impact on clinical trials; Trabecular Meshwork physiology; New drug development (basic and clinical); Infantile and Pediatric glaucoma.
Leadership Positions: Editorial Board, Ophthalmology; Program Chair, American Glaucoma Society; Board of Directors, Glaucoma Research Foundation. Special Honors: Senior Achievement Award, American Academy of Ophthalmology (2004); Secretariat Award, American Academy of Ophthalmology (2004).

Anne Brooks, MD, BS, PhD (Melb), FRANZCO, FRACP, FAAO, FRCPht
Affiliation: Head of General Eye Clinic 3 and Ophthalmologist to the Glaucoma Investigation and Research Unit, The Royal Victorian Eye and Ear Hospital (RVEEH), Melbourne; Senior Fellow, Department of Ophthalmology, University of Melbourne; Private practice (anterior segment).
Areas of Interest: Pseudoxfoliation; Corneal endothelial and iris changes in glaucoma; Selective Laser Trabeculoplasty; over 130 publications in peer-reviewed journals.
Leadership positions: Secretary, Australian and New Zealand Glaucoma Interest Group 1989-current; Past Chair of Victorian State Branch, RANZCO; Past Director of Eye, Ear, Nose and Throat Research Institute; Past Chair, Eye Section, Senior Medical Staff, RVEEH; Member of editorial boards of Clinical and Experimental Ophthalmology and Comprehensive Ophthalmology Update.

Reay H. Brown, MD
Areas of interest: glaucoma, glaucoma surgery and cataract surgery.
Leadership positions: Dr. Brown has published more than 80 peer-reviewed articles on glaucoma, cataract surgery, and other aspects of eye care. He frequently lectures on glaucoma at national and international meetings. He has been awarded 10 patents for new instruments to improve glaucoma and cataract surgery and has 4 other patents pending. He is continuing to work on novel and improved approaches to glaucoma and cataract surgery. Dr. Brown and his wife, Dr. Mary Lynch, invented the Eyepass, a trabecular bypass device in 1999. They directed four FDA studies on Eyepass. Eyepass was approved for use in Europe in 2005. Chairman, ASCRS Glaucoma Clinical Committee, 2005-date. Special Honors: Dr. Brown has received the Honor Award from the American Academy of Ophthalmology. He has been selected by his peers to be listed each year in Best Doctors in America. He has appeared numerous times on local and national television commenting on issues of glaucoma treatment.

Reinhard Burk, MD, PhD
Affiliation: Professor Dr. med. Dr. med. Habil, Department of Ophthalmology, Klinikum Bielefeld, Bielefeld, Germany. Teaching Position: Department of Ophthalmology, University of Heidelberg, Department of Ophthalmology, Klinikum Bielefeld, Department of Ophthalmology, University of Münster.
Areas of Interest: Glaucoma Diagnosis and Glaucoma Therapy including surgical procedures. Compliance and Adherence to treatment. Cost effectiveness of therapeutical approaches. Development of three-dimensional optic nerve head structure analysis by Laser Scanning Tomography (HRT) and Spectral Domain OCT. Surgical modifications of deep sclerectomy and visco-canalostomy by irrigation trabeculotomy and ab externo laser trabeculotomy (US patent).
Yvonne M. Buys, MD, FRCSC
Affiliation: Professor, Department of Ophthalmology and Visual Sciences, University of Toronto, Canada and the Co-Director of the Glaucoma Unit at the University Health Network. Teaching: Dr. Buys has designed and implemented a unique and comprehensive introductory course for ophthalmology residents at the University of Toronto. This course is the only one of its kind in Canada, and has been recognized nationally and internationally for its unique educational value.
Areas of Interest: Current research interests include health care delivery, epidemiology of glaucoma and glaucoma surgical procedures.
Leadership positions: President, Canadian Glaucoma Society, past president of the Toronto Area Glaucoma Society, member of the Glaucoma Clinical Practice Guidelines Expert Committee of the Canadian Ophthalmological Society, College of Physicians and Surgeons of Ontario, American Glaucoma Society, ARVO, and the Toronto Hospital Research Institute, among many others.
Awards: Toronto Hospital Anderson Award in 1998, and the University of Toronto Clive Mortimer Postgraduate Teaching Award in 1999. Dr. Buys has published over 65 peer-reviewed publications, 8 invited editorials and 7 book chapters.

Dave Calkins
Affiliation: Associate Professor of Ophthalmology and Visual Sciences, Neuroscience and Psychology, The Vanderbilt Eye Institute and Vanderbilt Brain Institute, Vanderbilt University Medical Center.
Areas of Interest: Cellular and molecular organization of the retina and visual pathways in health and disease. Early molecular events underlying the degeneration of retinal ganglion cells and their axons in glaucoma and related optic neuropathies with special emphasis on neuronal-glial interactions and on calcium-dependent cascades underlying loss of functional uptake and transport.
Leadership positions: Director of Research, The Vanderbilt Eye Institute and Dept of Ophthalmology and Visual Sciences.
Special Honors: Research to Prevent Blindness Lew Wasserman Merit Award, Alfred P. Sloan Foundation Neuroscience Fellow.

Louis B. Cantor, MD
Affiliation: Professor and Chair, Jay C. and Lucile L. Kahn Professor of Glaucoma Research and Education, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Department of Ophthalmology.
Areas of Interest: Glaucoma Clinical Research, Glaucoma Medical and Surgical Management, Ocular Blood Flow, Imaging in Glaucoma.
Leadership positions: Professor and Chair, Indiana University Department of Ophthalmology, Secretary for Ophthalmic Knowledge AAO, Chair, Ophthalmology RRC, ACGME, Board of Directors and Executive Committee, ACGME.

Roberto Carassa, MD
Affiliation: Director of the Italian Glaucoma Center, Milano, Italy.
Areas of Interest: Early glaucoma Diagnosis by Image analysis of the optic disc; lasers applications in glaucoma; non-penetrating surgery for glaucoma.
Leadership positions: President of the ‘Italian Association for Glaucoma Prevention’; Member of the Council of the ‘Italian Association for the Study of Glaucoma’; Member of the Scientific Editorial Board of the European Journal of Ophthalmology; Member of the International Editorial Board of the Journal Ocular Surgery News: Europe/Asia Pacific Edition.

Subho Chakrabarti, PhD
Affiliation: Research Scientist at the Brien Holden Eye Research Centre, L.V. Prasad Eye Institute, Hyderabad, India.
Areas of Interest: POAG, PACG, Primary congenital glaucoma, exfoliation syndrome, pigmentary glaucoma, Age-related macular degeneration and myopia. Understanding the molecular genetics of POAG, PACG and developmental glaucomas; Whole-genome association (WGA) studies on glaucomas; Evolution and migration of disease genes and haplotypes in glaucomas worldwide; Genotype-phenotype correlation in primary congenital glaucoma; Devising
molecular diagnostics for predictive testing in glaucoma and AMD.

Leadership positions: Associate advisory board member of WGA; Editorial Board Member for Journal of Glaucoma and IGR; Executive member, Indian Society of Human Genetics; Member of the Institutional review Board, LVPEI; Doctoral Advisory Committee, BITS-Pilani and University of Hyderabad, India, Visiting Scientist, National Eye Institute, NIH; Principal investigator in 3 extramural international grants on glaucoma and AMD; Scientific reviewer for 20 peer-reviewed indexed journals and 3 funding agencies; Organizing Secretary, Asia ARVO 2009.

Special Honors: Clinician Scientist Award of WGA (2005); International Genetics Federation Travel award (2003); ISER Travel Fellowships (2004 and 2006); National Academy of Sciences India Platinum Jubilee Award (2007); Indian National Science Academy (INSA) Young Scientist Medal (2006); Associate of the Indian Academy of Sciences (2004-2007); University Grants Commission (UGC) Research Fellowship (August, 1996-2000) and Lectureship in 1995; Government of India National Scholarship (1995); Chair in Genetics and Glaucoma symposia at second Asia ARVO (2009).

Balwantray Chauhan, PhD
Affiliation: Professor, Research Director and Chair in Vision Research, Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, N.S. Canada; Professor, Department of Physiology and Biophysics, Dalhousie University, Halifax, N.S. Canada; Affiliated Scientist, Queen Elizabeth II Health Sciences Centre, Halifax, N.S., Canada.
Research Interests: Structural and functional changes in glaucoma; Risk factors for the progression of glaucoma; Novel analytical techniques; Experimental optic nerve damage.
Leadership Positions: Chair, Programme Planning Committee, Glaucoma Section, Association for Research in Vision and Ophthalmology; Scientific Advisory Committee, Glaucoma Research Foundation; Medical Advisory Board, The Glaucoma Foundation.

Teresa C. Chen, MD
Affiliation: Assistant Professor of Ophthalmology, Harvard Medical School, Glaucoma Service, Massachusetts Eye and Ear Infirmary.
Areas of Interest: Pediatric glaucoma, Spectral domain optical coherence tomography.
Leadership positions: Director of Clinical Affairs, Glaucoma Service, Massachusetts Eye and Ear Infirmary, Chief Quality Officer for Ophthalmology, Massachusetts Eye and Ear Infirmary.
Special Honors: Heed Fellowship.

Paul T.K. Chew, MBBS (Singapore), MMed (Ophthalmology), FRCS (Edinburgh), FRCOphth
Affiliation: Associate Professor, Department of Ophthalmology, National University of Singapore; Chief, Department of Ophthalmology, National University Hospital; Head, Glaucoma Service, The Eye Institute, National Healthcare Group.

Scott R. Christensen, BA, MBA
Area of Experience: After spending 25 years in finance, banking and real estate, including a term as President and CEO of a financial institution, Scott moved into the not-for-profit sector. Prior to

Organized by The Hippocrates Glaucoma Foundation
Nathan Congdon, MD, MPA
Affiliation: Nathan Congdon, MD, MPH, Professor of Ophthalmology and Public Health, Chinese University of Hong Kong
Areas of Interest: The development of new techniques to screen for vitamin A deficiency in India, Nepal and Indonesia and angle-closure glaucoma in China. He has a long-term interest in improving the quality of sustainable cataract surgical programs and school-based refractive error projects in rural Asia. His recent work has included the Sanrao Cataract Outcomes and Uptake Study (SCOUTS) and the Xichang Pediatric Refractive Error Study (X-PRES), which have combined service delivery and novel programmatic research in the area of cataract surgery and school-based provision of spectacles respectively. Dr. Congdon’s current projects in rural China are supported by Oxford University, the Li Ka Shing Foundation and the World Bank.

Anne L. Coleman, MD, PhD
Affiliation: Dr. Coleman is a Professor of Ophthalmology in the Jules Stein Eye Institute of the David Geffen School of Medicine at UCLA and Professor of Epidemiology in the UCLA School of Public Health. She is a consultant to the U.S. Food and Drug Administration Ophthalmic Devices Panel, and she is the chair of the National Eye Health Education Program Planning committee of the National Institutes of Health. Since 2003, she has served as Executive Editor of Glaucoma for the American Journal of Ophthalmology and was president of Women in Ophthalmology from 2003-2006. She was co-editor of Management of Cataracts and Glaucoma, (2004). With contributions to numerous studies and peer-reviewed journal articles and other publications, she continues to serve as an investigator for a number of ongoing studies and clinical trials.

Anne L. Coleman, MD, PhD
Affiliation: Dr. Coleman is a Professor of Ophthalmology in the Jules Stein Eye Institute of the David Geffen School of Medicine at UCLA and Professor of Epidemiology in the UCLA School of Public Health. She is a consultant to the U.S. Food and Drug Administration Ophthalmic Devices Panel, and she is the chair of the National Eye Health Education Program Planning committee of the National Institutes of Health. Since 2003, she has served as Executive Editor of Glaucoma for the American Journal of Ophthalmology and was president of Women in Ophthalmology from 2003-2006. She was co-editor of Management of Cataracts and Glaucoma, (2004). With contributions to numerous studies and peer-reviewed journal articles and other publications, she continues to serve as an investigator for a number of ongoing studies and clinical trials.

Garry P. Condon, MD
Affiliation: Dr. Garry P. Condon is an Associate Professor of Ophthalmology at Drexel University College of Medicine and a Clinical Assistant Professor of Ophthalmology at the University of Pittsburgh. He is the Chairman of the Department of Ophthalmology at Allegheny General Hospital and the Director of the Glaucoma Division in the Department of Ophthalmology at Allegheny General Hospital in Pittsburgh, PA.

Anne L. Coleman, MD, PhD
Affiliation: Dr. Coleman is a Professor of Ophthalmology in the Jules Stein Eye Institute of the David Geffen School of Medicine at UCLA and Professor of Epidemiology in the UCLA School of Public Health. She is a consultant to the U.S. Food and Drug Administration Ophthalmic Devices Panel, and she is the chair of the National Eye Health Education Program Planning committee of the National Institutes of Health. Since 2003, she has served as Executive Editor of Glaucoma for the American Journal of Ophthalmology and was president of Women in Ophthalmology from 2003-2006. She was co-editor of Management of Cataracts and Glaucoma, (2004). With contributions to numerous studies and peer-reviewed journal articles and other publications, she continues to serve as an investigator for a number of ongoing studies and clinical trials.

Garry P. Condon, MD
Affiliation: Dr. Garry P. Condon is an Associate Professor of Ophthalmology at Drexel University College of Medicine and a Clinical Assistant Professor of Ophthalmology at the University of Pittsburgh. He is the Chairman of the Department of Ophthalmology at Allegheny General Hospital and the Director of the Glaucoma Division in the Department of Ophthalmology at Allegheny General Hospital in Pittsburgh, PA.

Anne L. Coleman, MD, PhD
Affiliation: Dr. Coleman is a Professor of Ophthalmology in the Jules Stein Eye Institute of the David Geffen School of Medicine at UCLA and Professor of Epidemiology in the UCLA School of Public Health. She is a consultant to the U.S. Food and Drug Administration Ophthalmic Devices Panel, and she is the chair of the National Eye Health Education Program Planning committee of the National Institutes of Health. Since 2003, she has served as Executive Editor of Glaucoma for the American Journal of Ophthalmology and was president of Women in Ophthalmology from 2003-2006. She was co-editor of Management of Cataracts and Glaucoma, (2004). With contributions to numerous studies and peer-reviewed journal articles and other publications, she continues to serve as an investigator for a number of ongoing studies and clinical trials.

Garry P. Condon, MD
Affiliation: Dr. Garry P. Condon is an Associate Professor of Ophthalmology at Drexel University College of Medicine and a Clinical Assistant Professor of Ophthalmology at the University of Pittsburgh. He is the Chairman of the Department of Ophthalmology at Allegheny General Hospital and the Director of the Glaucoma Division in the Department of Ophthalmology at Allegheny General Hospital in Pittsburgh, PA.
Francesca M.F. Cordeiro, MD, PhD

Vital P. Costa, MD
Affiliation: Associate Professor of Ophthalmology, University of Campinas, Brazil, Director, Glaucoma Service, University of Campinas, Brazil Areas of Interest: Glaucoma Surgery, Genetics, Visual Fields, Ophthalmic Imaging, Glaucoma Surgery, Genetics, Visual Fields, Ophthalmic Imaging Leadership positions: Director, Brazilian Glaucoma Society, Vice President, Ibero American Glaucoma Society.

Jamie Craig, MD
Affiliation: Associate Professor Ophthalmology, Flinders University, Consultant Ophthalmologist, Flinders Medical Centre; Australian NHMRC Practitioner-Fellow; Department of Ophthalmology, Flinders University, South Australia. Research Interests: Glaucoma Genetics, Cataract Genetics. Leadership Positions: Head Glaucoma Clinic – Flinders Medical Centre. Special Awards: Senior Achievement Award American Academy of Ophthalmology (2003); Director of International Relations American Society of Cataract and Refractive Surgery (2003).

Dr. Alan S. Crandall
Affiliation: Professor and Senior Vice Chair of Ophthalmology and Visual Sciences, Director of Glaucoma and Cataract, John A. Moran Eye Center, The University of Utah, Salt Lake City, Utah

Jonathan G. Crowston, MD, PhD
Affiliation: Professor, University of Melbourne and Centre for Eye Research Australia. Areas of Interest: Dr Crowston runs the Glaucoma Research Laboratory at CERA, and is actively engaged in translational research from the molecular and cellular level through to clinical studies. Current research is focused on neurodegeneration and the impact of aging of the optic nerve. Aging and mitochondrial dysfunction in glaucoma pathogenesis. Neuroprotection and mouse glaucoma models. Conjunctival wound healing post glaucoma surgery Leadership positions: Head of Glaucoma, Royal Victoria Eye and Ear Hospital, Director Centre for Eye Research Australia, Head of Dept. of Ophthalmology University of Melbourne, Associate EVP WGA.

Tanuj Dada, MD
Affiliation: Associate Professor of Clinical Ophthalmology, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi. Areas of Interest: Anterior Segment Imaging, Scanning Laser Polarimetry, Mechanism for primary angle closure glaucoma, Post Keratoplasty Glaucoma. Leadership positions: Editor-in-Chief Journal of Current Glaucoma Practice with DVD, Editor Glaucoma Section of World Ophthalmology Report, Associate advisory board member World Glaucoma Association (WGA), Member WGA Code of Practice Committee. Special Honors: South Asian Academy of Ophthalmology Achievement Award 2008, Special Poster Recognition...
at World Glaucoma Congress 2007, Second Best Poster Award at European Glaucoma Society meeting 2004, Gold Medal for best clinical research in 2000 by All India Institute of Medical Sciences, Gold Medal for best undergraduate and postgraduate in Ophthalmology by All India Institute of Medical Sciences, New Delhi, KS Singh Trophy for Best Clinical Talk twice (2007,2000) and AC Agarwal trophy for best research paper three times by the Delhi Ophthalmological society.

Elie Dahan, MD, Med Ophth
Affiliation: Senior Consultant in Glaucoma and Pediatric Ophthalmology, Ein Tal Eye Hospital Tel Aviv Israel. Honorary Senior Consultant in Glaucoma and Pediatric Ophthalmology, University of the Witwatersrand, Johannesburg, South Africa.

Helen Danesh-Meyer, MBChB, MD, FRANZCO
Affiliation: Associate Professor, University of Auckland New Zealand.
Areas of Interest: Optic Nerve Morphology, Normal Tension Glaucoma, Neuro-ophthalmology, Ocular Imaging Modalities, Ischemic Optic Neuropathy. Leadership positions: Founding Trustee Glaucoma New Zealand; Co-Editor Clinical Challenges Survey of Ophthalmology; Section Editor Clinical Experimental Ophthalmology, Editorial Board Clinical Journal of Neuroscience, Chairman of Research Committee, Save Sight Society; Scientific Research Committee of Ophthalmic Research Institute of Australia.

Michael Diestelhorst, MD
Affiliation: Professor of Ophthalmology at the University of Cologne, Cologne, Germany.
Areas of Interest: glaucoma surgery and ocular pharmacology. He has invented devices for ocular drug delivery and holds patents e.g. in the field of electronic treatment monitoring.
Leadership positions: member of several societies including the Association for Research in Vision and Ophthalmology, International Society of Ocular Fluorophotometry and the American Society for Cataract and Refractive Surgery. Professor Diestelhorst has authored over 70 papers in the field of ophthalmology and ocular pharmacology.

Dr. Rob O. Duncan
Affiliation: Assistant Professor, City University of New York / York College, University of California, San Diego / Hamilton Glaucoma Center.
Areas of Interest: fMRI of Glaucoma. My primary research interest is to develop novel fMRI techniques to quantify neuronal, vascular, and metabolic contributions to neurodegenerative visual disorders. My current research uses fMRI to compare measurements of neuronal activity and blood flow throughout the retina-cortical pathway to standard clinical measures of visual function.

Fathi El-Sayyad, FRCS, FRCOphth
Affiliation: Professor of Ophthalmology, Misr University for Science and Technology, Director, ElSayyad Eye Center, Cairo, Egypt.
Areas of Interest: Complex Glaucoma Surgery. Leadership positions: President of the Pan Arab Glaucoma Society.
Special Honors: - Clinical Professor of Ophthalmology, Louisiana State University, Achievement Award, American Academy of Ophthalmology, Distinction Labib Award, Middle East African Council of Ophthalmology.

Robert Fechtner, MD
Affiliation: Professor of Ophthalmology and Director, Glaucoma Division, Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark, NJ.
Areas of Interest: Glaucoma diagnostic technology, glaucoma pharmacology, glaucoma surgery.

Ronald Leigh Fellman, MD
Affiliation: Associate Clinical Professor of Ophthalmology, University of Texas Southwestern Medical Center, Glaucoma Associates of Texas, Dallas, TX, USA.

William J. Feuer, PhD
Affiliation: Senior Research Associate in Biostatistics at the Bascom Palmer Eye Institute, University of Miami School of Medicine. He is currently coordinating center principal investigator of the multi-center Ahmed Baerveldt Comparison clinical trial.
Areas of Interest: Application of regression, experimental design, and survival methods in ophthalmological settings.
Leadership positions: He has served as either study statistician or monitoring board statistician on numerous clinical trials of glaucoma treatments including the 5-FU treatment.
trial, the Ocular Hypertension Treatment Study, and the Tube Versus Trabeculectomy Study. He has authored and co-authored over 150 articles in the peer-reviewed literature. Special Honors: Has received the American Academy of Ophthalmology’s Achievement Award.

**Murray Fingeret, OD**

**John G. Flanagan, PhD**

**Brad A. Fortune, OD, PhD**
Affiliation: Associate Scientist and Director, Clinical Electrophysiology Service, Devers Eye Institute, Legacy Health Systems, Portland, OR; Clinical Instructor, Dept. of Ophthalmology, School of Medicine, Oregon Health Sciences University, Portland, OR. Research Interests: Visual Function and Retinal Nerve Fiber Layer Structure. Special Honors: Founding Member, Optometric Glaucoma Society (2002); Irvin and Beatrice Borish Award, American Academy of Optometry (2004); Junior Investigator Award, International Society for Clinical Electrophysiology of Vision (ISCEV) (2000).

**Jeffrey Freedman, Mb.Bch, PhD, FRCSE, FCS (SA)**

**Kevin Frick, PhD**
Affiliation: Associate Professor, Department of Health Policy and Management Johns Hopkins Bloomberg School of Public Health. Areas of interest: Cost-effectiveness, particularly for eye care. Burden of disease, particularly for visual impairment. Leadership positions: Serving on the National Advisory Council for the National Institute of Nursing Research. Has served on the
awards and program committee for the American Public
Health Association Vision Care Section.
Awards: John M. Eisenberg Article-of-the-Year in Health
Services Research, (2006); Student Coordinating Com-
mittee Faculty Award, Johns Hopkins University, Bloomberg
School of Public Health, Department of Health and Man-
agement (2001); Atlantic Economic Journal Best Article
Award for Cross product subsidization in the health in-
urance market with managed care: a model and issues
(2000).

David S. Friedman, MD, PhD
Affiliation: Professor, Wilmer
Eye Institute, Johns Hopkins
University School of Medicine,
Professor, Department of Inter-
national Health, Johns Hopkins
Bloomberg, School of Public
Health, Senior Ophthalmologist
Helen Keller International
Areas of Interest: Angle Closure
Glaucoma, Eye Disease and Ag-
ing, Evidence-Based Medicine,
Patient Adherence including Pa-
tient- Doctor Interactions, Eye
care in Developing Countries, Angle Closure Glaucoma,
Adherence to Glaucoma Therapies. Innovative approach-
to providing eye care to underserved populations in-
cluding better treatment of uncorrected refractive errors
and improved screening approaches for diabetic retino-
pathy.
Leadership positions: Editorial Board member of Ophthal-
mology and Journal of Glaucoma; Co-Chair: WGC Consen-
sus Panel on Angle Closure Glaucoma and WGC Research
Committee; AGS Representative to the AAO Preferred Prac-
tice Patterns Committee; Glaucoma Fellowship Director,
Wilmer Eye institute; Senior Technical Advisor of Helen
Keller International.
Special Honors: American Geriatrics Society Douglas Jah-
nigen Award (2003 – 2005), Research to Prevent Blind-
ness Robert E. McCormick Award (2000)

James G. Fujimoto, PhD
Affiliation: Professor of Electrical
Engineering and Computer Sci-
ence, Department of Electrical
Engineering and Computer Sci-
ence and Research Laboratory of
Electronics, Massachusetts Insti-
tute of Technology. Cambridge,
Massachusetts, USA.
Areas of Interest: His research in-
terests include the development
and application of femtosecond
laser technology and studies of
ultrafast phenomena. He is also
active in biomedical optics and optical imaging. Dr Fujim-
o’s group and collaborators were responsible for the in-
vention and development of optical coherence tomography
(OCT) imaging.
Special Honors: Dr. Fujimoto was awarded the Discover
Magazine Innovation Award for Medical Technologies in
1999, and was co-recipient of the Rank Prize in 2002. He
is a member of the National Academy of Science, Nation-
al Academy of Engineering and American Academy of Arts
and Sciences. Dr. Fujimoto co-founded the startup compa-
ny Advanced Ophthalmic Devices, which developed OCT
for ophthalmic imaging and was acquired by Carl Zeiss.
He is also co-founder of LightLabs Imaging, which devel-
ops cardiovascular and endoscopic OCT and was acquired
by Goodman, Ltd.

Stefano Gandolfi, MD
Affiliation: Professor of Ophthal-
mology and Chairman of the Uni-
versity Eye Clinic University of
Parma, Parma, Italy.
Areas of Interest: Glaucoma phar-
macology; evaluation of glaucoma
surgeries: non penetrating sur-
gery, Ex-press, trabecular stent
etc.; pigmentary glaucoma; neu-
roprotection; health economics in
 glaucoma; contrast sensitivity in
 glaucoma, biomarkers.
Special Honors: EGS award for
the best scientific contribution to the quadrennial Meet-
ing in London 2000 and Florence 2004 EGS award for
the 3rd scientific contribution to the quadrennial meeting,
Paris 1996. Accepted as a Member by the Glaucoma Re-

David Garway Heath, MD,
FRCooph
Affiliation: Consultant Ophthal-
mo logist and Clinical Research Lead,
Glaucoma Research Unit, Moor-
fields Eye Hospital, London; Hon.
Visiting Professor, City Universi-
ty, London; Hon. Senior Lecturer,
Institute of Ophthalmology, Lon-
don, United Kingdom. Research
Interests: optic nerve head and
retinal imaging, visual function,
structure/function relationships,
tonometry, phenotyping, measuring disease progression,
and determining risk factors for progression.
Leadership Positions: ARVO – Glaucoma Section Program
Committee Member; Imaging Morphometry Association for
Glaucoma in Europe (Secretary); International Glaucoma As-
sociation (Trustee); International Perimetric Society (Board
member); Glaucoma Research Society (member); Editori-
al Board Member: Eye, Current Eye Research, and Oph-
thalmic and Physiologic Optics.

Organized by The Hippocrates Glaucoma Foundation
Special Honors: Achievement Award – American Academy of Ophthalmology.

**Gus Gazzard, MB, Bchir, MA, MD, FRCOphth**

**Jian Ge, PhD**
Affiliation: Director and president, Zhongshan Ophthalmic Center, Eye Hospital, State Key Laboratory of Ophthalmology, Sun Yat-sen University Guangzhou, 510060, P.R. China. Area of interest: Phacoemulsification in the treatment of glaucoma; Shunt surgery in the refractive glaucoma; Gene screen and function in familial primary open angle glaucoma; Stem cell and tissue engineering in regenerative ophthalmology; Modulation of scar formation after anti-glaucoma surgery; Reconstruction of natural glaucoma animal model; Mechanism of experimental myopia in rhesus monkeys. Leadership positions: President of Chinese Glaucoma Society; Vice President of Chinese Ophthalmological Society.

**Steven J. Gedde, MD**
Affiliation: Professor of Ophthalmology, Bascom Palmer Eye Institute. Areas of Interest: Tube shunts, Complications of glaucoma surgery, Medical education. Leadership positions: Residency Program Director, Bascom Palmer Eye Institute, UMMC Leadership Council, University of Miami School of Medicine, Preferred Practice Pattern Glaucoma Panel, American Academy of Ophthalmology, Ophthalmology Research Foundation Board, Bascom Palmer Eye Institute, Program Director Council (President), Association of University Professors of Ophthalmology, Glaucoma Self-Assessment Committee (Chairman), American Academy of Ophthalmology, Accredited Standards Committee Z80, American National Standards Institute, ABO Program Director Task Force, American Board of Ophthalmology, Editorial Board, Journal of Academic Ophthalmology, Editorial Board, Ocular Surgery News. Special Honors: American Academy of Ophthalmology Achievement Award Best Doctors in America, Florida Super Doctors, Professor of the Year, First Year Teaching Award, Service Excellence Award.

**Ronnie George, MD**
Affiliation: Consultant, Glaucoma Services, Sankara Nethralaya, Chennai, India. Areas of Interest: Glaucoma epidemiology, Glaucoma diagnostics, Angle Closure Glaucoma. Special Honors: Thiru.CK. Kumaraswamy Gold Medal from the Tamil Nadu Medical University, Ruby Banik Award from Vision Research Foundation, Chennai; Dr TLK Row Endowment Award, Medical Research Foundation 2006.

**Orna Geyer, MD**
Affiliation: Chair, Department of Ophthalmology, Carmel Medical Center, Haifa; Associate Professor Ophthalmology Rappaport Faculty of Medicine, Technion Haifa. Areas of Interest: Prevention of retinal ischemia. Wound healing after glaucoma surgery. Retinal nerve fiber layer thickness in patients with Sleep Apnea Syndrome. Leadership positions: Associate Professor Ophthalmology, Rappaport Faculty of Medicine, Technion Haifa.

www.worldglaucoma.org

69
World Glaucoma Congress, July 8-11, 2009

Dr. Jo Ann A. Giaconi
Affiliation: Assistant Clinical Professor of Ophthalmology, Jules Stein Eye Institute, David Geffen School of Medicine, University of California at Los Angeles, USA. Areas of Interest: Glaucoma and Cornea.

Ivan Goldberg, MBBS, FRANZCO, FRACS
Affiliation: Clinical Associate Professor, Department of Ophthalmology, University of Sydney; Head, Glaucoma Services, Sydney Eye Hospital; Director, Eye Associates. Research Interests: Clinical glaucoma – diagnosis and management. Leadership Positions: Past-President, WGA (World Glaucoma Association); President of ANZGIG (Australian and New Zealand Glaucoma Interest Group); Vice President, Glaucoma Australia; Immediate Past President, SEAGIG (South East Asia Glaucoma Interest Group); Past President, Royal Australian and New Zealand College of Ophthalmologists; Past Censor-in-Chief, Royal Australian and New Zealand College of Ophthalmologists; Past Chair, Board of Examiners, Royal Australian and New Zealand College of Ophthalmologists; Executive Committee Member, Asian Oceanic Glaucoma Society; Chair, Working Party, Asia Pacific Glaucoma Guidelines. Special Honors: Tow Prize, Prince Henry, Prince of Wales Hospitals, University of New South Wales; Silver Cockerel Award, Royal Australian and New Zealand College of Ophthalmologists; Hollows Lecturer, Royal Australian and New Zealand College of Ophthalmologists.

Fernando Gomez Goyeneche, MD

Francisco Javier Goñi, MD, PhD
Affiliation: Consultant in the Barcelona Glaucoma Center, at USP-Instituto Oftalmológico de Barcelona (IOB), and Chief of Ophthalmology department at Hospital de Mollet-Barcelona, Barcelona, Spain. Areas of Interest: Glaucoma diagnosis and glaucoma medical treatment.

Stuart L. Graham, MBBS, PhD, MS, FRANZCO, FRACS
Affiliation: Professor Ophthalmology and Visual Science, Australian School of Advanced Medicine, Macquarie University, Sydney. Glaucoma sub specialist. Areas of Interest: Special interest in glaucoma diagnostic techniques, perimetry and imaging, and particularly electrophysiology. Extensive experience with the Multifocal VEP and its application to objective perimetry, including binocular and blue/yellow mfVEP. Developed the AccuMap multifocal system with Dr Alex Klistorner. Also investigating the role of central and peripheral blood pressure and vascular factors such as arterial stiffness and pulse waves in glaucoma pathogenesis. Leadership positions: Clinical Lecturer Sydney University Save Sight Institute, Visiting Medical Officer Sydney Eye Hospital, ANZGIG state representative, Secretary Ophthalmic Research Institute of Australia (ORIA). RANZCO Therapeutics Committee

Organized by The Hippocrates Glaucoma Foundation
David S. Greenfield, MD
Affiliation: Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
Areas of Interest: Glaucoma diagnosis and monitoring; optic nerve and retinal nerve fiber layer imaging. Also including optic disc and retinal nerve fiber imaging in glaucoma, bleb-related ocular infection, normal-tension glaucoma, and complex glaucoma filtration surgery. He is the recipient of an NEI consortium grant studying advanced imaging technology in glaucoma. He has lectured nationally and internationally on these topics and has published over 150 original scientific papers, abstracts and book chapters
Leadership positions: He currently serves as chair of the American Glaucoma Society Bylaws and Strategic Planning Committee, chair of the World Glaucoma Association Bylaws Committee, is Vice-Chair of the AGS Scientific Program Committee, and is a member of the AAO Glaucoma Subspecialty Day Committee and Technology Assessment Committee. Dr. Greenfield has served as Co-Chairman of the Glaucoma Subspecialty Day of the American Academy of Ophthalmology (2003-4), and was awarded the 2003 American Academy of Ophthalmology Achievement Award.
Special Honors: Awarded the 2003 American Academy of Ophthalmology Achievement Award, and National Institutes of Health grants R01 EY013516 and EY08684

Erik L. Greve, MD, PhD
Affiliation: Professor, Founding Editor International Glaucoma Review, former head Glaucoma Department University of Amsterdam, etc.
Areas of Interest: Progression, Angle Closure Glaucoma, Normal Pressure Glaucoma.
Leadership positions: Vice President WGA, Founding Editor International Glaucoma Review; Past President and co-founder of the EGS; Past Vice President of the Organization Committee of the ICO; Past Vice President of the Netherlands Ophthalmological Society; Past General Secretary and co-founder of the IPS; Past President and founder of the Netherlands Foundation for the Blind and Visually Handicapped Founder International Glaucoma Review, etc.
Special Honors: Knight in the Order of the Netherlands Lion; Guest of Honor lectures at numerous occasions, Honorary Member of the IPS; Honorary Fellow European Glaucoma Society.

Daniel E. Grigera, MD
Affiliation: Assistant Professor of Ophthalmology, Universidad del Salvador, Buenos Aires, Argentina; Head, Glaucoma Service, Hospital Oftalmológico Santa Lucía, Buenos Aires.
Areas of Interest: Glaucoma Surgery; Ultrasound Biomicroscopy; Medical Therapy.
Leadership positions: President, Latin American Glaucoma Society; Member of the Board of Governors of the WGA; Past President, Argentine Glaucoma Society; Past President, Pan American Glaucoma Society; Former member of the Steering Committee of the WGA.
Special Honors: Founding Member, Argentine Glaucoma Society; Honorary Member, Peruvian Ophthalmological Association.

Franz Grehn, MD
Affiliation: Chairman of the Department of Ophthalmology, Würzburg, Germany.
Research Interests: Basic and clinical research in glaucoma, microsurgery. Laboratory for cell biology in glaucoma research. Prospective Randomized Clinical Studies.
Leadership positions: Member of the Executive Committee of the European Glaucoma Society; President of the German Society of Ophthalmology (2002-2003); Member of the Executive board of the Glaucoma Society of the International Congress of Ophthalmology (2003); Honorary Member of the Romanian Academy of Medical Sciences (2005); Member of the Board of Governors of the WGA (2007)

Dr. Cynthia L. Grosskreutz
Affiliation: Associate Professor of Ophthalmology, Harvard Medical School.
Areas of Interest: Neuroprotection. Mechanisms of retinal ganglion cell death and survival
Leadership positions: Co-Director, Glaucoma Consultation Service, Massachusetts Eye & Ear Infirmary, Boston, MA.
Special Honors: 2009-AGS Mid
Franz Grus, MD, PhD
Affiliation: Head of Experimental Ophthalmology, Dept. of Ophthalmology, Universitäts Augenklinik, Mainz, Germany.
Research Interests: Glaucoma: changes in natural autoimmunity in glaucoma patients; Tear film: Biomarkers for non-invasive diagnostics and therapeutics; Ocular Proteomics: Protein Chips and Arrays, Mass-spectrometry, conventional Proteomics; Ocular Immunology; Computer Sciences: Pattern matching algorithms for diagnostics purposes; Development of specialized software modules.

Neeru Gupta, M.D, PhD, FRCSC, DABO
Affiliation: Professor of Ophthalmology and Vision Sciences and Laboratory Medicine and Pathobiology, University of Toronto, Director, Glaucoma and Nerve Protection Unit, Keenan Research Centre at the Li Ka Shing Knowledge Institute of St. Michael Hospital.
Areas of Interest: Glaucoma neural degeneration in the central visual system; mechanisms of glaucomatous disease; basic and clinical research toward preventing vision loss in glaucoma.
Leadership positions: Program Committee Member for the Glaucoma Section of the Association for Research in Vision and Ophthalmology; Program and Research Committee Member of the American Glaucoma Society; Glaucoma Basic Science and Clinical Course Committee of the American Academy of Ophthalmology; Physician Liaison and Advisory Committee Member of the Association of International Glaucoma Patient Organizations; Scientific Advisory Board Member of The Glaucoma Foundation; Board Member for Women in Ophthalmology; Editor, Vision Science Section, Canadian Journal of Ophthalmology; Panel Member, CIHR Operating Grants Committee, Canadian Institutes of Health Research, Clinical Investigation A; Director of the Institute of Medical Science Undergraduate Research Program and International Summer Student Program, University of Toronto; Executive Member of the Clinical Sciences Research Committee of the Keenan Research Centre in the Li Ka Shing Knowledge Institute of Michael’s Hospital; Chair of Glaucoma Surgeons Committee for Teaching Hospitals, University of Toronto; Editorial Board Member of International Glaucoma Review; Editorial Board Member of Glaucoma Today, Editorial Board Member, Ophthalmology Times.

Alon Harris, MD
Affiliation: Lois Letzter Endowed Professor of Ophthalmology, Professor of Cellular and Integrative Physiology, Director, Glaucoma Research and Diagnostic Center, Director, Ocular Vascular Reading Center, Department of Ophthalmology, Department of Physiology and Biophysics, Physiology graduate program.
Areas of Interest: To determine mechanisms involved in the etiology and pathophysiology of diseases of the eye such as glaucoma, age-related macular degeneration, diabetic retinopathy; specifically to determine the role of ischemia in the development and pathogenesis of these diseases by applying appropriate technology. To discover therapeutic agents for addressing ocular ischemia. Leadership positions: Director, Glaucoma Research and Diagnostic Center; Governing Board Member, International Society for Imaging in the Eye; Executive Committee Member, International Glaucoma Society; Associate Editor, Acta Ophthalmologica; Editorial Board Member, Acta Ophthalmologica, International Glaucoma Review, Journal of Current Glaucoma Practice, Journal of Ophthalmology. Special Honors: Research to Prevent Blindness William and Mary Greve International Research Scholar Award Recipient; Letzter Endowed Chair of Ophthalmology; Glenn W. Irwin Jr. MD. Experience Excellence Recognition Award Recipient; Edmund Benjamin Spaeth Oration Award for Outstanding Clinical Research; American Academy of Ophthalmology Achievement Award Recipient. Author of more than 200 peer-reviewed journal articles, 9 books and 35 book chapters.

Curt Hartleben, MD
Affiliation: Professor of Ophthalmology, Instituto de Oftalmología, Mexico City, Mexico. Head of Clinical Research, Glaucoma Department, Instituto de Oftalmología.
Areas of Interest: Early detection of Glaucoma, Epidemiology, Patient Awareness and Quality of Life. Leadership positions: Former Head of the Glaucoma Department, Instituto de Oftalmología, Mexico City, Mexico. Expresident, Asociación Mexicana de Glaucoma.
Ron Harwerth, OD, PhD

Affiliation: John and Rebecca Moores Professor of Optometry, College of Optometry, University of Houston, Houston, TX, USA.
Areas of Interest: Structure-function relationships in experimental and clinical glaucoma, perimetry, retinal nerve fiber layer, clinical psychophysics.
Leadership positions: Chair of the Department of Vision Sciences, College of Optometry
Special Honors: Doctor of Science (honorary), State University of New York (2000); Alumnus of the Year, University of Houston, College of Optometry (2000); International Glaucoma Research Award, (2000); Member, Board of the International Perimetry Society (2002); UHCO Outstanding Graduate Faculty Award (2003); Best Scientific Poster Presentation, World Glaucoma Congress (2005); Charles F. Prentice Medal, American Academy of Optometry (2006).

Michael Hauser, PhD

Affiliation: Associate Professor, Department of Medicine, Department of Ophthalmology, Department of Molecular Genetics and Microbiology, Department of Bioinformatics and Biostatistics, Duke University.
Areas of Interest: Molecular Genetics of human disease, Specific diseases under investigation include glaucoma, age-related macular degeneration, Parkinson’s disease, non-alcoholic fatty liver disease, amyotrophic lateral sclerosis, post-traumatic stress disorder, and limb girdle muscular dystrophy. Identification of causative mutations of susceptibility alleles in human disease, followed by translational research to develop new treatments based on genetic susceptibility. This work has included development of in vitro functional assays, as well as construction of mouse models of human disease
Leadership positions: Director of Duke BioBank, located in the Center for Human Genetics. Study program Director of Genetics, Duke Medical School Third Year Research Program. Chairman of Graduate Admissions for Duke University Program in Genetics and Genomics

Mingguang He, MD, PhD

Affiliation: Professor, Department of Preventive Ophthalmology, Zhongshan Ophthalmic Center;
Areas of Interest: Glaucoma; myopia; twin study; clinical trial; population-based study; Population-based study of eye diseases; natural history, mechanism and evidence-based intervention of angle closure; Genetic basis of glaucoma and myopia.
Special Honors: Graduate Research Scholarship, University College London (2002); Top 10 Best Poster, World Glaucoma Congress (2005); Best Paper Presentation, South East Asia Interest Group Conference (2006); New Century Excellent Talents in University (NCET), Ministry of Education (2007).

Paul R. Healey, BmedSc (Cell Biology), MBBS (Hons), Mmed (Clin.Epi.), FRANZCO

Affiliation: Department of Ophthalmology, University of Sydney, Centre for Vision Research and Western Sydney Eye Hospital, Westmead Hospital, Westmead, NSW, Australia; Eye Associates, Sydney NSW 2000, Australia; Clinical Senior Lecturer: University of Sydney, Department of Ophthalmology, Save Sight Institute and Westmead Millennium Institute; Director of Glaucoma Services, Western Sydney Eye Hospital, NSW; Visiting Medical Officer in Ophthalmology: Westmead Hospital, Sydney/ Sydney Eye Hospital (Assoc); Director of Glaucoma Research, Centre for Vision Research, Westmead Millennium Institute, Department of Ophthalmology, University of Sydney; Chief Glaucoma Investigator: Blue Mountains Eye Study.
Areas of Interest: Research Interests: Glaucoma; Ophthalmic Epidemiology and Public Health; Genetic Epidemiology; Cell Biology of ophthalmic diseases; Diagnostic Test and Screening Evaluation; Glaucoma Surgery Research.
Leadership positions: Director of Training, Sydney Eye Hospital Network; Treasurer, South East Asian Glaucoma Interest Group; Co-Chair, WGA Associate Advisory Board. Member, WGA Steering Committee. Co-Chair, WGA World Glaucoma Day Committee.
Special Honors: Association of International Glaucoma Societies – AIGS Award for best paper of 2003 (Prof P Mitchell senior author and recipient 2004); World Glauco-

**Anders Heijl, MD, PhD**

Affiliation: Professor and Head at the Department of Ophthalmology, Malmö University Hospital, University of Lund, Sweden.
Areas of Interest: Diagnostics (particularly perimetry), treatment, epidemiology, quality of life. Diagnostics (particularly perimetry), treatment, epidemiology, quality of life.
Leadership positions: Vice Prefect Department of Clinical Sciences in Malmö of Lund University.

**Dr. Magdi Helal**

Affiliation: Fellow, The Royal College of Surgeons of Edinburgh, Chief of Cataract and Glaucoma Unit Magrabi Hospital Cairo
Leadership positions: Chief of Cataract and Glaucoma Unit, Chairman Continuing Medical Education Magrabi Hospital Cairo.
Special Honors: American Academy Achievement Award year 2000.

**Rosario R. Hernandez, DDS**

Affiliation: George and Edwina Tarry Professor of Ophthalmology, Department of Ophthalmology and Northwestern University Neuroscience Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Areas of Interest: Mechanisms of glaucomatous damage in Human and non-Human primates; in vitro models of intraocular pressure-related stress in optic nerve astrocytes and retinal Müller cells; molecular biology and bioinformatics in human glaucoma.
Awards and Honors: RPB Lee Wasserman Merit Award (1998); RPB Senior Scientific Investigator Award (2002).

**Leon W. Herndon, Jr, MD**

Affiliation: Associate Professor of Ophthalmology, Medical Director, Duke University Medical Center, Durham, North Carolina.
Areas of Interest: Medical and surgical management of glaucoma. His research interests include studying novel treatment approaches in the diagnosis and management of glaucoma. He has ongoing research projects evaluating the high prevalence of primary open angle glaucoma in Ghana, West Africa, where he travels yearly.
Leadership positions: Dr. Herndon is a member of the American Academy of Ophthalmology (AAO) and the Association for Research in Vision and Ophthalmology. He is on the editorial board of Glaucoma Today. He is an Associate Examiner for the American Board of Ophthalmology and has been involved in the Leadership Development Program of the AAO. He has authored numerous papers, lectured nationally and internationally, and participated in several research projects related to glaucoma. He currently serves as Medical Director of the Duke University Eye Center.
Special Honors: Dr. Herndon has been recognized for his service in the community by receiving the Achievement Award from the AAO and the Dedicated Humanitarian Service Award presented by Dr. Leonel Fernandez Reyna, President of the Dominican Republic, on the occasion of the 2nd Ophthalmology Mission in the Dominican Republic.
Dale K. Heuer, MD
Affiliation: Professor and Chairman of Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin; Director, Froedtert and Medical College of Wisconsin Eye Institute, Milwaukee, Wisconsin.
Areas of Interest: Dr. Heuer has published extensively on the use of conventional filtering procedures with wound-healing modulation and aqueous shunting procedures for the management of glaucomas with poor surgical prognoses. He has participated in several glaucoma clinical trials, including the Fluorouracil Filtering Surgery Study, the Collaborative Normal-Tension Glaucoma Study, and the Collaborative Initial Glaucoma Study.

Roger A. Hitchings, FRCS, FRCOphth
Affiliation: IGA Professor of Ophthalmology, University of London. Moorfields Eye Hospital London.
Research Interests: The process of research, the health economics of glaucoma, normal pressure glaucoma.
Leadership position: Senior Specialist Glaucoma Service, Moorfields Eye Hospital; ex-Director of Research & Development Department, Moorfields Eye Hospital; President European Glaucoma Society.
Special Honors: Bowman Lecture, Royal College of Ophthalmologists 2008; Duke-Elder Lecturer, Royal College of Ophthalmologists; Shaffer Lecturer American Academy of Ophthalmology; Goldmann Lecturer, Glaucoma Research Society.

Ching Lin Ho, MD
Affiliation: Head and Senior Consultant, Glaucoma Service, Singapore National Eye Centre. Visiting Consultant, National University Hospital, Changi General Hospital, Kerdang Kerbau Women’s and Children’s Hospital. Clinical Teacher, National University of Singapore.
Areas of Interest: Pediatric glaucoma, aqueous shunt devices, lasers in glaucoma, angle closure glaucoma, anterior segment imaging.
Leadership positions: Board member, South East Asian Glaucoma Interest Group (SEAGIG). Secretary, Glaucoma Surgeons of Singapore, Organizing committee member of several regional and international meetings. Invited speaker and teaching faculty at many regional and international meetings, courses and workshops. Workgroup member of Asia Pacific Clinical Practice guidelines on Glaucoma and Singapore Glaucoma Clinical Practice Guidelines workgroup. Guidelines workgroup for Pediatric Glaucoma at the World Glaucoma Congress 2007. Reviewer for several peer-reviewed journals including Ophthalmology, Eye, Expert Opinion on Emerging Drugs, Annals Academy of Medicine and Ophthalmologica. Associate Councilor, North West Community Development Council.
Special Honors: Gold Medal for most outstanding candidate for Pediatrics. Beecham Prize for best candidate in Biochemistry. Fellowship in Glaucoma from both Singapore National Eye Centre and National University Hospital. Fellow in Ophthalmology (Glaucoma and Paediatric Glaucoma) from Massachusetts Eye and Ear Infirmary, Harvard Medical School. Asia Pacific Academy of Ophthalmology (APAO) Prevention of Blindness award, APAO Distinguished Service Award, Wong Hock Boon Gold Medal, Excellent Service Star and Silver awards, Parmigiani Fleurier Woman of Exception award for career achievements in the Science Category, Singapore.

Esther M. Hoffmann, MD
Affiliation: Consultant ophthalmologist specializing in glaucoma, Department of Ophthalmology, University of Mainz, Mainz, Germany.
Research interest: Optic Nerve Head and RNFL imaging using scanning laser ophthalmoscopes, structure-function relationship in glaucoma; Glaucoma diagnosis using different tonometry devices.

www.worldglaucoma.org
Anton Hommer, MD  
Affiliation: Oberarzt, Chief of Glaucoma unit Hera Hospital.  
Areas of Interest: Glaucoma epidemiology, Diagnosis; medical therapy, Laser treatment. Perimetry. Imaging.  
Leading positions: member of the Executive Board of the EGS; former head of Glaucoma Unit 2nd University Eye Clinic Vienna; Secretary of Glaucoma Section of the Austrian Ophthalmological Society; former President of the Viennese Ophthalmological Society; Collaboration with Institute of Clinical Pharmacology at the University Hospital of Vienna.

Megumi Honjo, MD, PhD  
Affiliation: Department of Ophthalmology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan. 173-0015, Japan.  
Research Interests: Aqueous outflow, neuroprotection, cell adhesion.  
Areas of Interest: glaucoma, aqueous humor dynamics, scarring  
Leadership Positions: Assistant director, Ophthalmology, Tokyo Metropolitan Geriatric Hospital.  
Special Honors: Suda Glaucoma Research Foundation Research Award (2003); Imai Research Foundation Research Award (2003); JSPS Research Fellowships for Young Scientist Scholarship (1998).

Thomas B. Hutchinson, MD  
Affiliation: President and Co-Founder, Ophthalmic Consultants of Boston  
Areas of Interest: Professional interests include quality assurance, credentialing and public service programs.  
Leadership positions: For 25 years Dr. Hutchinson was the Academy’s founding Chairman of Eye Care America, the largest public service program in American medicine and has been recognized by both President Ronald Regan and President George W. Bush for public service volunteering. Associate Clinical Professor of Ophthalmology, Harvard Medical School. Consulting Editor, Harvard Medical School Health Newsletter. Past President, Massachusetts Eye and Ear Infirmary. Founding Officer and Past-President, Massachusetts So-

Special Honors: Dr. Hutchinson has received several awards from the Academy including the Senior Honor Award, the Lifetime Achievement Award and the Distinguished Service Award; he was a Guest of Honor at the Academy’s 100th anniversary. Other honors include Man of the Year in 1998 from the New England Ophthalmological Society, a similar award from the Massachusetts Society of Eye Physicians and Surgeons in 1999, a Man of Vision award from Prevent Blindness America-Massachusetts in 2001, as well as the Howe Medal from the Buffalo Ophthalmological Society and a Distinguished Service Award from Ophthalmology Times.

Murat Irkec, MD
Affiliation: Professor, Hacettepe University Faculty of Medicine.
Areas of Interest: Diagnostic features of scanning laser polarimetry in glaucoma and retinal diseases. He and his team also completed projects on the role of glaucoma medications in conjunctival apoptosis and ocular imaging in exfoliation glaucoma. Dr. Irkec’s research and publications also cover various aspects of glaucoma genetics. He is in collaboration with an international team of glaucoma specialists in the medical treatment of glaucoma.

Leadership positions: Prof. Irkec served as the Chairman of the Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey for nine years. He is the Director of the Glaucoma Service at that Department. He has more than 100 scientific papers published in peer-reviewed international journals and has given many lectures in international meetings and various European Universities on invitation. He is a reviewer for many international ophthalmology journals and is member of international scientific societies, such as EGS, ESCRS, ARVO, AAO, WGO, EVER.

Kyoko Ishida, MD, PhD
Affiliation: Assistant professor, Gifu University Graduate School of Medicine, Gifu, Japan.

Aiko Iwase, MD
Affiliation: Director, Tajimi Iwase Eye Clinic, Gifu, Japan, Visiting Guest Professor, Tokai University, Kanagawa, Japan, Visiting Assistant Professor, Gifu University, Gifu, Japan, Visiting Assistant Professor, Kanazawa University, Ishikawa, Japan.
Areas of Interest: Glaucoma. Epidemiology
Leadership positions: Board Member, International Perimetric Society, Council Member of Japan Glaucoma Society (JGS), Council Member of Japanese Ophthalmological Society.
Special Honors: AIGS Award (2004) On behalf of the Tajimi Study group, Japan Ophthalmologists Association Chairman Award 2006.

Henry D. Jampel, MD
Affiliation: Odd Fellows Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University.
Areas of Interest: Patient-oriented outcomes of glaucoma treatment and detection of glaucoma progression.
Leadership positions: Associate Editor-in-Chief of Ophthalmology; Chairman of the Research Committee of the American Glaucoma Society; Member of the AAO Ophthalmic Technology Panel.

www.worldglaucoma.org
Simon W.M. John, PhD
Affiliation: Investigator/Professor, HHMI/Jackson Laboratory.
Areas of Interest: Genetics, Genomics, muscular degenerative mouse models.
Leadership positions: 1995–Present: Associate Staff, Staff and then Senior Staff Scientist/Professor (since 2006, institutional title change to professor system in 2008)), The Jackson Laboratory, Bar Harbor, ME; 1997–Present: Research Assistant/Professor, Ophthalmology, Tufts University School of Medicine, Boston, MA; 1998–Present: Assistant Investigator, Associate Investigator and then Investigator (since 2005), Howard Hughes Medical Institute; 2000–Present: Graduate Faculty, The University of Maine; 2003–Present: Cooperating Professor, Functional Genomics, University of Maine, Orono, ME.

Chris A. Johnson, PhD
Affiliation: Professor, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA 52242 USA.

Jost B. Jonas, MD
Affiliation: Professor, Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the Ruprecht-Karls-Universität Heidelberg, Germany.
Areas of Interest: Intravitreal application of medication as treatment of intraocular edematous, proliferative and neovascular diseases; Femtosecond laser surgery of the cornea; Contact lens associated ophthalmodynamometry; Accommodative cataract surgery; Near-Infrared inferometry for diagnosis of ocular diseases; Retinal stem cell research; Morphologic diagnosis of optic nerve diseases including the glaucoma’s; Leadership positions: Professor of Ophthalmology and Chairman.

Fridbert Jonasson, MD
Affiliation: Professor of Ophthalmology, Faculty of Medicine, University of Iceland. Consultant Ophthalmic Surgeon, National University Hospital, Iceland.
Areas of Interest: Epidemiology of Eye Disease, in particular Age related Eye Disease. Genetics of Eye Disease and more recently combining Epidemiology and Genetics of Eye Disease. Definitions and Classifications of Glaucoma; combining Glaucoma /Exfoliation Epidemiology and Genetics.

Malik Kahook, MD
Affiliation: Associate Professor, Director of Clinical Research, Department of Ophthalmology, University of Colorado School of Medicine, Rocky Mountain Lions Eye Institute.
Areas of Interest: The role of lasers in the treatment of glaucoma. The role of oxidative stress in glaucomatous optic neuropathy. Combined glaucoma and cataract surgery.

Organized by The Hippocrates Glaucoma Foundation


Kenji Kashiwagi, MD
Affiliation: Associate Professor, Department of Ophthalmology, University of Yamanashi, Faculty of Medicine
Leadership positions: Counselor of the Japanese Glaucoma Society; Counselor of Japanese Ophthalmological Society; Counselor of Japanese Society for Ocular Pharmacology
Special Honors: Suda award (Japan Glaucoma Society); Rohto award (Rohto pharmaceutical company).

Michael A. Kass, MD
Affiliation: Professor and Chairman, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Areas of Interest: Glaucoma, Aqueous humor dynamics, Clinical trials in ophthalmology.


Jay Katz, MD, FACS
Affiliation: Professor, Jefferson Medical College, Attending Surgeon and Director, Glaucoma Service, Wills Eye Institute, Philadelphia, Pennsylvania; Professor of Ophthalmology at Jefferson Medical College, Thomas Jefferson University, in Philadelphia, Pennsylvania and Director of the Glaucoma Service at Wills Eye Institute.
Awards: Dr. Katz has been the recipient of various awards, including the American Academy of Ophthalmology (AAO) Senior Achievement Award in 2002 and the Joint Commission on Allied Health Personnel in Ophthalmology’s Faculty Award in 2003. He was named Distinguished Alumnus of the Yale University Eye Center in 2003 and became a Honored Life Member of the Philadelphia Ophthalmic Club in 2007. Dr. Katz has published more than 120 articles in such journals as Archives of Ophthalmology, the American Journal of Ophthalmology, Ophthalmology, and the Journal of Glaucoma. He is an Editorial Board member for Journal of Glaucoma, Survey of Ophthalmology, Clinical Therapeutics and Graefe’s Archives of Clinical and Experimental Ophthalmology. He has authored, co-authored, or edited more than 30 books and book chapters.

Paul L. Kaufman, MD
Affiliation: Professor and Chair of the Department of Ophthalmology and Visual Sciences at the University of Wisconsin Medical School, Madison, Wisconsin, U.S.A.
Areas of Interest: Dr. Kaufman is a physician-scientist, specializing in glaucoma and studying the mechanisms of aqueous humor formation and drainage, and the age-related loss of near vision (presbyopia).

www.worldglaucoma.org
Leadership positions: Past President and current Executive Vice President of the Association for Research in Vision and Ophthalmology; Past President of the International Society for Eye Research. Past/present member of the US National Advisory Eye Council, numerous foundation and corporate scientific advisory boards; reviewer for all the major eye journals and guest editor or editorial board member for many of them; continuous research funding from the US National Eye Institute for 28 years; authored nearly 300 original scientific articles and 50 book chapters, co-edited several textbooks including the most recent edition of Adler’s Physiology of the Eye: Editor-in-Chief of Invest. Ophthalmol Vis Sci commencing in 2008. Distinguished lectures: Numerous. Special Honors: Doctor Honoris Causa, Medical Faculty, University of Uppsala, Uppsala, Sweden (2003); Association of International Glaucoma Societies Award (formerly International Glaucoma Reviews Award) for best glaucoma paper of 2003 (Gabelt BT, Gottanka J, Lütjen-Drecoll E, Kaufman PL: Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. Invest Ophthalmol Vis Sci 44:2118-2125, 2003.)

Anastasios G. Konstas, MD, PhD
Affiliation: Associate Professor in Ophthalmology, Head of the Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece. Research Interests: Medical therapy. Pathogenesis and management of exfoliative and primary open-angle glaucoma. 24-hour IOP monitoring and control in glaucoma. Role of fixed combinations in glaucoma. Adherence with medical therapy. Overall, more than 90 glaucoma publications in 16 peer-reviewed journals and 11 chapters in various glaucoma books. Leadership Positions: Board member of the Greek Glaucoma Society (2001-2005); Vice President of the Pan-Hellenic Ophthalmological Society (2003-2005). Member of the IGS Executive Committee (2005-07).

Michael S. Kook, MD
Affiliation: Professor of Ophthalmology at the University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea. Areas of Interest: Imaging studies in glaucoma; Wound healing in glaucoma surgery; Normal-tension Glaucoma; pharmacotherapy in glaucoma; Imaging devices in glaucoma, Ocular blood flow and its association with glaucoma, Natural course of normal tension glaucoma, Glaucoma progression, Pharmacologic approach to glaucoma treatment, Blood flow enhancement in the treatment of glaucoma, Glaucoma progression and its detection. Leadership positions: Executive member of the Korean Glaucoma Society; Chief ophthalmology consultant for 121 US Army Hospital in Seoul, Korea; Executive director of Korean American Ophthalmology Circle. Special Honors: Special honors: Best publication awards at International Glaucoma Symposium (IGS); Who’s Who in America (Marquis); International scientist of the Year (IBC, England); Glaucoma Publication of the year 06” - the Korean Glaucoma Society. Award by the American Academy of Ophthalmology.; who’s Who in Medicine by Marquis; special honors by various international society meetings.

Leadership positions: Past President and current Executive Vice President of the Association for Research in Vision and Ophthalmology; Past President of the International Society for Eye Research. Past/present member of the US National Advisory Eye Council, numerous foundation and corporate scientific advisory boards; reviewer for all the major eye journals and guest editor or editorial board member for many of them; continuous research funding from the US National Eye Institute for 28 years; authored nearly 300 original scientific articles and 50 book chapters, co-edited several textbooks including the most recent edition of Adler’s Physiology of the Eye: Editor-in-Chief of Invest. Ophthalmol Vis Sci commencing in 2008. Distinguished lectures: Numerous. Special Honors: Doctor Honoris Causa, Medical Faculty, University of Uppsala, Uppsala, Sweden (2003); Association of International Glaucoma Societies Award (formerly International Glaucoma Reviews Award) for best glaucoma paper of 2003 (Gabelt BT, Gottanka J, Lütjen-Drecoll E, Kaufman PL: Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. Invest Ophthalmol Vis Sci 44:2118-2125, 2003.)

Peng Khaw, PhD, FRCS, FRCophth, FRCP, FIBiol, FRCPath, FMedSci
Affiliation: Professor of Glaucoma and Ocular Healing, and Consultant Ophthalmic Surgeon. Affiliation: Moorfields Eye Hospital and UCL Institute of Ophthalmology, London. Areas of Interest: Wound healing, tissue repair and regeneration, stem cells, glaucoma surgery techniques, clinical trials. Leadership positions: Director, UK National Institute for Health Biomedical Research Centre (Ophthalmology). Director of Research and Development, Moorfields Eye Hospital, London, UK. Head, Ocular Repair and Regeneration Unit, and Pediatric Glaucoma Service Moorfields Eye Hospital. Special Honors: First ARVO/Pfizer Translational Research Award (2005); 25th Dame Ida Mann Lecture (2004); Alcon Research Award for Scientific Excellence. 12th Sir Stewart Duke Elder Lecture (2003); Elected to British Academy of Medical Sciences (2002); Hunterian Professorship, Royal College of Surgeons. IGR Award for Best Research Pa-
Theodore Krupin, MD
Affiliation: Professor, Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Areas of Interest: Current research interests include coordination of a multicenter study of low pressure glaucoma and clinical outcomes of glaucoma surgical therapies.
Leadership positions: American Glaucoma Society (AGS); President Glaucoma Foundation, New York; Board of Directors World Glaucoma Association (WGA); Board of Governors

Cost-effectiveness research, Measurement of Quality of Life.

Yves Lachkar, MD
Affiliation: Head of department of Ophthalmology at the Saint-Joseph Foundation Hospital; director of the Institute of Glaucoma in Paris. Professor, College of Medicine of Paris Hospitals.
Areas of Interest: His research interests are non penetrating surgery and wound healing.
Special Honors: In 1992 Yves Lachkar wrote his doctorate thesis at the faculty of medicine Necker-Enfants Malades in Paris and he was awarded a fellowship in Glaucoma (European Glaucoma Society) from Western Eye and Moorfield Eye Hospitals in London in 1996.

Dennis Lam, MD, FRCOphth (UK)
Affiliation: Chairman of the Department of Ophthalmology & Visual Sciences of the Faculty of Medicine, The Chinese University of Hong Kong; Director of the Joint Shantou International Eye Centre of the Shantou University and the Chinese University of Hong Kong.
Areas of Interest: Research Interests: Angle-closure glaucoma; Glaucoma surgeries; Glaucoma genetics.
Leadership positions: Member of the Board of Governors of the World Glaucoma Association; One of the four program directors of the 3rd World Glaucoma Congress 2009; Council Member of the International Council of Ophthalmology; Congress President and Chairman of the Organizing Committee of the World Ophthalmology Congress 2008; Secretary-General of the Asia-Pacific Academy of Ophthalmology; Founding President of the Asia-Pacific Society of Eye Genetics (2002-2007); Founding and Current President of the Project Vision Charitable Foundation; a Hong Kong Deputy of China’s National People’s Congress (2008-2012).

www.worldglaucoma.org
World Glaucoma Congress, July 8-11, 2009

Special Honors: Special Honors: AAO Senior Achievement Award (2008); Asia-Pacific Academy of Ophthalmology De Ocampo Lecture (2003); Hong Kong Humanity Award (2007); Ten Outstanding Young Persons of the World (1995).

**George N. Lambrou, MD, PhD**
Affiliation: George Lambrou, an Athenian by birth, graduated from the University of Strasbourg, where he also trained in Ophthalmology. He completed a four-year fellowship in the Glaucoma Department of the University of Amsterdam, where he obtained his PhD based on his research on Ocular Blood Flow. After another six years as Consultant in the Eye Clinic of the University of Strasbourg, he served as Global Head of Ophthalmic Research at Novartis for eight years. He is currently practicing Ophthalmology, with special emphasis on Glaucoma, in the Athens Ophthalmologic Institute.
Areas of Interest: Ocular Blood Flow, Pharmacology and Fundus Imaging.
Leadership positions: Executive Vice-Chair of the Liaison Committee of the World Glaucoma Patient Organization, and of the World Glaucoma Day Committee of the WGA, he is the Global Project Leader for the World Glaucoma Day.

**Marc Latina**
Affiliation: Associate Clinical Professor of Ophthalmology, Tufts University School of Medicine. Surgeon, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Leadership positions: Director, Glaucoma fellowship Program. Course Director- Cape Cod Innovations in Ophthalmology.
Special Honors: Honor Award - American Academy of Ophthalmology.

**Hans G. Lemij, MD, PhD**
Affiliation: Rotterdam Eye Hospital, Rotterdam, The Netherlands.
Research Interests: Glaucoma, notably imaging, perimetry and genetic epidemiology.
Leadership positions: He took the lead in establishing the Imaging and Morphometry Association for Glaucoma in Europe (IMAGE). Several research fellows have graduated as a PhD under his supervision. He also chairs the Dutch Glaucoma Group. He is a visiting Professor at the Catholic University Leuven, Belgium. University Leuven, Belgium.

**Fabian Lerner, MD**
Affiliation: Director, Glaucoma Section, Postgraduate Department, University Favaloro School of Medicine, Buenos Aires, Argentina.

**Ed U. Leuenberger, MD**
Affiliation: Director of the Glaucoma Fellowship Program of the Asian Eye Institute, Philippines; Assistant Professor in Ophthalmology and Chief of the Glaucoma Service at the University of the East Ramon Magsaysay Memorial Medical Center (ERMMMC).
Areas of interest: Improvement and development of glaucoma diagnostic and surgical procedures.

Organized by The Hippocrates Glaucoma Foundation
Christopher K.S. Leung, MD, MB, ChB  
Affiliation: Associate Professor, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong. Areas of Interest: Glaucoma diagnostics, Retinal ganglion cells Imaging, Angle closure glaucoma. Leadership positions: Leadership Positions: Associate advisory board member, WGC. Special Honors: Special Honors: Chevening Scholar, Fellow of Croucher Foundation.

Michele Lim, MD  
Affiliation: Associate Professor of Ophthalmology at the University of California, Davis School of Medicine. Vice Chair and Medical Director of the UC Davis Eye Center. Areas of Interest: Dr. Lim is a glaucoma specialist and divides her time between patient care, teaching, and research. Her area of interest is the Electronic medical record. Dr. Lim oversaw the implementation of the electronic medical record at the UC Davis Eye Center. She continues to work on its evolution as a patient care tool for ophthalmology. Her research interests include optic nerve imaging, patient adherence to glaucoma medication, and personality studies in glaucoma patients. Leadership positions: Vice Chair and Medical director, UC Davis Eye Center. Co-Chair, Ambulatory Care Work Group, UC Davis Health System. Co-Chair, Pay for Performance Committee, UC Davis Health System. Preferred Practice Panel - American Academy of Ophthalmology 2009. Special Honors: 2008: UC Davis Health System Dean’s Award for Excellence in Clinical Care. 2005-present: American Board of Ophthalmology, Associate Examiner. 2005: Best Doctors in Sacramento.

Shan Lin, MD  
Affiliation: Associate Professor, Glaucoma Service, University of California, San Francisco. Director of Glaucoma Service, San Francisco General Hospital. Areas of Interest: Endoscopic Cyclophotocoagulation. He has numerous peer-reviewed publications on this field including a histopathological and vascular study of the effects of endoscopic versus transscleral cyclophotocoagulation. Angle Closure Glaucoma; Trabecular Meshwork. Dr. Lin has conducted several retrospective and prospective studies in Chinese Americans related to anterior segment imaging and risk for angle closure glaucoma. His laboratory interest is in fetal cell transplantation for replacement of trabecular meshwork cells in glaucoma. Leadership positions: Past President, Pacific Coast Oto-Ophthalmological Society; Organizer and Co-Founder, Meshwork Society; Program Chair and Co-Founder, UCSF Glaucoma Symposium; Chair of the Ophthalmic Technology Assessment Committee Glaucoma section; Chair of the American Glaucoma Society Subcommittee on Documents; Principal Investigator at UCSF for the Ocular Hypertension Study (OHTS) and the Allergan Memantine Study (Phase III).

Jeffrey M. Liebmann, MD  
Affiliation: Clinical Professor of Ophthalmology, New York University School of Medicine; Director, Glaucoma Services, Manhattan Eye, Ear and Throat Hospital and New York University Medical Center, New York, New York, U.S.A. Research Interests: Investigations into the causes of glaucoma, ocular imaging, and neuroprotection. Leadership Positions: Vice President and President-Elect, American Glaucoma Society; Board of Governors, World Glaucoma Association; Secretary-Treasurer of the New York Glaucoma Society; Board of Directors, The Glaucoma Foundation.

www.worldglaucoma.org
World Glaucoma Congress, July 8-11, 2009

Dr. Beverley Lindsell
Affiliation: Beverley Lindsell is the National Executive Officer of Glaucoma Australia. For the past ten years, her position has entailed: overseeing the administration of the Association and its staff, acting as the Association’s media relations officer, traveling extensively to lead glaucoma meetings around Australia, conducting telephone counseling, managing fundraising programs, producing newsletters and brochures and overseeing support groups. She has established new offices in Victoria and Western Australia. During her time with Glaucoma Australia she has assisted with the formation of the New Zealand and Singapore Glaucoma Associations. Beverley is a member of the Lions’ Eye Health Program, Vision 2020 Australia, is a past member of the Fundraising Institute of Australia and is Vice-President of the Association of International Glaucoma Patients Organisation.

James Lindsey, MD, PhD
Affiliation: Adjunct Professor of Ophthalmology, Hamilton Glaucoma Center and Department of Ophthalmology, School of Medicine, University of California San Diego, La Jolla, CA, U.S.A.
Areas of Interest: Cellular and tissue mechanisms of optic nerve damage, brain changes, and aqueous humor outflow in glaucoma. Mechanisms of neuronal repair, plasticity, and glaucoma cell biology. Topics of study have included neuronal aging, fast axonal transport, retinal neuron survival factors, uveoscleral outflow, pigment regulation, matrix metalloproteinases, and the development of mouse models of glaucoma.

John Liu, PhD
Affiliation: Adjunct Professor and Director of Molecular Pharmacology, Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego. Faculty member, Graduate Program in Neurosciences, Sam and Rose Stein Institute for Research on Aging, and Institute of Engineering in Medicine, University of California, San Diego.
Areas of Interest: Regulation of intraocular pressure and ocular blood flow, aqueous humor dynamics, ocular pharmacology, circadian rhythm, and continuous monitoring of intraocular pressure.
Leadership positions: Past vice president of the Association for Ocular Pharmacology and Therapeutics.

Da-Wen Lu, MD
Affiliation: Associate Professor of Dept of Ophthalmology, Tri-Service General Hospital, Taipei, Taiwan. Chief of Glaucoma Services at Tri-Service General Hospital.
Areas of Interest: Investigation in the causes of glaucoma, Glaucoma filtering surgery, clinical trials and neuroprotection. Ocular pharmacology, Glaucoma surgery, Neuroprotection
Leadership positions: President of Taiwan Glaucoma Society, Board member of South East Asia Glaucoma Interest Group, Board member of Glaucoma Research Society, Board member of Taiwan Academy of Ophthalmology
Special Honors: Outstanding performance awards from National Science Council of Taiwan. Outstanding performance award from Asia-Pacific Academy of Ophthalmology.

David Mackey, MD, FRANZCO
Affiliation: Professor, Lions Eye Institute, University of Western Australia. University of Tasmania; Centre for Eye Research Australia, University of Melbourne.
Areas of Interest: Genetic Eye Disease, with a particular interest in Glaucoma and Optic Atrophy.

Organized by The Hippocrates Glaucoma Foundation

Anil Kumar Mandal, MD
Affiliation: Director, Jasti V Ramannama Childrens Eye Care Centre, Consultant, VST Centre for Glaucoma care, L V Prasad Eye Institute, Banjara Hills, Hyderabad, India.
Honors and Awards: Winner of International Film Festival, ASCRS (2002); Shanti Swarup Bhatnagar Prize in Medical Science (2003); Col. Rangachari Award AIOS (2003); CS Reshmi Award for best film in AIOC (2004); Apollo Award of Medical Excellence (2004-05); Bharat Jayanti Award by India International Friendship Society 2006. Senior achievement award by American Academy of Ophthalmology in 2008.

Baskaran Mani, DO, DNB (India)
Affiliation: Clinical Research Fellow, Singapore National Eye Centre and Singapore Eye Research Institute, Singapore.
Areas of Interest: IOP correction factors, Angle Closure Glaucoma, Epidemiology of Glaucoma, Lifestyle and glaucoma.
Leadership Positions: Associate board member, WGA.

Steven L.M. Mansberger, MD, MPH
Affiliation: Associate Scientist and Director of Ophthalmic Clinical Trials for Devers Eye Institute, Portland, Oregon; Director of Glaucoma Services at the Veterans Administration Hospital, Portland, Oregon; appointments at Oregon Health Science University (OHSU) as Adjunct Assistant Professor of Ophthalmology and Clinical Assistant Professor of Public Health and Preventive Medicine.

Areas of Interest: Biostatistics and Ocular Epidemiology; Glaucoma research.
Leadership Positions: a.o. Surgical Advisory Committee, Legacy Health System; Communications Committee, American Glaucoma Society; Editor, American Glaucoma Society Quarterly Newsletter; Association of International Glaucoma Societies Co-Chair- Economics and Clinical Trials.

Keith R.G. Martin, MA, DM, MRCP, FRCOphth
Affiliation: University Lecturer and Consultant in Ophthalmology; Cambridge University Centre for Brain Repair, Cambridge; Eye Department, Addenbrooke’s Hospital, Cambridge, UK.
Areas of Interest: Research work is focused on the mechanisms of visual loss in glaucoma and the development of new treatment approaches. Currently developing gene therapy and stem cell techniques to try to prevent visual loss due to glaucoma and ultimately to restore vision in those blind due to the disease.
Leadership positions: World Glaucoma Association (Executive Committee Member and Treasurer, 2009 -). Basic Science Section, Co-Editor, Journal of Glaucoma; Glaucoma Research Lead, University of Cambridge; Lead Clinician for Glaucoma, Cambridge University Teaching Hospitals NHS Foundation Trust.
Special Honors: American Glaucoma Fellows Award Program Merit Award (for Best Research by a Glaucoma Fellow in the USA, 2002); Awarded Doctor of Medicine degree by Oxford University in 2004 for glaucoma research; NC3R Prize 2009, GSK Clinician Scientist Fellowship, 2005–2010.
World Glaucoma Congress, July 8-11, 2009

Dr. Cynthia Mattox
Affiliation: Vice Chair, Dept Ophthalmology, Tufts University School of Medicine. Director, Glaucoma and Cataract Service, New England Eye Center, Boston, MA.
Special Honors: AAO Achievement Award

Eugenio Maul, MD
Affiliation: Professor and Chairman, Department of Ophthalmology, Universidad Catolica Medical School, Santiago, Chile.
Areas of Interest: Developmental Glaucomas, Secondary Glaucomas, Optic disc and Visual Field Correlations.

James McAlister FRCS, FRCOph
Affiliation: Consultant Ophthalmic Surgeon, Prince Charles Eye Unit, King Edward VII Hospital, Windsor UK.
Areas of Interest: Extensive research and publications in glaucoma, particular interest in laser surgery techniques. Author of a number of publications in glaucoma and lasers, several book chapters and a text book.
Continuing interest in laser techniques for treating glaucoma, more recently in the use of SLT.
Leadership positions: UK & Eire Glaucoma Society, Secretary.

Dr. Grant D. McLaren
Affiliation: Principal specialist at St John Eye Hospital, University of Witwatersrand Division of Ophthalmology. Head of the St John Eye Hospital.
Areas of Interest: medical management of glaucoma and the adjunctive use of SLT in glaucoma. Cyclodiode ablation in the management of refractory glaucoma and its possible application as primary therapy in glaucoma. Neurological aspects of glaucoma and IOP independent causes of glaucoma progression. Ocular perfusion and progression is a special fascination of mine. I am supervising registrar M. Med dissertations on analysis of reasons for late presentation of glaucoma and vascular risk factors in incident/newly developing POAG and progression of glaucoma.

Felipe Medeiros, MD
Affiliation: Associate Professor of Ophthalmology, Hamilton Glaucoma Center, University of California San Diego, La Jolla, CA, U.S.A.
Research interests: Imaging of the optic disc and retinal nerve fiber layer, development of new methods for early detection of glaucoma, and elucidation of potential risk factors for development and progression of glaucoma.
Leadership Positions: Associate member of the Advisory Board of the Association of International Glaucoma Societies (AIGS); member of the Latin American Glaucoma Society and Association for Research in Vision and Ophthalmology (ARVO).

Organized by The Hippocrates Glaucoma Foundation
Shlomo Melamed, MD, PhD
Affiliation: Professor of Ophthalmology, Tel Aviv University Medical School, Tel Aviv, Israel; Director, the Sam Rothberg Glaucoma Center, Goldschleger Eye Institute, Tel Hashomer, Israel.

Georg Michelson, MD
Affiliation: Extraordinary Professor, Head of Outpatient Department, Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany.
Research Interests: Automatic Glaucoma Screening; Ocular Circulation in Glaucoma; Telemedical Assessment of Retinal Images; Tele-education in Ophthalmology.

Clive Migdal, MD, FRCS, FRCOphth
Affiliation: Western Eye Hospital, London.

Stefano Miglior, MD
Affiliation: Professor of Ophthalmology, Department of Neurosciences, University of Milan-Bicocca; Head of the Department of Ophthalmology, Polyclinico di Monza, Monza (MI), Italy.
Areas of Interest: Glaucoma, all areas; Imaging of the optic disc and RNFL; Visual field evaluation; Medical therapy of glaucoma; Clinical trials; Risk factors for glaucoma; Cataract and glaucoma.
Leadership positions: Principal Investigator of the study: ‘European Glaucoma Prevention Study’, Funded by the European Commission in the BIOMED 2 program and Merck; Co-Investigator of the study: ‘EGPS-OHTS Collaborative Analysis’, funded by the National Eye Institute; Co-Investigator of the study: ‘EGPS-OHTS Collaborative Analysis’ - role of Confocal Scanning Laser Ophthalmoscopy, funded by the National Eye Institute; Member of the Scientific Board of the ‘International Society of Imaging in the Eye (ISIE)’.

Richard Mills, MD, MPH
Affiliation: Former Clinical Professor of Ophthalmology and Acting Chair, University of Washington and Chair, University of Kentucky. Current: Glaucoma Consultants NW, Seattle and Chief Medical Editor, Eye Net Magazine.
Areas of Interest: Visual fields, Optic disc imaging, Angle surgery, Compliance.
Leadership Positions: President, AAO; Secretary, AGS; Director, ABO; General Secretary, IPS; Program Chair, AOS; Chair, Eye Care America, Foundation of the AAO; Vice-Chair, Residency Review Committee; Delegate, AMA and ABMS, Trustee, WSMA, Past-president, WAEPS.
Special Honors: Sigma Xi, Phi Beta Kappa, Alpha Omega Alpha, AAO Senior Honor Award.

Donald S. Minckler, MD

www.worldglaucoma.org
Hiromu Mishima, MD, PhD
Affiliation: Professor, Director of JR Hiroshima General Hospital, Former Professor and Chairman of Department of Ophthalmology and Visual Science Hiroshima University, Former Special Advisor of Hiroshima University President, Special Advisor of Japanese Health and Welfare Ministry.
Leadership Positions: Executive Counsel of Japanese Glaucoma Society, Representative JGS of AIGS, Executive Counsel of APAO, Former Vice President of ISER, Member of IGS, Executive Counsel of Japanese Ocular Pharmacological Society.
Special Honors: Special Award of ISER, Special Award of Minister of Japanese Health and Welfare Ministry, Award of AIGS, Special Award of Alumni of Hiroshima Medical School.

Paul Mitchell, MD, PhD, FRANZCO, FRCOphth
Affiliation: Professor of ophthalmology at the University of Australia; Hospital Director of Ophthalmology for the western Sydney area.
Research Interest: Epidemiology of eye diseases, including glaucoma. His research has contributed to public health and ophthalmic epidemiology via the Blue Mountains Eye Study (BMES) that has already yielded 285 publications including the New England Journal of Medicine (NEJM). He has published 380 peer-reviewed scientific papers and has supervised 21 completed PhD students.

Organized by The Hippocrates Glaucoma Foundation

Special honors: Paul Mitchell was awarded the 2004 AIGS award for research into the epidemiology of glaucoma.

Dr. Anthony Molteno
Affiliation: Head of the Ophthalmology Section at the University of Otago Dunedin School of Medicine in Dunedin New Zealand.
Areas of Interest: Glaucoma, visual development and the application of photostress techniques to investigate and manage infants with strabismus and amblyopia, photostress for cataract diagnosis and long term outcomes of bone derived hydroxyapatite orbital implants. His Otago Glaucoma Surgery Outcome Study, which follows over 1,860 of his eponymous Molteno implant operations or trabeculectomy operations at Dunedin Hospital since 1976, is producing numerous studies on the outcomes of different glaucoma groups and the histology, immunohistochemistry and electron microscopy of capsules surrounding Molteno implants. He has published over 90 journal articles and 6 book chapters.
Leadership positions: He is a previous president of the Ophthalmological Society of New Zealand.
Special Honors: Goldmann Medal from the International Glaucoma Societies in 1998. He was admitted as an Honorary Fellow of the College of Ophthalmologists of the Colleges of Medicine of South Africa in 2001. He was awarded an Officer of the New Zealand Order of Merit in the New Year’s Honors List in 2005 for his services to ophthalmology and people with glaucoma.

Mr. James Morgan
Affiliation: Reader in Ophthalmology, School of Medicine, Cardiff University, Cardiff, UK.
Areas of Interest: Low tension glaucoma and the management of complications arising from glaucoma surgery or trauma. We work closely with optometrists to share the care of glaucoma patients and are devising clinical pathways in which patient information is monitored electronically. We have developed novel software tools based on digital stereoscopic disc analysis to teach optic disc assessment and to detect the earliest signs of optic disc damage. My laboratory uses a variety of glaucoma models to study changes in retinal ganglion cells and optic nerve that occur in glaucoma. We are currently focusing on the development of digital imaging methods, based on ultrahigh resolution OCT to detect...
changes in retinal ganglion cells that precede neuronal death. It is possible that these OCT techniques will also be able to monitor some of the function effects of damage (optophysiology). I have a longstanding interest in understanding the changes that precede RGC death; these are manifest as cell shrinkage and neurite pruning - both of which can be quantified in experimental glaucoma models with a view to reversing these early changes for the restoration of vision.


Dr. Sameh S. Mosaed
Affiliation: University of California, Irvine, Assistant Professor of Ophthalmology, Glaucoma/Cataract Surgery.
Areas of Interest: Treatment and management of complicated glaucoma. She is a highly-skilled clinician, surgeon, and teacher, and has particular expertise in the surgery of complicated glaucoma and cataracts. Dr. Mosaed has continued with her commitment to meaningful research in the field of ophthalmology, and has presented the results of her work at the annual meeting of the Association for Research in Vision and Ophthalmology over the past several consecutive years.

Leadership positions: Dr. Mosaed is regularly invited to speak at prestigious national and international meetings to discuss the results of her clinical and surgical research. She is a member of the American Academy of Ophthalmology, the New York State Ophthalmic Society, The Orange County Glaucoma Society, and is a certified member of the American Board of Ophthalmology. Dr. Mosaed is currently the Director of the Glaucoma Fellowship Training Program at UC Irvine, and she is also the Director of Glaucoma Services at the Long Beach Veteran’s Hospital, where she is the principal instructor of glaucoma surgery to the residents in training.

Special Honors: Dr. Mosaed has been honored with serving as an examiner for the American Academy of Ophthalmology’s national board examination and serves on the editorial board for the International Glaucoma Review.

Dr. Marco Nardi
Affiliation: Full Professor, Neuroscience Department, University of Pisa, Pisa, Italy
Areas of Interest: Glaucoma, Cornea.
Leadership positions: From 1983 to 1988 Hospital Assistant at Ophthalmic Department I of Florence University. From 1988 to 2002 Associated Professor, first in the Faculty of Medicine and Surgery of Cagliari University and thereafter in the University of Pisa. From 2002 Full Professor of Diseases of the Visual Apparatus at the University of Pisa. From 1994 Director of the School of Ophthalmic Specialization of Pisa University. From 1997 he has been Coordinator of the Corneal Transplant Program for the Tuscany Region. From 2000 to 2004 he was Italian Delegate for the UEMS Ophthalmology Section. Actually he is Italian Delegate for the European Board of Ophthalmology (EBO).

Special Honors: Vice president of Italian Glaucoma Society (SIGLA)

Dr. Peter Netland
Affiliation: Siegal Professor of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN, USA

Areas of Interest: Neuroscience. Ganglion cell death in glaucoma.

Leadership positions: Vice Chair, Research

Rob Nickells, MD, PhD
Affiliation: Professor, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA
Areas of Interest: Neuroscience. Ganglion cell death in glaucoma.

Leadership positions: Vice Chair, Research

Marcello T. Nicolela, MD, PhD
Affiliation: Associate Professor and Director of the Fellowship Program, Department of Ophthalmology and Visual Sciences of the Dalhousie University in Halifax, Canada.
Areas of Interest: Optic disc imaging, blood flow in glaucoma and clinical and surgical outcomes in glaucoma. He has several book chapters and over 45 peer-reviewed articles published in the main Ophthalmologic Journals.

www.worldglaucoma.org
World Glaucoma Congress, July 8-11, 2009

Leadership positions: Dr. Nicolela is currently the Secretary-Treasurer of the Canadian Glaucoma Society. He has been a member of Several Societies, including the AGS, AAO, COS, ARVO and others. In 2008 he was invited to join the Glaucoma Research Society, an international society including prominent scientists from all over the world.

Winnie Nolan, MD, FRCOphth
Affiliation: Glaucoma fellow, Moorfields Eye Hospital, London, UK; Honorary research fellow, Institute of Ophthalmology, London, UK.
Areas of interest: Angle closure glaucoma, Epidemiology of glaucoma, anterior segment imaging.

Constance Okeke
Affiliation: Glaucoma Specialist, Virginia Eye Consultants, Norfolk, VA, USA. Adjunct Assistant Professor of Ophthalmology, Scheie Eye Institute/ University of Pennsylvania, Philadelphia, PA, USA.

Paul Palmberg, MD, PhD
Affiliation: Professor, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine.
Areas of Interest: Clinical trial derived target pressures, long term outcomes of filtering surgery (CSI-Miami), techniques to avoid or repair complications of anti metabolite filtering surgery, novel slit lamp procedures in glaucoma management, gonioscopy; clinical trials in glaucoma (AGIS, CIGTS, FFSS), diabetes control and complications (DCCT), corneal transplantation media (HEPES buffer, color indicator), mentoring glaucoma specialists (81 Fellows, 106 foreign Fellows and Observers).
Leadership Positions: Past-President, Pan-American Glaucoma Society; Board member, Pan-American Association of Ophthalmology; President, Miami Ophthalmological Society; Chief of Staff, Anne Bates Leach Eye Hospital; Institutional Review Board, UM Med School.
Special Honors: Co-recipient, AGIS Award, 2001; Banting and Best Award (American Diabetes Association); Shaffer Lecture, AAO, 2005; Senior Honor Award, AAO; Professor of the Year, Bascom Palmer Eye Institute, 1995; Teaching Medals: Curso Andino 2001, Curso Guillermo Pico Santiago 2002; Honorary member Ophthalmological Societies of Chile, Costa Rica, Columbia, Dominican Republic, Peru, Venezuela, Guest of Honor 56 countries; Lectureships: Bryan (Duke), Wolfe (Iowa), Sugar (Henry Ford), Schoenfeld (Illinois), Demorest (UC Davis), Krieger (Mt. Sinai, Baltimore); Leopold (Allergan), Sampaolosi (PAGS), Latin-American Glaucoma Society; Best Doctors in America (1994-2007).

Rajul Parikh, MS, DO
Affiliation: Glaucoma Consultant and Head, Bombay City Eye Institute & Research Center, Mumbai, India.
Areas of Interest: Optic disc imaging, Primary Angle Closure Glaucoma, Progression, glaucoma epidemiology, evidence based ophthalmology, clinical epidemiology, angle closure progression, Identify appropriate strategy for glaucoma screening, Newer surgical option for glaucoma.

Organized by The Hippocrates Glaucoma Foundation
Leadership positions: Associate Board Member WGA, Member of WGA Committee on Glaucoma Society Organization. Past treasurer of Glaucoma Society of India. Co-investigator for international projects on primary congenital glaucoma

KiHo Park, MD, PhD
Affiliation: Associate Professor, Seoul National University College of Medicine, Seoul National University Hospital; Director of Public Relation of Korean Ophthalmological Society.
Areas of Interest: Normal Tension Glaucoma, Angle Closure Glaucoma, Neuroprotection, Early Detection of Structural Damage, Disc Hemorrhage and Peripapillary Atrophy.
Leadership Positions: Steering Committee Member of WGA; Consensus and Guidelines Committee Member of WGA; General Secretary of 2008 SEAGIG Organizing Committee; Board Member of SEAGIG; Editorial Board of Asian Journal of Ophthalmology; Scientific Program Committee Co-Director of Asian Angle-Closure Glaucoma Club (AACGC); Associate Editor of AACGC Textbook; Director of Public Relation of Korean Ophthalmological Society; Editorial Board of Korean Journal of Ophthalmology; Past Director of Scientific Program of Korean Glaucoma Society. Special Honors: Invited Lectures and Speakers of Courses in Asia Pacific Academy of Ophthalmology (APAO), WGC, WOC, SEAGIG, AACGC, and AOGS, Topcon Ophthalmology Award, Jules Stein Eye Institute Laboratory Research Award, Yonahm Academy Award from Korean Glaucoma Society, Taejoon Service Award from Korean Ophthalmological Society, Distinguished Service Award from APAO.

Richard Parrish, MD
Affiliation: Professor, Associate Dean for Graduate Medical Education, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Designated Institutional Official, Jackson Memorial Hospital, Miami, FL, U.S.A.
Areas of Interest: Glaucoma surgery outcomes, patient education, quality of life.
Leadership positions: Co-chairman, Ocular Hypertension Treatment Study; Associate Editor, American Journal of Ophthalmology; Editor, Ophthalmology. Monograph Series; Transactions of the American Ophthalmological Society. Editorial board member, Evidence-Based Eye Care, Ophthalmic Surgery Lasers & Imaging; Clinical & Surgical Ophthalmology. Special Honors: Named Lecturers: Schutz (Manhattan Eye, Ear and Throat Hospital, 1998); Hogan (Cordes Eye Society, 1998); Schoenberg (New York Society of Clinical Ophthalmology, 1998); Barnshaw (Wills Eye Hospital, 1999); Doheny (University of Southern California, 1999); Humphries (University of Virginia, 1999); Feldman (Krieger Eye Institute, 1999); King Khaled (Saudi Ophthalmological Society, 2000); Bradley (University of Iowa, 2000); Lorenzetti (McGill University, 2000); Norton (Bascom Palmer Eye Institute, 2001); Arnold (University of Tennessee Health Sciences Center, 2001); King (Uniformed Services University, 2002); Jampeal (Wayne State University, 2002); Schoenberg (Illinois Eye and Ear Infirmary, 2003), and the American Journal of Ophthalmology lecture at the 2007 meeting of the Pan American Association of Ophthalmology meeting in Cancun, Mexico.

Lou Pasquale, MD
Affiliation: Co-Director, Glaucoma Service Massachusetts Eye and Ear Infirmary. Director, Teleretinal Program Massachusetts Eye and Ear Infirmary. Research Director Ocular TeleHealth Center, Boston VA Hospital, Associate Professor of Ophthalmology Harvard Medical School.
Areas of Interest: Primary open-angle glaucoma (POAG), Telemedicine. I have taken a candidate approach to discover gene-environment interaction terms in POAG. This work has generated the largest known population-based, case-control group consisting of incident POAG cases with archived DNA samples and repeated, validated environmental exposure information. I am now funded through the National Human Genome Research Institute to use this case control sample in a high throughput genotyping effort with the long-term goal of identifying the full complement of genes, gene-gene and gene-environment interactions associated with POAG.
Leadership positions: AGS Program Committee and Research Committee. Co-Chair Local Organizing Committee World Glaucoma Congress. Special Honors: 2006: Achievement Award, American Academy of Ophthalmology. 2007: Best Doctors in Massachus-
Lutz E. Pillunat, MD, PhD
Affiliation: Professor, Chairman, Augenklinik und Poliklinik, Medizinische Fakultät Carl Gustav Carus, Dresden, Germany.

Dr. Vittorio Porciatti
Affiliation: Research Professor of Ophthalmology, Interim Research Director, Bascom Palmer Eye Institute.
Areas of Interest: Visual neurophysiology, applied to clinical and experimental models of glaucoma.
Leadership positions: P.I. on two NEI-funded grants focus in on glaucoma. P.I. on a NEI-funded Vision Research Coree Grant, Bascom Palmer Eye Institute. Interim Research Director, Bascom Palmer Eye Institute. Faculty, Neuroscience Graduate Program, U Miami. Faculty, Biomedical Engineering Graduate Program, U Miami.

Dr. Bruce E. Prum
Affiliation: Associate Professor with Tenure, Department of Ophthalmology, University of Virginia


Harry Quigley, MD
Affiliation: Director, Glaucoma Service, Director, Dana Center for Preventive Ophthalmology, Wilmer Institute, Johns Hopkins University, Wilmer 120, Johns Hopkins Hospital, Baltimore, Maryland, U.S.A.
Research Interests: Glaucoma.
Special Honors: Senior Honor Award, American Academy of Ophthalmology (1997); International Glaucoma Review Award, Best Paper of the Year (2000); L. Harrell Pierce Teaching Award, Wilmer Residents (2003, 2nd time); Friedenwald Award, Association for Research in Vision and Ophthalmology (2004); Doyne Medal, Oxford Ophthalmological Congress (2004); Friedenwald Award (2004).

Dr. R. Ramakrishnan
Affiliation: Chief Medical Officer at Aravind Eye Hospital, Tirunelveli, India, one of the branches of World renowned Aravind Eye Care System, Madurai.
Leadership positions: At present he is the Head of Glaucoma Services, Aravind Eye Care System. President of Glaucoma Society of India during 2002-2004. He is very much actively involved in teaching and training of Residents, Glaucoma Fellows from India and other countries. He is closely associated with Johns Hopkins University. He was the Principal Investigator for the Aravind Comprehensive Eye Survey (ACES) and Mitomycin-C in Trabeculectomy Study.
Special Honors: He has published more than 40 papers in peer reviewed journals. He has been awarded many awards for his contribution in Academic and Community services.

Dr. Pradeep Ramulu
Affiliation: Assistant Professor, Wilmer Eye Institute, Johns Hopkins University.
Areas of Interest: Functional implications of eye disease, Utilization of health-care resources.
My research focuses on how eye disease affects important daily tasks, which an emphasis on directly measuring how tasks are performed.

Tony Realini, MD
Affiliation: Associate Professor of Ophthalmology, West Virginia University Eye Institute, Morgantown, WV, USA

Dr. Doug Rhee
Affiliation: Assistant Professor, Massachusetts Eye & Ear Infirmary, Harvard Medical School
Leadership positions: Medical Director of Satellite Facilities, Massachusetts Eye & Ear Infirmary.
Medical Director of Strategic Development & Networking, Massachusetts Eye & Ear Infirmary.

Robert Ritch, MD
Affiliation: Dr. Robert Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Surgeon Director and Chief of Glaucoma Services at the New York Eye & Ear Infirmary, and Professor of Clinical Ophthalmology at New York Medical College. He is a Fellow of the American Academy of Ophthalmology, American College of Surgeons, and Royal College of Ophthalmology.
Areas of interest: Glaucoma. He has co-authored or edited seven textbooks and over 1300 medical and scientific papers, book chapters, articles and abstracts. He has given 30 named lectures. He founded or co-founded the Glaucoma Foundation, the Optic Nerve Rescue and Regeneration Think Tank, the New York Glaucoma Research Institute, the World Glaucoma Patient Association, the Ophthalmic Laser Surgical Society, the New York Glaucoma Society, the Lindberg Society, the Von Graefe Society, and the ARVO Host-a-Research Program. He was one of the three organizers of the first annual World Glaucoma Day in 2008.

Leadership positions: He is a member of the Advisory Committee of the International Council of Ophthalmology and has been a Trustee and Vice-President of ARVO.

Special honors: Dr. Ritch has received the Ophthalmologist of the Year award (Heed Foundation), Gold Medal (Greek Glaucoma Society), Louis Rudin Award, Jesse H. Neal Award for Editorial Achievement, Bernstein Award for outstanding contributions to medicine, AAO Lifetime Achievement Award, Doan’s Distinguished Research Award (New York Medical College), The Glaucoma Foundation Award for Innovation and Excellence, TKC Liu Memorial Award, Distinguished Alumnus Award (Albert Einstein College of Medicine), and the ARVO Distinguished Service Award.

Prin RojanaPongpun, MD
Affiliation: Chief, Glaucoma service, Chulalongkorn University, Bangkok, Thailand; Chief glaucoma consultant, The Queen Sirikit National Institute of Child Health, Ministry of Public Health.
Research interest: Angle closure glaucoma, Medical therapy, Surgical treatment, Diagnosis & investigation, and Epidemiology.

Prin RojanaPongpun, MD
National representative to the International Federation of Ophthalmological Societies (IFOS).
Special honors: ‘Distinguished Service Award’ and ‘Prevention of Blindness Award’ from the Asia Pacific Academy of Ophthalmology. ‘ACE Educator’ award from Asia Pacific Society of Cataract & Refractive Surgery. AS-CRS Film Festival ‘First Place’ winner. Thai Red Cross Society Honor Award. Guest lecturer at numerous international congresses. The Knight Commander (Second Class) of the Most Exalted Order of the White Elephant of Thailand.

Luca Rossetti, MD
Affiliation: Associated Professor of Ophthalmology, University of Milan, San Paolo Hospital, Milan, Italy.
Areas of interest: Main research interest: Clinical research in glaucoma.
Leadership positions: Fellowships in the Clinical Epidemiology Laboratory at the Mario Negri Institute in Milan, and in the Clinical Trial Unit in the Department of Ophthalmology at the University of Maryland in Baltimore; Responsible for the Glaucoma Unit at the San Paolo Hospital since 2000.

Paul Roux, Mmed, FCO (SA), FRCOphth
Affiliation: Professor and Head of the Department of Ophthalmology of the University of Pretoria, South Africa.
Areas of interest: Glaucoma Surgery in Black Africans and Exfoliation Glaucoma in South Africa.
Leadership Positions: President SAGS (South African Glaucoma Society), Past General Secretary of the SASCRS (South African Cataract and Refractive Surgery Society). Special Honors: Award for Service from the Bureau for the Prevention of Blindness of the SA Council for the Blind.

Dr. Jose Sahel
Affiliation: Professor of Ophthalmology Pierre and Marie Curie Medical School, Paris VI, France.
Leadership positions: Academie des Sciences, Institut de France. Director of the Vision Institute, INSERM-UPMC Research Center 988 Paris. Cumberlege Professor of Biomedical Sciences, Institute of Ophthalmology, University College London. Chairman, Department of Ophthalmology: Centre Hospitalier National
Hiroshi Sakai, MD, PhD
Affiliation: Lecturer, Ophthalmology University of the Ryukyus, Okinawa, Japan. Areas of interest: Primary angle closure glaucoma, imaging of the anterior chamber.

Lisandro Sakata, MD, PhD
Affiliation: Glaucoma mentor of Universidade Federal do Parana, Brazil.
Areas of interest: Angle closure glaucoma, anterior segment imaging, glaucoma epidemiology, intra-ocular pressure, and biomechanics of the optic nerve head.
Leadership positions: He is a member of the WGA Associate Advisory Board, adjunct member of the Latin America Glaucoma Society, and member of the ARVO International Committee. He has served as an invited lecturer at research and educational events throughout the world. He also served as a reviewer for several publications, including Investigative Ophthalmology and Visual Science, Archives of Ophthalmology, Journal of Glaucoma, British Journal of Ophthalmology, and Eye. Dr. Sakata has authored or coauthored over 70 journal articles, abstracts, and book chapters in major ophthalmic publications.

Special Honors: He has been awarded the Tyson ARVO Award 2006, and ARVO International Travel Grant 2007.

Pamela Sample, PhD
Affiliation: Professor, Co-Director, Clinical Vision Research, Hamilton Glaucoma Center, Department of Ophthalmology, University of California at San Diego, La Jolla, California, U.S.A.
Research Interests: Improved diagnosis and management of glaucoma. Psychophysical assessment of specific retinal ganglion cell populations using visual function specific perimetry to determine ganglion cell susceptibility to glaucoma, rate of progression, and response to neuroprotective agents. Improved methods for visual field analysis and for separating true glaucomatous progression from change in visual function due to other factors such as variability. Application of machine learning classifiers in a multifactorial model for improved diagnosis and management of glaucoma. Understanding loss of visual function due to ancestry, aging, gender, genetics, and socioeconomic and cultural factors.
Leadership Positions: Principal Investigator: NEI funded Diagnostic Innovations in Glaucoma Study (DIGS): Visual Function; Principal Investigator: multicenter NEI-funded African Descent and Glaucoma Evaluation Study (ADAGES); Director, Visual Function Research Laboratory, Department of Ophthalmology, UCSD; Director, Visual Field Assessment Center (VisFACT), a reading center.
Dr. Thomas Samuelson
Affiliation: Founding partner and past managing partner of Minnesota Eye Consultants in Minneapolis. He also is Adjunct Associate Professor of Ophthalmology at the University of Minnesota. Areas of Interest: Glaucoma and anterior segment surgery. His research interests are in the medical and surgical treatment of glaucoma, especially exfoliation syndrome, canal based glaucoma surgery, intraocular lenses, and the management of coincident cataract and glaucoma. Additionally, Dr. Samuelson has performed research on the safety of LASIK in patients with other ocular disorders, especially glaucoma. Leadership positions: Past President of the International Society of Spaeth Fellows/Wills Eye Hospital Glaucoma Fellows Society. Past Chairman of the Phillips Eye Institute Medical Staff. Member of the American Glaucoma Society (AGS) and served on its Executive Committee. He is currently the Treasurer of the AGS. Chairman of the ASCRS Glaucoma Clinical Advisory Committee. He serves on the AAO Basic Science Board Review Committee, the AAO Skills Transfer Course Committee and as the Glaucoma Section Editor for Ocular Surgery News. He serves also as a scientific reviewer for several ophthalmology journals. Medical Director of the Kirby Puckett Education Center at the Phillips Eye Institute. Special Honors: Board certified by the American Board of Ophthalmology. AO Achievement Award in 2002 and the AAO Senior Achievement Award in 2008.

Ursula Schlötzer, PhD
Affiliation: Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany. Areas of Interest: Research Interests: Pseudoexfoliation syndrome, glaucoma, ophthalmopathology, corneal stem cells, extracellular matrix.

Dr. Leopold Schmetterer
Affiliation: Professor, Department of Clinical Pharmacology, Center of Biomedical Engineering and Physics, Medical University of Vienna. Areas of Interest: Ocular blood flow, glaucoma pathogenesis, retinal imaging. Leadership positions: Member of ARVO program committee, member of EVER board, EBM of Progress in Retinal and Eye Research, Acta Ophthalmologica, Current Eye Research, The Open Physiology Journal, President of Ocular Blood Flow Research Association (OBFRA), Chair of Scientific Committee of the Austrian Ophthalmological Society.

Dr. Joel Schuman
Affiliation: Eye and Ear Foundation Professor and Chairman of Ophthalmology, the Eye and Ear Institute, University of Pittsburgh School of Medicine and Director of the University of Pittsburgh Medical Center (UPMC) Eye Center; Professor of Bioengineering at the Swanson School of Engineering, University of Pittsburgh, and Professor in the Center for the Neural Basis of Cognition, Carnegie Mellon University and University of Pittsburgh and a member of the McGowan Institute for Regenerative Medicine. Areas of Interest: Glaucoma; Glaucoma surgeries; Ocular Regeneration and Vision Restoration Leadership positions: Founding member of the ARVO Multidisciplinary Ophthalmic Imaging cross-sectional group, served on the program committee from its founding and chairs the MOI program committee 2007-2008; Founder and chair of ARVO/ISIE (The International Society for Imaging in the Eye, inaugurated 2002). Co-chair of the International Glaucoma Symposium 1998-2007, the world’s largest meeting devoted to glaucoma, which merged with the World Glaucoma Congress in 2007, for which he is Program co-Chair 2007-2011. With the exception of a three year hiatus, he has chaired the Hawaiian Eye meeting glaucoma section since 1993. Special Honors: 2006 received the Association for Research in Vision and Ophthalmology (ARVO) Translational Research Award. 2008 elected to the American Ophthalmological Society. Received a 2006-2009 American Medical Association Physician’s Recognition Award with Commendation. Named in Who’s Who in America, Who’s Who in Medical Sciences Education, America’s Top Doctors and

Organized by The Hippocrates Glaucoma Foundation
Dr. Gail Schwartz
Affiliation: Assistant Professor, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Assistant Professor, University of Maryland School of Medicine, USA.

Michal Schwartz, PhD
Affiliation: Professor of Neuroimmunology, Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel.
Areas of interest: Neuroimmunology, Neuroprotection in glaucoma, cross-talk between immune and nervous systems in health and disease; Immunobased therapy for acute and chronic CNS insults; Immune and adult neurogenesis.
Special Honors: Career Woman of the year 2000, Israel; ARVO Award for outstanding research in the basic or clinical sciences as applied to ophthalmology (Friedenwald Award) (2002); The International Glaucoma Review Award for daring, breakthrough, creative, original research in glaucoma (2002); NARSAD Distinguished Investigators Award (2007).

Tarek Shaarawy, MD
Affiliation: Head of Glaucoma Department, in the University of Geneva, Switzerland.
Research Interests: New surgical techniques of glaucoma surgery.
Leadership Positions: Secretary General of the International Society of Glaucoma Surgery.

Mark Sherwood, MD, PhD
Affiliation: Daniels Professor Ophthalmology and Cell Biology, and Director of Vision Research Center, University of Florida.
Areas of Interest: Glaucoma Surgery and Wound Healing. Detection of Progression of Glaucoma, Social effects of Glaucoma
Leadership positions: Chair, American Academy Ophthalmology Online Education Committee; Past-Chair American Glaucoma Society Program Committee; Past-Chair ARVO Glaucoma Section Program Committee. Special Honors: American Academy Ophthalmology Senior Honors and Secretariat Award.

Bruce Shields, MD
Affiliation: Marvin L. Sears Professor and Chairman Emeritus, Department of Ophthalmology and Visual Science, Yale University School of Medicine.
Areas of Interest: Laser and incisional surgery for glaucoma.
Leadership positions: Past President of American Glaucoma Society; Past President of the North Carolina Ophthalmologic Society; Past Chairman of Board of Directors of American Board of Ophthalmology, Glaucoma Committee of National Society to Prevent Blindness and Glaucoma Program Committee of Association for Research in Vision and Ophthalmology. Special Honors: Forty-two named lectures, Life Achievement Honor Award of American Academy of Ophthalmology, Excellence in Teaching Awards at Duke University School of Medicine and Duke University Eye Center; ‘Ophthalmol-
World Glaucoma Congress, July 8-11, 2009

Organized by The Hippocrates Glaucoma Foundation

ogist of the Millennium’ by the International Academy for Advances in Ophthalmology; 2008 Honoree of American Glaucoma Society.

Brad Singleton, MD
Affiliation: Ophthalmic Consultants of Boston, Associate Clinical Professor of Ophthalmology, Harvard Medical School.
Areas of Interest: Cataract and glaucoma surgery; pseudoexfoliation.
Leadership positions: Past President, American Society of Cataract and Refractive Surgery.
Special Honors: Award and Senior Achievement Award, American Academy of Ophthalmology.

Ramanijt Sihota, MD, FRCS, FRCOphth
Affiliation: Head, Glaucoma research facility and clinical services at Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Areas of Interest: Primary Angle Closure Glaucoma, imaging, surgical techniques and drug therapy in glaucoma.
Leadership positions: Member, Glaucoma advisory group and Project evaluation committee of the Indian Council of Medical Research, the executive committee of SEAGIG and various committees of the WGA. She is a past president of the Glaucoma Society of India.
Special Honors: Many national and international awards for research in glaucoma, especially pertaining to primary angle closure glaucoma, neovascular glaucoma and imaging in glaucoma.

Kuldev Singh, MD, MPH
Affiliation: Professor of Ophthalmology, Director, Glaucoma Service, Stanford University, Stanford, CA, U.S.A.
Areas of Interest: Glaucoma, clinical epidemiology, economics of health care delivery, and ophthalmic approaches in developing countries.
Leadership positions: Executive Vice President, World Glaucoma Association; Chair, Board of Directors, Glaucoma Research Foundation; Board of Directors, American Glaucoma Society, Chair, Glaucoma Section of the Ophthalmology Technology Assessment Panel of the American Academy of Ophthalmology (AAO, 2002-2008); Glaucoma Subspecialty Day Co-Chair, AAO (2002, 2003), Medical Advisory Board, Unite for Sight; Faculty Senate, Stanford University School of Medicine.
Special Honors: Senior Achievement and Secretariat Awards from AAO in 2005 and 2006; First Prize, Cataract Surgery Section of the Challenge Cup, ASCRS, 2006; Franklin G. Ebaugh Award, Stanford University 2006.

Arthur Sit, SM, MD
Affiliation: Assistant Professor of Ophthalmology, Mayo Clinic College of Medicine. Consultant, Mayo Clinic, Rochester, MN, U.S.A.
Areas of Interest: Aqueous humor dynamics (basic physiology, circadian variations, changes with glaucoma therapy); Development of devices for continuous monitoring of IOP and measurement of episcleral venous pressure; Novel surgical devices and techniques; Epidemiology of glaucoma and blindness.
Special Honors: Special Honors: AGS 2007 Clinician-Scientist Award; AGS 2008 Young Physician-Scientist Award; Research to Prevent Blindness Robert & Helen Schaub Special Scholar Award.

Dr. Gregory Skuta
Affiliation: James P. Luton Clinical Professor at the Dean McGee Eye Institute/University of Oklahoma in Oklahoma City.
Areas of Interest: He has a particular research and clinical interest in wound healing and its modulation in glaucoma filtering surgery and glaucoma clinical trials. He has contributed to more than 100 publications, book chapters, and educational products.
Leadership positions: Member of the editorial board for the Journal of Glaucoma and an active member of the Glaucoma Research Society (formerly known as the Glaucoma Society of the International Congress of Ophthalmology). Senior Secretary for Clinical Edu-

Special Honors: Among his honors and awards are Phi Beta Kappa, president of the University of Illinois Varsity Men’s Glee Club, Alpha Omega Alpha Honor Medical Society, the Resident Teaching Award from the University of Michigan Department of Ophthalmology, and the AAO’s Honor Award and Senior Achievement Award. He is listed in Marquis’ Who’s Who in America, in Woodward/White’s The Best Doctors in America, and among America’s Top Ophthalmologists by the Consumers’ Research Council of America.

Dr. Kwok-Fai So
Affiliation: Chair Professor and Head, Dept of Anatomy, Jessie Ho Professor in Neuroscience, University of Hong Kong (HKU). Member of Chinese Academy of Sciences.
Areas of Interest: Axonal regeneration in visual system and spinal cord. Neuroprotective and regenerative factors including: peptide nanofiber scaffold, trophic factors, herbal extracts, other small molecules, immune responses and environmental manipulation.
Leadership positions: Co-Director, State Key Laboratory of Brain and Cognitive Sciences, HKU; Co-Chairman, Board of Director of China Spinal Cord Injury Network.
Special Honors: 2008 Research Output Prize (Li Ka Shing Faculty of Medicine), HKU, as co-author on the publication in Nature Medicine, 2007, 13 (10), 1228-33. 2006 China Spinal Cord Injury Rehabilitation Achievement Award by the (China Association of Rehabilitation of Disabled Persons (CAR), Committee on Spinal Cord Injury Rehabilitation), and (CARD-International Spinal Cord Society (CARD-ISCoS)). 1995 National Award in Natural Science, National Natural Science Foundation of China.

George Spaeth, MD
Affiliation: Louis J. Esposito Research Professor, Director, Glaucoma Service, Wills Eye Hospital, Philadelphia, Pennsylvania, U.S.A.
Areas of Interest: Developing valid, quantitative clinical measures, specifically of the nature of the anterior chamber angle, the optic nerve head, the ability to perform the activities of daily living and quality of life as they relate to vision, and surgical procedures. Being a mentor to all those wanting to create environments that encourage health of individuals, especially as related to those with glaucoma. Originally homocystinuria and blood flow to the optic nerve. More recently the optic disc, the anterior chamber angle, physician/patient communication, including development of a Code of Ethics.

Detlev Spiegel
Affiliation: Prof. Dr. med. Dr. med. habil. Attending surgeon, Klinik Vincentinum, Augsburg, Germany. Teaching faculty and consultant, University of Regensburg/Germany.
Areas of Interest: Glaucoma, glaucoma surgery (devices and wound healing).

Robert L. Stamper, MD
Affiliation: Professor and Director of the Glaucoma Service, University of California, San Francisco (UCSF), San Francisco, California, U.S.A.
Research Interests: Early diagnosis, Surgical approaches, pharmacology of glaucoma.
Dr. James Standefer  
Affiliation: Adjunct Professor of Ophthalmology at the University of Minnesota.  
Areas of interest: Glaucoma. Since 1993 he has a nearly full time job as an international volunteer. Utilizing the trainer of trainers principle he has taught a two week glaucoma workshop 36 times in the training centers of 26 developing countries. An incidental finding while conducting the workshops is the large knowledge gap in basic clinical ophthalmology in the majority of the training centers. Because glaucoma diagnosis demands a complete history and ocular examination, the workshop participants emerge with a marked improvement in basic clinical skills. At present, he is developing a plan to recruit senior ophthalmologists to serve 1-2 weeks teaching basic clinical ophthalmology to beginning residents in developing country training centers.  
Leadership positions: Chair of the AAO International Education Development Committee from 2001–2008.  
Special honors: He has been an invited speaker at numerous international meetings and has received awards including the AAO Outstanding Humanitarian Service Award, The AAO Foundation International Public Service Award, and AAO Global Alliance Secretariat Award. In 2003 he received the Distinguished Alumni Award from the Washington University Eye Alumni Association.

Kazuhisa Sugiyama, MD  
Affiliation: Professor & Chairman, Department of Ophthalmology & Visual Science Kanazawa University Graduate School of Medical Science, Kanazawa, Japan  
The in vivo imaging of retinal ganglion cells. One eye trial and how to determine glaucoma medication for each patient. Glaucoma screening methods using glaucoma imaging systems.  
Leadership positions: Board Member of Japan Ophthalmological Society (2003-). Executive Board Member of Japan Glaucoma Society (1998-). Board Member of Japan Ocular Pharmacology Society (2001-).  

Remo Susanna Jr, MD  
Affiliation: Associated Professor in Ophthalmology.  
Leadership positions: President and founder of The Latin America Glaucoma Society; President of World Glaucoma Association; Member International Committee ARVO 2002-2007; Member International Advocacy Committee ARVO 2002-2007; Member and Governor International Society for Imaging in the Eye 2000-2007. Member of the Executive committee of Glaucoma Research Society: Chairman World Glaucoma Consensus in IOP Fluctuation –2007. Special honors: Several awards in Latin America and Achievement Award American Academy of Ophthalmology. Patent: Susanna’s sets for glaucoma S-1 and S-2; suprachoroidal Shunt for glaucoma.

Ernst Tamm, MD  
Affiliation: Professor and Chairman, University of Regensburg, Institute of Human Anatomy and Embryology, Regensburg, Germany.  
Research Interests: Molecular pathogenesis of primary open-angle glaucoma; Control of gene expression in the outflow pathways of aqueous humor; Development of genetically engineered mouse models for primary open angle glaucoma; Molecular regulation of anterior eye development. Continuously funded for this work by the German Research Council since 1992.  
Leadership Positions: Professor and Chairman, Institute of Human Anatomy and Embryology, University of Regensburg, Regensburg, Germany; Council Member of the International Society for Eye Research (Counselor Europe), Member Editorial Board ‘Experimental Eye Research’, Section Editor ‘Aqueous Humor and Outflow Pathways‘; Member Editorial Board ‘Current Eye Research‘; Special Section Editor ‘Journal of Glaucoma‘, Member Scientific Advisory Committee of the Glaucoma Research Foundation, San Francisco, CA. Ad hoc grant reviewer of the German Research Foundation, the Israel Science Foundation and the Swiss National Science Foundation. Heisenberg-Award of the German Research Foundation.  
Special Honors: Glaucoma-Award of the German Society of Ophthalmology; Walther Kalkhof-Rose-Award of the Academy for Science and Literature, Mainz, Germany; Ruth Sal-
ta Junior Investigator Achievement Award of the National Glaucoma Research Program, American Health Assistance Foundation, Rockville, Maryland.

**Hidenobu Tanihara, MD**
Affiliation: Professor and Chairman, Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, Japan.
Areas of Interest: Aqueous Outflow Pathway, Retinal Ganglion Cell Death and Neuroprotective Therapy.

**Dr. Clement Tham**
Affiliation: Professor, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong. Coordinator of Glaucoma Service, Hong Kong Eye Hospital, Hong Kong.
Areas of Interest: Primary Angle-Closure Glaucoma (PACG). Role of lens extraction as treatment for established PACG, alone and in combination with other glaucoma procedures. Treatment by goniolysis (GSL) with or without lens extraction. New alternative first-line treatments in acute PACG – Argon Laser Peripheral Irido-plasty (ALPI) and Immediate Paracentesis. Prevention of progression of acute PACG to chronic PACG – ALPI and early lens extraction.

**Angelo P. Tanna**
Affiliation: Assistant Professor of Ophthalmology, Director, Glaucoma Service, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.
Areas of Interest: Diagnosis of glaucoma progression. Nocturnal intraocular pressure in normal-tension glaucoma. Optic disc and retinal nerve fiber layer imaging.

**Dr. Gulgun Tezel**
Affiliation: Professor, Department of Ophthalmology and Visual Sciences and Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Louisville, KY, USA.
Leadership positions: Investigative Ophthalmology and Visual Science Editorial Board Member; Von Graefe’s Society Charter Member; The Glaucoma Foundation Scientific Advisory Board Member.
Special Honors: Recipient of the Research to Prevent Blindness Sybil B. Harrington Scholars Award (2004); Louisville Science Center Kentucky-HEROS Award (2005); World Glaucoma Association Potential Future Impact Award (2008).

**S. Thanos, MD**
Affiliation: Prof. Dr. Dr. Experimental Ophthalmology, University of Münster, Germany.
Areas of Interest: Ophthalmology, glaucoma, optic nerve injury, optic nerve regeneration, axonal regeneration, optic nerve repair, stem cells and optic nerve.

Leadership positions: Head of Department

Ravi Thomas, MD
Affiliation: Director of Glaucoma Services and Education, Queensland Eye Institute, Brisbane, Australia. Professor University of Queensland, Brisbane, Australia.
Research Interests: Glaucoma, Cataract and Clinical Epidemiology.

Areas of Interest: Normal Pressure Glaucoma, Angle Closure Glaucoma, Image Analysis.

Leadership Positions: Past Editorial Board, Journal of Japanese Ophthalmological Society; Trustee, Japan Glaucoma Society; General Secretary of 14th Annual Meeting of Japan Glaucoma Society; Program Committee of 16th, 17th and 18th Annual Meeting of Japan Glaucoma Society; Executive Member of Asian Angle Closure Glaucoma Club. Special Honor: The Third Suda Award (Japan Glaucoma Society).

Goji Tomita, MD, PhD
Affiliation: Professor, Department of Ophthalmology Toho University School of Medicine, Director, Department of Ophthalmology Toho University Ohashi Medical Center.
Areas of Interest: Normal Pressure Glaucoma, Angle Closure Glaucoma, Image Analysis.

Leadership Positions: Past Editorial Board, Journal of Japanese Ophthalmological Society; Trustee, Japan Glaucoma Society; General Secretary of 14th Annual Meeting of Japan Glaucoma Society; Program Committee of 16th, 17th and 18th Annual Meeting of Japan Glaucoma Society; Executive Member of Asian Angle Closure Glaucoma Club. Special Honor: The Third Suda Award (Japan Glaucoma Society).

Areas of Interest: Ophthalmology, glaucoma, optic nerve injury, optic nerve regeneration, axonal regeneration, optic nerve repair, stem cells and optic nerve.

Leadership positions: Board member of Japan Glaucoma Society.

Fotis Topouzis, MD, PhD
Affiliation: Assistant Professor of Ophthalmology at the A Department of Ophthalmology, Aristotle University of Thessaloniki, Greece
Areas of Interest: Ophthalmic epidemiology, risk factors, glaucoma screening, genetic epidemiology in glaucoma, glaucoma pheno- typing, imaging, glaucoma surgical and medical management, age-related macular degeneration (AMD) screening, genetic epidemiology in AMD, AMD phenotyping, and AMD man- age- ment.

Leadership positions: Head and Founder of the Laboratory of Research and Clinical Applications in Ophthalmology, Aristotle University of Thessaloniki, Greece. Principal investigator of two large population-based studies: the Thessaloniki Eye Study and the Eureye Study. Secretary of GlaucoGENE, a special Interest group of the European Glaucoma Society. Board Member Executive Committee of the European Glaucoma Society. Co-chair Reporting and Publishing Committee of the World Glaucoma Association. Special Honors: 1988-1989 Distinguished foreign resident Award from the College of Medicine of the Hospitals in Paris; Post Doctoral Award from the Aristotle University of Thessaloniki, Greece; Shaffer International Fellowship Award from the Glaucoma Research Foundation, San Francisco, CA.

Dr. John Thygesen
Affiliation: Associate Professor. Director of The Glaucoma Clinic, Rigs Hospiatalet, University of Copenhagen, Denmark.
Leader- ship Positions: Founder and President of the Danish Interest Group of the European Glaucoma Society; Member of the Editorial Board American journal of Ophthalmology.
Special honors: Distinguished foreign resident Award from the College of Medicine of the Hospitals in Paris; Post Doctoral Award from the Aristotle University of Thessaloniki, Greece; Shaffer International Fellowship Award from the Glaucoma Research Foundation, San Francisco, CA.

Dr. Atsuo Tomidokoro
Affiliation: Assistant Professor, Department of Ophthalmology, University of Tokyo, Graduate School of Medicine.
Areas of Interest: Basic and clinical researches on ocular blood flow, imaging of the optic disc and anterior ocular segment, and epidemiological study on glaucoma.
Leadership positions: Board member of Japan Glaucoma Society.

Dr. John Thygesen
Affiliation: Associate Professor. Director of The Glaucoma Clinic, Rigs Hospiatalet, University of Copenhagen, Denmark.
Leadership Positions: Founder and President of the Danish Interest Group of the European Glaucoma Society; Member of the Editorial Board American journal of Ophthalmology.
Special honors: Distinguished foreign resident Award from the College of Medicine of the Hospitals in Paris; Post Doctoral Award from the Aristotle University of Thessaloniki, Greece; Shaffer International Fellowship Award from the Glaucoma Research Foundation, San Francisco, CA.

Dr. Atsuo Tomidokoro
Affiliation: Assistant Professor, Department of Ophthalmology, University of Tokyo, Graduate School of Medicine.
Areas of Interest: Basic and clinical researches on ocular blood flow, imaging of the optic disc and anterior ocular segment, and epidemiological study on glaucoma.
Leadership positions: Board member of Japan Glaucoma Society.

Organized by The Hippocrates Glaucoma Foundation
Dr. Carol Toris  
Affiliation: Professor and Director of Glaucoma Research, Department of Ophthalmology, Nebraska Medical Center, Omaha, NE, U.S.A.  
Areas of Interest: Aqueous humor dynamics. The production and drainage of aqueous humor in the eyes of animals including humans and nonhuman primates. We have investigated the effects on the eye of aging and circadian rhythms, various pathological states (including diabetes, pigmentary dispersion syndrome, exfoliation syndrome and ocular hypertension), new therapeutic agents, glaucoma drainage devices and combinations of therapeutic treatments. We also are involved in phase III and IV clinical trials of new glaucoma medications. Uveoscleral outflow remains my primary interest. Currently, we are studying aqueous humor dynamics and intraocular pressure in mice.  
Special Honors: 2006: Dr. Stan Truhlsen Research Award, Prevent Blindness Nebraska. 2009: ARVO Fellow (gold level)  

Dr. Graham E. Trope  
Affiliation: Professor of Ophthalmology at the University of Toronto.  
Areas of interest: Glaucoma research and treatment.  
Leadership positions: He has directed the Glaucoma Service at University Health Network since 1984. Past Chairman of Ophthalmology at the University of Toronto and past Ophthalmologist in chief at University Health Network. He has published over 150 scientific articles. He has been involved in Glaucoma Research and Treatment for over 30 years and is the Founder and Scientific Director of Glaucoma Research Society of Canada. He is the past Editor in Chief of the Canadian Journal of Ophthalmology. He has trained 30 glaucoma fellows from all over the world and is a past examiner for the Royal College of Physicians and Surgeons of Canada. He is a member of a number of learned societies and has published two books, one titled ‘Glaucoma, A patient’s guide to the disease’ is in its 3rd edition and the other, Glaucoma Surgery is considered a major text on the Surgery of the Glaucomas  
Special honors: The Ontario College of Physicians and Surgeons Council Award for his contributions to patient care.  

Jim C. Tsai, MD  
Affiliation: Robert R. Young Professor and Chairman, Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, U.S.A.  
Leadership positions: Fellow of the American Academy of Ophthalmology, the American College of Surgeons, and the Royal Society of Medicine in the United Kingdom; Panel consultant for the Ophthalmic Devices Panel of the U.S. Food and Drug Administration; Associate examiner for the American Board of Ophthalmology; Member of the National Eye Health Education Program Planning Committee of the National Institutes of Health; Member, Board of Directors of the Glaucoma Foundation, Chairman of its Medical Advisory Board.  
Special honors: Achievement Award from the American Academy of Ophthalmology.  

Anja Tuulonen, OYS, MD, PhD  
Affiliation: Professor of Ophthalmology, Institute of Clinical medicine/Ophthalmology, University of Oulu, Finland, Clinic head (Ophthalmology), Northern Ostrobotnian Hospital District, Oulu, Finland, Professor, Tampere School of Public Health, University of Tampere, Tampere, Finland, Project head, Tampere University Hospital, Tampere Finland.  
Areas of Interest: Critical evaluation of literature: evidence-based medicine and eye care. Leadership issues is health care. Health sciences research (glaucoma and eye care systems, health economics, modeling studies, prioritization), glaucoma screening, diagnostics, treatment and follow-up.  
Special Honors: Awards in teaching, lecturing and quality improvement
Rohit Varma, MD, MPH  
Affiliation: Professor of Ophthalmology and Preventive Medicine, University of Southern California, Keck School of Medicine; Director, Glaucoma Service, Ocular Epidemiology Center and Clinical Trials Center, USC Department of Ophthalmology, Los Angeles, CA, U.S.A.

Areas of Interest: Epidemiology of Eye disease, Imaging of the retina and the optic nerve, Clinical trials in ophthalmology.

Leadership Positions: Program Committee for Clinical Research, ARVO; Member, Executive Committee, Doheny Eye Medical Group; Board of Scientific Counselors, National Eye Institute; Editorial Board Member Ophthalmology; Member, AAO Anterior Segment Preferred Practice Patterns Panel; Member, AAO Basic and Clinical Science Course Section I Committee.

Special Honors: National Eye Institute National Research Service Award, Research to Prevent Blindness Career Development Award, Research to Prevent Blindness Sybil B. Harrington Scholar Award, American Academy of Ophthalmology Honor Award and Senior Honor Award.

Lori Ventura, MD  
Affiliation: Bascom Palmer Eye Institute, University of Miami Miller School of Medicine.

Areas of Interest: PERG in the early detection of glaucoma and Psychoneuroimmunology.

Leadership positions: Director Fourth Year Clerkship

Hani Verbin-Levkovitch, MD  
Affiliation: Director, Sam Rothberg Ophthalmic Molecular Biology Laboratory, Senior Ophthalmologist, Glaucoma Service, Goldschleger Eye Institute, Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel.

Areas of Interest: She is a clinician-scientist involved in basic and clinical research in the field of glaucoma and optic nerve injuries. Her area of interest includes pathogenesis of retinal ganglion cells death in glaucoma, neuroprotection, genetics and improving surgical approaches in glaucoma. Stem cells, drug development for increasing survival of RGC in glaucoma, regulation of proapoptotic and prosurvival gene expression, signal transduction pathways in RGC death, secondary degeneration, aging of RGC in glaucoma, and axonal transport in the injured optic nerve.

Leadership positions: Chair of the ISOPT glaucoma program. She is elected member in the Israel association of Ophthalmologists, the Israel Society for Eye and Vision Research and the Sheba Medical Center.


Lingam Vijaya, MD  
Affiliation: Director of Shrimati Jadavbai Nathmal Singhvee Glaucoma Services, Sankara Nethralaya, Chennai, India;

Areas of Interest: Epidemiological studies of glaucoma in India. Angle closure disease. Molecular genetics of glaucoma.


Special Honors: Rustom Ranji Oration Medal for the year 2007, given by AP State Ophthalmological Society. Dr Rustom D Ranji Rotary Award - 2008 for Contribution to Ophthalmology – Given by LV Prasad Eye Institute and Rotary Club Hyderabad Dist 3150.

Ananth Viswanathan, BSc (Hons) MBBS (Lond), FRCOphth  
Affiliation: Consultant Surgeon (Glaucoma), Moorfields Eye Hospital, London; Honorary Senior Clinical Research Fellow, Inst. of Ophthalmology, London; Member of Statistical Genetics Group, Inst. of Psychiatry. London, United Kingdom.

Research interests: Quality of life in glaucoma. Visual psychophysics in glaucoma. Complex ge-
nnetics in common eye disease.
Leadership positions: Chairman of Glaucogene (European Glaucoma Society Genetic Epidemiology Network); Chairman of UK Glaucoma Early Diagnosis Programme; Member of WGA Junior Advisory Board; Member of European Glaucoma Panel.
Special honors: Member of Honorary Medical Advisory Panel to the Secretary of State on Visual Disorders and Driving.

Steven D. Vold, MD
Affiliation: Chief Executive Officer, Glaucoma and Cataract Surgery Consultant, Boozman-Hof Regional Eye Clinic, P.A.
Areas of Interest: Diagnosis and management of glaucoma; laser and surgical care in glaucoma; management of complex glaucoma, cataract and secondary intraocular lens cases; small-incision cataract surgery.
Leadership positions: Past Vice Chairman of the Department of Ophthalmology, Director, Division of Glaucoma and Assistant Professor in the Department of Ophthalmology and Surgery at the Scott and White Eye Institute and Texas A&M College of Medicine in Temple, Texas; Director of the Center for Ophthalmic Advancement and the primary instructor in glaucoma diagnosis and management for resident physicians and medical students; Consultant for the Olin E. Teague Veteran's Administration Hospital in Temple.
Special honors: He has been awarded numerous scholarships and academic awards.

David S. Walton
Affiliation: Harvard Medical School Ophthalmology, Boston, MA USA

Martin Wand
Affiliation: Clinical Professor of Ophthalmology, University of Connecticut School of Medicine
Areas of Interest: Medical and laser treatment of glaucoma, angle closure glaucoma, neovascular glaucoma.
Leadership positions: Chair of Council and Trustee, American Academy of Ophthalmology; Vice-Chair and Director, American Board of Ophthalmology; past President, New England Ophthalmological Society.
Special Honors: Honor Award, Senior Honor Award, Secretary Award, American Academy of Ophthalmology

Lan Wang, MD, PhD
Affiliation: Clinical associate professor of Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.
Areas of Interest: Angle-closure glaucoma, Glaucoma surgery, Glaucoma treatment, Clinical research on PACG.
Leadership positions: Past Vice Chairman of the Department of Ophthalmology, Director, Division of Glaucoma and Assistant Professor in the Department of Ophthalmology and Surgery at the Scott and White Eye Institute and Texas A&M College of Medicine in Temple, Texas; Director of the Center for Ophthalmic Advancement and the primary instructor in glaucoma diagnosis and management for resident physicians and medical students; Consultant for the Olin E. Teague Veteran's Administration Hospital in Temple.
Special honors: He has been awarded numerous scholarships and academic awards.

Dr. Ningli Wang
Affiliation: Chairman of Beijing Tong Ren Eye Center; Professor of Ophthalmology; Chief Ophthalmologist; Supervisor of MD & PhD program in Ophthalmology, Beijing, People’s Republic of China.
Research Interests: Gene therapy; Treatment of glaucomatous optic neuropathy; Glaucoma Surgery.
Leadership positions: Vice President of Beijing Tong Ren Hospital; Capital Univ. of Medical Sciences (CPUMS); Chairman of Beijing Tong Ren Eye Center; Dean of Beijing School of Ophthalmology, Capital Univ. of Medical Science; Director of Vision Science Laboratory, School of Ophthalmology, CPUMS.

www.worldglaucoma.org
World Glaucoma Congress, July 8-11, 2009

Tsing-Hong Wang, MD, PhD
Affiliation: Assistant Professor, Glaucoma Division, Department of Ophthalmology, National Taiwan University Hospital.
Areas of Interest: Angle closure glaucoma, myopia and glaucoma.

Jany Wiggs, MD, PhD
Affiliation: Associate Professor of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary.
Areas of Interest: Glaucoma genetics. The overall goal of my research program is to identify genetic factors that predispose to various forms of inherited glaucoma. Current investigations include studies designed to identify and char-

Robert N. Weinreb, MD
Affiliation: Distinguished Professor of Ophthalmology, Director, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, California, U.S.A.
Research Interests: Glaucoma diagnosis. Optic nerve (optic disc and retinal nerve fiber layer) imaging. Molecular and cellular mechanisms of aqueous outflow. Molecular and clinical aspects of glaucoma neuroprotection. Wound healing and glaucoma surgery.

Tony Wells, MD
Affiliation: Glaucoma Specialist, Capital Eye Specialists, Wellington, New Zealand.
Areas of Interest: Glaucoma Surgery and Bleb Grading, Ocular Imaging, Pseudoexfoliation Syndrome.
Leadership positions: Director, Capital Eye Specialists.

Marty B. Wax, MD
Affiliation: Vice President of R&D and Head of Ophthalmology Discovery Research and Preclinical Sciences at Alcon Laboratories in Ft. Worth, Texas; Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, Texas.
Research Interests: Cell biology of aqueous humor formation and the role of the immune system in glaucomatous optic neuropathy. Leadership positions: He currently serves on several national and international Scientific Advisory Committees and Editorial Boards.
Special honors: Recipient of the 1991 Robert E. McCormick Scholarship; the 1995 Lew R. Wasserman Merit Award for his contributions to basic eye research; the 1999 Rudin Prize from the NY Academy of Medicine; the 2001 Senior Investigator Award from Research to Prevent Blindness; the 2003 Clinician-Scientist Award from the American Glaucoma Society.

Robert N. Weinreb, MD

Special Honors: Helmholtz Award for Research Excellence; Alcon Research Institute Award for Outstanding Contributions to Research in Visual Sciences (1983 and 1992); WGA Award for Outstanding Glaucoma Research; Research to Prevent Blindness Physician-Scientist Award; Best Doctors in America (1992-2009); University of California San Diego, Outstanding Teacher; Senior Honor Award of American Academy of Ophthalmology; Heed Ophthalmic Foundation Award in recognition of leadership and contributions in ophthalmology; Research to Prevent Blindness Senior Scientific Investigator Award; Benjamin Waterhouse Fellow, Harvard Medical School; Honorary Member, la Sociedad Latino-Americana de Glaucoma; Ronald Lowe Medal, Australia-New Zealand; Inaugural ARVO Fellow (Gold); Ridley Medal, St. Thomas’ Hospital, London; Moecyr E. Alvaro Medal, Universidade Federal de Sao Paulo, Brazil.

Jany Wiggs, MD, PhD
Affiliation: Associate Professor of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary.
Areas of Interest: Glaucoma genetics. The overall goal of my research program is to identify genetic factors that predispose to various forms of inherited glaucoma. Current investigations include studies designed to identify and char-

Organized by The Hippocrates Glaucoma Foundation
acterize gene responsible for adult onset primary open angle glaucoma (POAG), pseudoexfoliation glaucoma, pigment dispersion syndrome and pigmentary glaucoma, juvenile open angle glaucoma and congenital glaucoma. We have formed the NEIGHBOR consortium to collect POAG cases and controls for a genomewide association study (GWAS) that will be harmonized with the GENEVA GLAUGEN study, a recently funded GWAS to investigate gene-environment interactions in glaucoma. Research support: NIH/NEI: R01EY015872, R21EY018149, R01EY009847, R01EY015473 (Pasquale PI); R21EY019161 (Li, PI); P30EY014104; NIH/NHGRI: U01HG004728 (Pasquale PI); RPB (Lew Wasserman Award), Lions Research Fund of Massachusetts.


Richard Wilson, MD
Affiliation: Professor of Ophthalmology, Thomas Jefferson University, Co-Director, Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, U.S.A.


Leadership Positions: Chair, Glaucoma Eye Care Program, American Academy of Ophthalmology Foundation; Chairman of the World Glaucoma Association Committee on Glaucoma Society Organization, Past President of the American Glaucoma Society, Past Editor of Mosby’s Yearbook of Ophthalmology from 1996 to 2002.

Special Honors: Golden Apple Award for best teacher, Wills Eye Hospital; Inaugural Richard P. Wilson Faculty Teaching Award by The International Society of Spaeth Fellows and The Wills Glaucoma Fellowship Program; Honor and Senior Honor Awards from the American Academy of Ophthalmology.

Roy Wilson, MD, MS
Affiliation: Chancellor, University of Colorado Denver, Denver, Colorado.

Areas of Interest: Epidemiology and ophthalmology, especially in fostering the evolving field of glaucoma epidemiology. Major scientific contributions have been in bridging the fields of epidemiology and ophthalmology. He has delivered more than 200 invited lectures, many internationally, and has published more than 300 articles, book chapters and abstracts.

Leadership positions: In addition to the board of the University of Colorado Hospital, for which he is the chairman, he serves on the governing boards of The Children’s Hospital, Auraria Higher Education Center, Fitzsimons Redevelopment Authority, Institute of International Education, Association of Academic Health Centers, and the Coalition of Urban Serving Universities. He was an initial Advisory Council member of the National Center on Minority Health and Health Disparities of NIH, and served four years as chair of its Strategic Plan subcommittee. He currently serves on the Advisory Council of the National Center for Research Resources of NIH.

Special Honors: Selected in ‘Best Doctors in America’ from 1996-2008. Among his many awards are the Distinguished Physician Award from the Minority Health Institute, the Honored Alumnas Award from the Mass Eye and Ear Infirmary, the Senior Achievement Award from the American Academy of Ophthalmology, and the Association of American Medical College’s Herbert W. Nickens Award.

Dr. Gadi Wollstein
Affiliation: Assistant Professor of Ophthalmology and Director of Ophthalmic Imaging Research Laboratories, UPMC Eye Center, University of Pittsburgh School of Medicine.


Leadership positions: Author of more than 55 peer-reviewed manuscripts and more than 10 book chapters. Reviewer for more than a dozen ophthalmic and bioengineering journals. Ad hoc advisor for national science foundations.

Special Honors: Achievement award from the American Academy of Ophthalmology and selected the Editor’s Choice for the best peer-review manuscript. Israel Medical Association Fellowship Scholarship.

www.worldglaucoma.org
Organized by The Hippocrates Glaucoma Foundation
Alan H. Zalta, MD
Affiliation: Director of the Glaucoma Service in the Department of Ophthalmology at the University of Cincinnati Medical Center (since 1984). In 1991, he received tenure as an Associate Professor and has been an Associate Clinical Professor since affiliating with the Cincinnati Eye Institute in 1998.
Areas of Interest: Dr. Zalta has published numerous articles on pitfalls in automated perimetry and laser treatment of glaucoma. He has developed stereoscopic atlases of glaucomatous disc damage and gonioscopy and has taught stereoscopic instructional courses at the annual American Academy of Ophthalmology meeting for the last 20 years.
Leadership positions: Director of Medical Student Education from 1984-2000; Dr. Zalta was invited to teach a stereoscopic course at the 6th International Glaucoma Symposium in Athens, Greece in 2007 and at the 4th Biennial Glaucoma Congress in Buenos Aires, Argentina in 2008.
Special Honors: Honor Award from the American Academy of Ophthalmology in 1994. He has been honored for outstanding resident teaching at the University of Cincinnati. He has been selected by his peers to be included in Best Doctors in America from 1996 through 2008.

Linda Zangwill, PhD
Affiliation: Professor, Director, Diagnostic Imaging Laboratory, Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California, U.S.A.
Areas of Interest: Techniques for detection and monitoring of glaucomatous structural damage and change over time. Characterization of the relationship between structural and functional change. Identification of predictive factors for the development and progression of glaucoma.
Leadership positions: Journal of Glaucoma Editorial board (since 1999); International Perimetric Society (Board member 2002- present); Glaucoma Research Society (elected 2002); UC San Diego The Sam and Rose Stein Institute for Research on Aging (elected 2004); International Glaucoma Review Editorial Board Member (2007-present); Current Glaucoma Practice Editorial Board Member (2007-present); Faculty Co-chair: UC San Diego Chancellor’s Advisory Committee on the Status of Women (2004-2007); Women in Science and Engineering Subcommittee of the Chancellor’s Advisory Committee on the Status of Women, Chair: 2000-Present.

Chun Zhang, MD, PhD
Affiliation: Clinical Professor and Glaucoma Specialist, Peking University Eye Center, Peking University Third Hospital. Director, The Clinical Stem Cell Center, Peking University Third Hospital. Chief, Department of Research Administration, Peking University Third Hospital.
Areas of Interest: Glaucoma, Nanotech, Traditional Chinese Medicine, and stem cell study. Neuroprotection on retinal ganglion cell, glaucoma treatment, and stem cell study.
Leadership positions: Member of national board of younger ophthalmologist, The Chinese Society of Ophthalmology, Member and secretary, ocular pathology section of the Chinese Society of Ophthalmology.

Dr. Jialiang Zhao
Affiliation: Professor, Department of Ophthalmology, Beijing Union Medical College Hospital, Beijing; Director, Eye Research Center, Chinese Academy of Medical Sciences, Beijing, China.
Research Interests: Glaucoma, Ophthalmic epidemiology. Early detection of ACG.
Leadership Positions: President, Chinese Ophthalmological Society; Editor-in-Chief, Chinese Journal of Ophthalmology; President, Chinese Ophthalmologist Association, Member of Academia Ophthalmologica Internationalis, Member of International Council of Ophthalmology, Member of Asia Pacific Academy of Ophthalmology. Special Honors: Kupfer Award for Prevention of Blindness in 1999; Arthur Lim Award in 2007.

www.worldglaucoma.org
SOCIAL PROGRAM

Wednesday evening (July 8, 2009): Welcome Reception in the Hynes Convention Center
The Welcome Reception will be held in the exhibition area of the Hynes Convention Center. This gathering will enable you to meet with your colleagues in the field of Glaucoma from all over the world, while you can enjoy some typical local food and drinks. Included in Registration fee for participants and accompanying persons.

Thursday evening (July 9, 2009): Free for National Social Gatherings
After the courses, which will end at 6.00 p.m., the WGA has purposely not planned any specific World Glaucoma Congress events. Therefore this evening is for smaller groups of participants to enjoy the numerous restaurants and cultural events in Boston. The dinner for presidents of the Glaucoma Societies, Committee members, Glaucoma Industry members and Faculty will be by invitation only.

Friday evening (July 10, 2009): Gala Evening at the Boston Public Library
The Gala Evening of the World Glaucoma Congress will be held at the Boston Public Library. The Boston Public Library is the largest municipal public library in the United States. This library has made its mark as a cultural institution, tourist attraction and a unique and beautiful venue for all kinds of special occasions. The WGC has a reputation for organizing a grand and entertaining gala evening. For more information, please visit the website www.worldglaucoma.org.
Admission: $50 per person

Saturday evening (July 11, 2009): Farewell Reception
The Farewell Reception is planned in the Hynes Convention Center. It is included in the Registration fee for participants and accompanying persons.

Organized by The Hippocrates Glaucoma Foundation
EXCURSION PROGRAM

All tours will depart and return at the Hynes Convention Center.

Complete tour of Boston: 350 years in a day

Boston is comprised of many neighborhoods, each with its own architecture and atmosphere. You’ll have an overview of the city when you see the major neighborhoods and the historic sites that make Boston such a fascinating place to visit. You’ll see Beacon Hill, Boston’s most prestigious address, and visit the Back Bay, an elegant section of Boston which, one hundred years ago, was built according to the plan of Paris’ Bois de Boulogne. You’ll pass by the Midtown Cultural District, Chinatown, and the South End, which boasts the largest Victorian neighborhood in the United States. Fenway Park is on your route, and the Fens section of Boston, which contains the Museum of Fine Arts, Symphony Hall, and the Isabella Stewart Gardner Museum will also be seen.

You’ll drive by the Waterfront and then walk into the North End, Boston’s famous Italian neighborhood where you will visit the Old North Church to see where the lanterns were hung to signal the beginning of Paul Revere’s famous ‘midnight ride’. Boston’s Freedom Trail continues from here. You will see the USS CONSTITUTION, as well as the Massachusetts State House, the Old South Meeting House, Boston Common, and other sites along the Trail.

Time: 4 hours
Price: $44 per person (included in the fee for accompanying persons)
Includes: Roundtrip transportation via executive coach, professional guide service, admissions and taxes
Minimum: 40 guests
Maximum: Based on availability

Note: This tour involves a considerable amount of walking on hills and cobblestones. Participants should be aware of these conditions and are advised to wear walking shoes.

A Tour of Newport and its Mansions

Newport, Rhode Island, is rich in both history and culture. A town which was established in the colonial era, made a name for itself during America’s Gilded Age, and since has become the yachting capital of the world. Today, the town thrives as a hub for American culture and visitors are faced with an abundance of activities, quaint B&B’s, museums, shops, beaches, and outstanding restaurants. Newport is

www.worldglaucoma.org
Inspired by the Petit Trianon at Versailles, the cost of the house was reported in contemporary press accounts to be $11 million, of which $7 million was spent on 500,000 cubic feet of marble. After a morning spent touring these homes, guests will have the opportunity to explore Newport Harbor and will subsequently enjoy a luncheon at one of the town's most charming restaurants. The group will then take pleasure in a tour of the famed 10 mile Ocean Drive for a view of the area's estates and gardens which dot this beautiful shoreline.

Time: 8:30 a.m. to 5:00 p.m.
Price: $99 per person (included in the fee for accompanying persons)
Includes: Roundtrip transportation via executive coach, professional guide service, admissions, tours, luncheon and taxes
Minimum: 40 guests
Maximum: Based on availability

not to be missed. Located seventy miles south of Boston, guests will be whisked to Newport for an opportunity to explore the town and USS Constitution experience the lifestyles of the rich and famous while touring the infamous mansions. You will visit the spectacular ‘Breakers’ mansion, the summer ‘cottage’ of Cornelius Vanderbilt, Chairman and President of the New York Central Railroad system. In 1893, Cornelius Vanderbilt II, commissioned architect Richard Morris Hunt to design and create a 70 room Italian Renaissance- style palazzo inspired by the 16th-century palaces of Genoa and Turin. Guests will also have the opportunity to tour The Marble House, built for William K. Vanderbilt. Constructed between 1888 and 1892, the Marble House was to become a social and architectural landmark that set the pace for Newport’s subsequent transformation from a quiet summer colony of wooden houses to the legendary resort of opulent stone palaces.
THE WORLD GLAUCOMA ASSOCIATION
THE GLOBAL GLAUCOMA NETWORK

The WGA is an independent, impartial, ethical, global organization for glaucoma science and care.

Mission
To optimize the quality of glaucoma science and care through communication and cooperation among international Glaucoma Societies, with Glaucoma Industries, Glaucoma Patient Organizations and all others in the glaucoma community.

Vision
Curiosity, creativity, quality and integrity are essential ingredients for science and care. The WGA is the first global subspecialty effort involving all stakeholders: ophthalmologists, other eye specialists, industrialists and patients.

Goals
Unite, communicate, meet, create personal contact, support, inform, guide, educate, investigate, aim for quality.

GLAUCOMA SOCIETIES

National Glaucoma Societies or related groups from the following countries:
Argentina, Austria, Azerbaijan, Bangladesh, Belgium, Brazil, Bulgaria, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Indonesia, Iran, Ireland, Israel, Italy, Kenya, Korea, Latvia, Lesotho, Lithuania, Mexico, Netherlands, Nigeria, Norway, Pakistan, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Rumania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, Zambia.

Regional Glaucoma Societies
African Society of Glaucoma
American Glaucoma Society
Asian-Oceanic Glaucoma Society
Australian and New Zealand Glaucoma Interest Group
Canadian Glaucoma Society
Chinese Glaucoma Society
European Glaucoma Society
Glaucoma Society of India
Japan Glaucoma Society
Latin-American Glaucoma Society
Pan American Glaucoma Society
Pan Arab Glaucoma Society
South-East Asian Glaucoma Interest Group

Supranational Glaucoma Societies
Glaucoma Research Society International
Optometric Glaucoma Society
Society for Glaucoma Surgery

www.worldglaucoma.org
Glaucoma Industry Members
Alcon
Allergan
Merck
Pfizer

Associate Members
Carl Zeiss Meditec
Heidelberg Engineering
Oculus
Topcon

Supporting Glaucoma Industry Members
AMO
Clarity
EyeIC
Glaukos
Haag Streit Group
Iridex
Lumenis
NeoMedix
Optonol
Optovue
Otsuka
Reichert
Santen
Senju
Vistakon
Ziemer Ophthalmic Systems

Global WGA Directory of Glaucoma Societies
The WGA has identified 75 Glaucoma Societies and has compiled a Global WGA Directory of Glaucoma Societies, which includes basic information on the Glaucoma Society. This directory is available through the WGA website. The Directory includes information on:

○ Society Name
○ Officers (+ Contact information)
○ Contact Information
○ Publications, etc.

World Glaucoma Patient Organization
At the initiative of the WGA, a Global Glaucoma Patient Organization was founded in October 2004, New Orleans, LA, US. The aim of the organization is a further cooperation between national and regional Glaucoma Patient Organizations. Contacts between the WGPA and the WGA are formalized through the World Glaucoma Day Committee.

Goals of the WGA
○ To further develop an effective world-wide organisation to realise common goals and improve standards for glaucoma management and research
○ To facilitate and coordinate communication and collaboration between Glaucoma Societies, Glaucoma Industries and Glaucoma Patient Organizations and other organizations in the field
○ To maintain and update an WGA Global Code of Practice
○ To maintain and update global guidelines for glaucoma diagnosis and treatment
○ To maintain and update global guidelines on publication and reporting on glaucoma treatment
○ To maintain and update global guidelines for the conduct of Glaucoma Meetings
○ To present, classify and review information on glaucoma through International Glaucoma Review
○ To improve the awareness of glaucoma

Organized by The Hippocrates Glaucoma Foundation
President was Roger Hitchings; Robert Weinreb became President Elect and Erik Greve became the Executive Vice President. In the six and a half years of its existence, the WGA achieved the following.

WGA achievements 2002-2003
○ Global organization, network
○ Global communication, IGR
○ Cooperation with Glaucoma Industries
○ Global Quality Standards
○ Code of Practice
○ Guidelines on Reporting and Publishing
○ Guidelines on Quality for Glaucoma Meetings
○ Guidelines on Glaucoma Society Organization
○ Information and Planning Exchange Meetings
○ Consensus Meeting on ‘Structure and Function in the Management of Glaucoma’

WGA achievements 2004
○ Guidelines Reporting and Publishing now available online; evaluation in WGA and other meetings.
○ Guidelines on Quality of Glaucoma Meetings now available online; evaluation in WGA and other meetings
○ Criteria for Glaucoma Society Organization now available online
○ Global Guidelines on Diagnosis and Treatment in statu nascendi
○ Report on Screening for Primary Open Angle Glaucoma started
○ First Global WGA Congress with representatives of Glaucoma Patient Organizations completed
○ Six new Glaucoma Industry Members

History
The WGA officially started its activity on January 1, 2002 after extensive preparations in 2001. The first intercontinental cooperation started in the early nineties, when the American Glaucoma Society and the Japan Glaucoma Society joined the European Glaucoma Society as supporters of IGR and organized combined meetings. In 2001 R.N. Weinreb and E.L. Greve developed the idea to create a global Association of Glaucoma Societies, starting with the then thirteen Glaucoma Societies involved in IGR. Roger Hitchings joined immediately and this triumvirate started to realize a dream. An essential aspect of the dream was to include everyone involved in glaucoma: Glaucoma Societies and Glaucoma Industries and Glaucoma Patient Organizations. The first Board of Governors consisted of R.A. Hitchings, R.N. Weinreb, E.L. Greve, Y. Kitazawa and R. Susanna Jr. The first
World Glaucoma Congress, July 8-11, 2009

- Book on first Global WGA Consensus Meeting on Structure and Function published
- Preparations on second Global WGA Consensus
- Meeting on Surgical Treatment of Open-Angle Glaucoma

WGA achievements 2005
- Organization of second Consensus Meeting on Surgical Treatment of Open-Angle Glaucoma
- World Glaucoma Congress July 2005, Vienna

WGA achievements 2006-2007
- World Glaucoma Congress, July 2007, Singapore
- Increased the distribution of IGR among all members of the regional and national Glaucoma Societies; from 4000 to up to 8000
- Publication of the report from the Committee on Cooperation with Medical Therapy; implement research proposals (report published in IGR 7-3)
- Publication of the report from the Committee on Screening for POAG (report published in IGR 7-3)
- Organization of the 3rd Consensus meeting and published the report on Angle Closure Glaucoma
- Organization of the 4th Consensus meeting on the report on Intraocular Pressure
- Increasing of worldwide knowledge about glaucoma through the WGA Diagnosis and Treatment System:
  - research committees; identification of priorities
- consensus meetings and publications
- continuously evolving Guidelines based on consensus meetings
- promulgation of consensus outcomes through books, IGR, Guidelines, National Glaucoma Societies

WGA Achievements 2008-2009
- Organization of the 3rd World Glaucoma Congress, Boston, USA
- Organization of the 1st & 2nd World Glaucoma Day (March 6, 2008 & March 12, 2009) (www.wgday.net)
- Searched for and stimulated creation of new national Glaucoma Societies worldwide
- Involvement in the National Glaucoma Societies in the association through:
  - coordination of organization structure
  - being part of consensus process
  - being part of WGA National Glaucoma Society Assembly
  - participance in WGC-2009
- Increaseamnt of the distribution of IGR among all members of the regional and national Glaucoma Societies from 8,000 to up to 10,000
- Publication of the WGA Guidelines on Design and Reporting of Glaucoma Surgical Trials (Kugler Publications, Amsterdam)
- Organization of the 5th Consensus Meeting on Screening for Glaucoma and publication of the report (Kugler Publications, Amsterdam)
- Organization of the 6th Consensus Meeting on Blood flow and publication of the report (Kugler Publications, Amsterdam)
**Membership WGA**

The WGA is an association of Glaucoma Societies. It has no individual members. New or undiscovered Glaucoma Societies that desire to become a member of the WGA are asked to contact the WGA Executive Office through info@worldglaucoma.org. The involvement in the WGA of the Glaucoma Societies is planned to be through:

1. Joining of forces, cooperation, coordination of efforts in order to improve quality of glaucoma science and care
2. Meeting and communicating in the Global Assembly, WGC, Committees activities, special *ad hoc* meetings
3. Distribution of information through International Glaucoma Review, WGC, Consensus Outcomes and Guidelines, publications
4. Participation in the Consensus & Guidelines process
   4.1 Preparation
   4.2 Meeting
   4.3 Publication
   4.4 Promulgation
5. Cooperation in development of Glaucoma Patient Organizations
6. Improving glaucoma curriculum in ophthalmology training
7. Training of glaucoma sub specialists / fellowships
8. Glaucoma Society Organization
   8.1 Support in developing an even more effective organization
   8.2 Training in:
      8.2.1 Organization of societies
         8.2.1.1 Development
         8.2.1.2 Management
         8.2.1.3 Communication
         8.2.1.4 Leadership development
      8.2.2 Organization of congresses/meetings
      8.2.3 Development of educational programs
      8.2.4 Manual on glaucoma (Guidelines from EGS, AAO, JGS, SEAGIG and others)
8.3 Advocacy; prevention of blindness, support for eye care
8.4 Critical research: necessary clinical studies, access to care
8.5 Availability of Project Forum for internet discussions within each national Glaucoma Society.

www.worldglaucoma.org
WGA COMMITTEES

Board of Governors
M. Araie, J. Ge, I. Goldberg, F. Grehn,
E. Greve, D. Grigera, R. Hitchings,
Y. Kitazawa, T. Krupin, D. Lam, J. Liebmann,
K. Martin, C. Migdal, K. Singh,
R. Susanna Jr, R. Thomas, R.N. Weinreb

Executive Committee
R. Susanna Jr, President
I. Goldberg, Past President (2006-2007)
R.N. Weinreb, Past President (2004-2005)
E. Greve, Vice President
K. Singh, Executive Vice President
K. Martin, Treasurer

Associate Executive Vice Presidents
T. Aung, J. Crowston, T. Shaarawy

Advisory Board
A. Alm, D. Anderson, M. Aquino,
G. Baerveldt, C. Baudouin, C. Camras,
D. Epstein, J. Flammer, Y. Hong, P. Hung,
M. Kass, P. Kaufman, D. Kim, G. Kriegstein,
L. Leske, E. Maul, D. Minckler, H. Mishima,
A. Molteno, S. Obstbaum, P. Palmberg,
B. Shields, G. Spaeth, R. Stamper,
R. Wilson, J. Zhao, K. Singh
(EVP, ex-officio)

Associate Advisory Board
A. Boehm, R. Casson, S. Chakrabarti,
T. Dada, P. Foster (co-chair), R. George,
C. Girkin, M. He, P. Healey (co-chair),
E. Hoffman, M. Honjo, C. Leung, K. Martin,
F. Medeiros, W. Nolan, R. Parikh, L. Sakata,
A. Sit, C. Tham, A. Viswanathan, T. Wells,
T. Wong, K. Singh (EVP, ex-officio)

Gluacoma Society Representatives Committee
M. Agulto (SEAGIG), K. Ben Amor (ASG),
Y. Buys (CanGS), F. Fantes (PAGS), J. Ge
(ChinGS), I. Goldberg (ANZGIG), A. Heijl
(GRS), D. Mills (AGS), H. Mishima (AOGS),
M. Patella (OGS), T. Shaarawy (ISGS),
B. ShridharRao (GSI), J. Thygesen (EGS),
T. Yamamoto (JGS), M. Yaqub (PArGS),
K. Singh (EVP, ex-officio)

Steering Committee
M. Aihara, M. Araie, A. Azuara Blanco,
J. Cioffi, A. Coleman, R. Fechtner,
D. Friedman, S. Gandolfi, T. Garway Heath,
J. Ge, I. Goldberg, F. Grehn, E. Greve,
C. Greve-Geijssen, D. Grigera, N. Gupta,
P. Healey, A. Heijl, R. Hitchings, P. Khaw,
Y. Kitazawa, T. Krupin, D. Lam, G. Lambrou,
R. Lewis, J. Liebmann, K. Martin,
C. Melamed, C. Migdal, J.-P. Nordman,
K. Park, R. Perez-Grossman, H. Quigley,
R. Ritch, P. RojanaPongpun, J. Schuman,
G. Skuta, R. Susanna Jr, R. Thomas,
C. Traverso, N. Wang, R.N. Weinreb,
R. Wilson, K. Singh (EVP, ex-officio)

Liaison Committees

World Glaucoma Day Committee
E. Ancker, P. Chew, H. Danesh, R. Dolgoff,
D. Gatton, I. Goldberg (co-chair), P. Healey
(co-chair), E. Hoffman, F. Kanadini,

Subcommittee on Guidelines for Reporting on Glaucoma Surgery Results
F. Grehn (co-chair), T. Shaarawy (co-chair), M. Sherwood (co-chair), K. Singh (EVP, ex-officio)

Guidelines on Quality and Quantity of Glaucoma Meetings

Consensus and Guidelines Committee

Glaucoma Industry
D. Friedman, I. Goldberg, E. Greve (co-chair), F. Medeiros, R. Thomas (co-chair), R.N. Weinreb (co-chair), R. Chan (Alcon), J. Joedcke (MSD), H.-P. Pfleger (Allergan), K. Singh (EVP, ex-officio)

Global Research and Screening

World Glaucoma Association Liaison Committee
R. Hitchings, Y. Kitazawa, K. Singh (co-chair), R. Susanna Jr (co-chair)

Quality Committees

Code of Practice
T. Dada, C. Girkin, I. Goldberg, K. Kashiwagi (co-chair), M. Sherwood (co-chair), R.N. Weinreb, T. Yamamoto, R. Halprin (Alcon), T. Huhuhtanen (Santen), J. Joedecke (MSD), M. Long (Heidelberg), M. Patella (CZM), H. Pfleger (Allergan), K. Singh (EVP, ex-officio)

Guidelines for Reporting and Publishing
M. Araie, K. Barton, A. Coleman (co-chair), P. Foster, S. Gandolfi (co-chair), M. Honjo, D. Minckler, T. Shaarawy (co-chair), F. Topouzis (co-chair), A. Viswanathan, R. Wormald, J. Grunden (Pfizer), R. Halprin (Alcon), J. Joedecke (MSD), H. Pfleger (Allergan), K. Singh (EVP, ex-officio)
World Glaucoma Congress, July 8-11, 2009

Clinician Scientists
M. Aihara, J. Crowston, A. Harris, M. He (co-chair), P. Khaw (co-chair), C. Leung (co-chair), J. Schuman (co-chair), A. Sit, R.N. Weinreb, K. Singh (EVP, ex-officio)

Glaucoma Society Organization

Promulgation Committee
C. Chakrabarti, J. Crowston, R. Fechtner, D. Friedman, R. George (co-chair), P. Healey, K. Martin, P. Palmberg, A. Sit (co-chair), A. Viswanathan (co-chair), R.N. Weinreb (co-chair), K. Singh (EVP, ex-officio)

Advocacy Committee

Global Projects Committee
K. Ben Amor, L. Herndon, S. Melamed (co-chair), H. Quigley (co-chair), P. RojanaPongpun, J. Schuman, T. Shaarawy (co-chair), R. Thomas, R. Wilson, K. Singh (EVP, ex-officio)

WGA Executive Office
Mariska van der Veen
Executive General Manager
Corresponding address:
Jan van Goyenkade 11
1075 HP Amsterdam, The Netherlands
Tel: +31 20 679 34 11
Fax: +31 20 673 73 06
E-mail: vanderveen@worldglaucoma.org
www.worldglaucoma.org.

The World Glaucoma Association is an association founded according to Swiss law. Founded January 1, 2002. Registered office Geneva, Switzerland

Organized by The Hippocrates Glaucoma Foundation
INTERNATIONAL GLAUCOMA REVIEW

International Glaucoma Review – 25 years

The International Glaucoma Review (IGR), which has been published since 1984, became the official journal for the WGA in 2002. IGR is a journal for glaucomatologists and general ophthalmologists with an interest in glaucoma from all over the world. It aims at being a forum for the world’s Glaucoma Societies. It is distributed to all members of the Member Glaucoma Societies of the WGA free of charge. Subscriptions of each Glaucoma Society Member to IGR are supported by the WGA. IGR expects to provide:

1. Efficient and easy availability, four times per year, of virtually all glaucoma literature world-wide, with a critical review of selected papers (approximately 10%).
2. Increased awareness of the activities of fellow Glaucoma Societies by means of co-operation and reporting.

The uniqueness of IGR is its attempted completeness, its classification, the Editor’s Selection, and its literature database. IGR has the most complete collection of abstracts from the glaucoma literature which are otherwise not available, certainly not within the same time span. It is the only journal that presents a three-monthly critical review of selected glaucoma literature. Furthermore IGR contains a Glaucoma Dialogue- and a Glaucoma Opinion section, and reports from the Glaucoma Societies involved. It may also include complete selected papers, reports of meetings, interviews, hypotheses, reviews, and anything else considered to be of interest to the members of the Glaucoma Societies. IGR is supported by a grant from the WGA and advertising income.

IGR online Database

As per July 1 2007, the abstracts were provided online only. All abstracts published in IGR since 1999 are already available through the fully searchable IGR glaucoma literature database. But that’s not all. The comments from the Editor’s Selection have also been put into a database and are also fully searchable and linked to the abstracts. This makes it possible to read what experts have to say about important abstracts and then directly read these abstracts, or vice versa. Furthermore, you can use several features when searching both databases. Amongst others it is possible to:

- limit your search by abstracts with comments in the Editors’ Selection only
- limit your search by classification.
- limit your search to (a range) of year(s) of publication.
- use operators to refine your queries.
- use the internal bookmarking system to keep track of your searches and easily reproduce your searches later on
- find related abstracts with one click of your mouse
- browse abstracts by classification, journal or author. Or just start reading from the first abstracts of an issue and on
- download pdf-files of abstracts.
Registration for IGR online
Access to IGR Online remains complimentary for all members of glaucoma societies associated in the WGA. However, you are required to register before you can access the abstracts and make use of other features of the IGR website.

Webaddress: www.e-igr.com

GEM: the IGR Glaucoma E-Mail announces upcoming online issues and communicates special news items to members of the glaucoma societies.

History of IGR

International Glaucoma Review and its predecessor Glaucoma Abstracts have been serving the glaucoma-interested community for 25 years. The first issue appeared in 1984. Glaucoma Abstracts, as the name was in these days, was an initiative of the European Glaucoma Society. The aim was and is to provide members of Glaucoma Societies with concise, classified information on glaucoma literature. It was sponsored by Chibret (Merck) who had the vision never to interfere with editorial matters. The first editorial, by the Honorary President of the EGS Professor Baron Jules François and Erik Greve as chief editor, has been reproduced at www.e-IGR.com, the IGR website. The EGS was soon joined by the American and Japanese Glaucoma Societies. The AGS in these days was represented by George Spaeth, Dick Simmons, Bruce Shields and Douglas Anderson. They made that important move together with Yoshi Kitazawa, representing the Japanese Glaucoma Society to join the EGS in an alliance that can be seen as a predecessor of the WGA. Bruce Shields and Yoshi Kitazawa for many years provided editorial support for International Glaucoma Review (IGR). Glaucoma Abstracts International changed into International Glaucoma Review in 1998 and sponsorship was taken over by Pharmacia. IGR started serving all major regional Glaucoma Societies in the world, which was reflected in the members of the editorial board, particularly the Society Editors. With the foundation of the Association of International Glaucoma Societies (AIGS; After the WGC-2007 the name was changed into World Glaucoma Association - WGA) in 2002, IGR became the journal for the WGA and Robert Weinreb joined the board as editor. The journal has now been serving the WGA membership for more than five years. In 2007 major changes have taken place: Robert N. Weinreb has taken over the Chief Editorship and the unique IGR database is functioning. A new era has started.

WGA-Award

The WGA-Award is the only global glaucoma research award supported by all member Glaucoma Societies. The award was started in 1999 as the IGR Award, later called AIGS-Award, and now it is called the WGA-Award. At the WGC-2009, the 10th Award ceremony will be held.

Organized by The Hippocrates Glaucoma Foundation
Excerpt from the WGA-Award Rules:

1.1 There are three (3) Award categories: *The Classic* for long-term impact, *The Present* for present impact, *The Promise* for potential future impact. The Awards are for the purpose of stimulating creativity and originality and rewarding daring and breakthrough research in the field of glaucoma, to help protect the research time of junior researchers for the benefit of glaucoma patients.

1.2 There will be a maximum of two (2) *The Present* awards and a variable number of *The Classic* and *The Promise* awards per year.

1.3 The WGA Awards will be presented to papers on glaucoma published in the scientific literature in each full calendar year, starting from January 1.

1.4.1 *The Present* WGA Award will consist of:
(a) a total amount of USD 25,000
(b) the WGA Award diploma and
(c) the WGA Award Crystal Bowl
The award money is intended to be used for further research.

1.4.2 *The Classic and The Promise* WGA Awards will consist of:
(a) the WGA Award diploma and
(b) the WGA Award Crystal Bowl
*Note:* If *The Classic* award has not received *The Present* award in previous years, the recipient will receive also a monetary reward

2. The Nomination Committee
2.1 Phase 1: Members of the Steering Committee, Associate Advisory Board of the WGA and the Editorial Board of IGR nominate each two papers.

2.2 Phase 2: The nominated papers of phase 1 are sent to the Regional and large National Glaucoma Societies and the members of the WGA Advisory Board. The Societies and Advisory Board members each nominate 2 papers from this list. The Top-ten of this list is sent to the Selection Committee.

3. The Selection Committee
3.1 The Selection Committee consists of nine (9) members. These members consist of the Chief Editor and eight (8) members of the editorial board of IGR who have not served on the nomination committee. The nominated papers will be sent to external reviewers. The selection committee will select the two award winning papers based on all available information provided included that by the external reviewers.

6. Selection Criteria
6.1 The WGA-Award will be presented to the researcher who actually conceived the idea, and who has been actively involved in transforming his/her idea into the published results of a well presented study. This does not necessarily have to be the first author of a publication. It could also be a senior coauthor, if the selection committee has information that he/she is the major contributor to the paper. The Award may also be presented jointly to more authors. The Award will be presented independent of age, and it can be presented more than once to the same researcher.
6.2 Publications selected for the WGA-Award shall:
- Contain clinical or pre-clinical research fundamentally related to glaucoma;
- Be published in a peer-reviewed journal; and
- Represent original, creative, daring, and breakthrough research work.
- Be published between January 1st and December 31st of the year in which the Award is presented.

7. The WGA-Award Ceremony
7.1 The awardees will be invited to the Award ceremony.
7.2 The WGA-Award ceremony will take place at the World Glaucoma Congress and in alternate years at a meeting of one of the Glaucoma Societies in the year following the year of publication.

WGA-Award Winners 1999-2006
1999, London
Peng Khaw and Francesca Cordeiro
Ronald Harwerth
2000, Seoul
Paul Palmberg and Douglas Gaasterland
Harry Quigley
2001, Orlando
Michal Schwartz
Jack Crawford, Yeni Yücel and Robert Weinreb

Special Recognition: Douglas Anderson, Dunbar Hoskins and Stephen Drance
2002, Tokyo
Michael Kass and Mae Gordon
Anders Heijl
2003, Firenze
Elke Lütjen-Drecoll and Paul Kaufman
Paul Mitchell
2004, Vienna
Aiko Iwase
Claude Burgoyne
2005, Chennai
Simon John
Hiroshi Sakai
2006, Singapore
Terete Borras
Neeru Gupta and Yeni Yücel
2007, Berlin
‘The Present’ Award: Fridbert Jonasson and Kari Stefansson
‘The Promise’ Award: Gulgun Tezel
‘The Promise’ Award: Robert Duncan

The 2009 WGA-Award Ceremony for the Global WGA-Award 2008 will be held on Wednesday, July 8 as part of the Opening Ceremony (3.00–5.30 p.m.). The WGA-Award is supported by an unrestricted educational grant from Pfizer Ophthalmics.
# CME DISCLOSURES

**Speaker/Planner Disclosure Information** *(Disclosure not available at press time, but will be available at the time of the meeting)*

<table>
<thead>
<tr>
<th>Name</th>
<th>Salary, Royalty, Honoraria</th>
<th>Patent Holder/Receipt of intellectual property</th>
<th>Advisory Board/Consulting</th>
<th>Speakers’ Bureau</th>
<th>Supported/contracted research</th>
<th>Ownership interest (stocks, stock options, etc)</th>
<th>Off Label or unapproved treatment/device discussion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agulto, M.B.A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ahmed, I.*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aihara, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Allingham, R.R.</td>
<td>None</td>
<td>New World Medical Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Alvarado, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Alward, W.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Andersson, O.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Aquino, M.</td>
<td>Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Aquino, N.</td>
<td>Alcon</td>
<td>None</td>
<td>Alcon, Pfizer</td>
<td>Alcon, Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Araie, M.</td>
<td>Santen, Alcon, Pfizer</td>
<td>None</td>
<td>Kowa Senju, Topcon</td>
<td>None</td>
<td>Kowa Senju, Topcon, Zeiss</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Arvind, H.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Asawaphureekorn, S.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Aung, T.</td>
<td>Alcon, Pfizer, Carl Zeiss, Meditec, Clarity</td>
<td>None</td>
<td>Alcon, Pfizer</td>
<td>None</td>
<td>Alcon, Allergan, Carl Zeiss, Meditec</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Azuara Blanco, A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Baerveldt, G.</td>
<td>AMO, Neomedix</td>
<td>AMO, Neomedix</td>
<td>AMO, Neomedix</td>
<td>None</td>
<td>AMO, Neomedix</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Barton, K.</td>
<td>Alcon Allergan, AMO, Merck, New World Medical, Pfizer</td>
<td>None</td>
<td>Alcon, Allergan, Merck</td>
<td>None</td>
<td>Alcon</td>
<td>None</td>
<td>Yes Mitomycin C - unlicensed in UK, not sure about US</td>
</tr>
<tr>
<td>Baudouin, Ch.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, MSD, Pfizer, Santen, Theu</td>
<td>None</td>
<td>Alcon, Allergan, MSD, Pfizer, Santen, Theu</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Beck, A.D.</td>
<td>Alcon, Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Salary, Royalty, Honoraria</td>
<td>Patent Holder/Receipt of intellectual property</td>
<td>Advisory Board/Consulting</td>
<td>Speakers’ Bureau</td>
<td>Supported/contracted research</td>
<td>Ownership interest (stocks, stock options, etc)</td>
<td>Off Label or unapproved treatment/device discussion</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>------------------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Bellows, R.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ben Amor, K.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Bengtsson, B.</td>
<td>None</td>
<td>None</td>
<td>Zeiss, Meditec</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Bhattacharija, S.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Bloom, P.</td>
<td>None</td>
<td>None</td>
<td>Allergan, Pfizer</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Blumenthal, E.</td>
<td>Volk Lenses</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Zeiss, Meditec</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Boehm/Bohm, A.</td>
<td>Allergan, Pfizer (honoraria)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Borras, T.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Boume, R.</td>
<td>Allergan</td>
<td>None</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>Allergan</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Bowd, C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Brandt, J.</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>Alcon, Allergan, Pfizer, AMO, Glaukos</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Brooks, A.</td>
<td>None</td>
<td>None</td>
<td>Pfizer</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Brown, R.H.</td>
<td>None</td>
<td>None</td>
<td>Pfizer Australia</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Burgoyne, C</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Heidelberg Engineering</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Burk, R.</td>
<td>Alcon, Allergan, Merck, Pfizer</td>
<td>Heidelberg</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Buys, Y.M.</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>Pfizer</td>
<td>Alcon, Allergan, Pfizer</td>
<td>Merck, Frosst, Pfizer-Canada</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Calkins, D.</td>
<td>None</td>
<td>None</td>
<td>Alcon Research, Allergan</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Cantor, L.B.</td>
<td>Allergan</td>
<td>None</td>
<td>Allergan, AMO, QLT</td>
<td>Allergan</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Caprioli, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Carassa, R.</td>
<td>Allergan, Merck, Thea, Sif</td>
<td>None</td>
<td>Pfizer Alcon</td>
<td>Allergan, Merck, Pfizer, Thea</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Chakrabarti, S.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Chauhan, B.</td>
<td>None</td>
<td>None</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>Heidelberg, Zeiss</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Chen, T.C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Chew, P.T.K.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Conflict</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christensen, S.R.</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coleman, A.L.</td>
<td>None, Alcon, Allergan, Pfizer, Science Basel Health</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condon, G.P.</td>
<td>Alcon, Allergan, Optonol, I-Science, Optonol</td>
<td>Alcon, Allergan, Optonol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congdon, N.</td>
<td>Reichert Instruments, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cordeiro, M.F.</td>
<td>Allergan, Patent application DARC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Costa, V.P.</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Craig, J.</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crowston, J.G.</td>
<td>Alcon, Pfizer, Allergan, Alcon, Pfizer, Allergan, Alcon, Allergan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dada, T.</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dahan, E.</td>
<td>None, Optonol Ltd (Israel)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>de Moraes, C.G.V</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diestelhorst, M.</td>
<td>Patent on new technology to monitor compliance with conventional eye drop bottles - Owner - Diestelhorst</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drexler, W.*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duncan, R.</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>El-Sayyad, F.</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epstein, D.L.</td>
<td>Financial interest through Duke Univ Patent policies, Alcon, Glaukos</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Yes - Ahmed Capsule Tension Segments & Cionni Ring (Morcher); MA 60 AC IOL (Alcon)  
Yes - DARC UCL London  
Yes - New technology to monitor compliance with conventional eye drop bottles
<table>
<thead>
<tr>
<th>Name</th>
<th>Salary, Royalty, Honoraria</th>
<th>Patent Holder/Receipt of intellectual property</th>
<th>Advisory Board/Consulting</th>
<th>Speakers’ Bureau</th>
<th>Supported/contracted research</th>
<th>Ownership interest (stocks, stock options, etc)</th>
<th>Off Label or unapproved treatment/device discussion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fang, S.K.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Fechtner, R.</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>Alcon, Allergan</td>
<td>None</td>
<td>Alcon, Pfizer</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Fellman, R.L.</td>
<td>None</td>
<td>None</td>
<td>iScience</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Feuer, W.J.</td>
<td>Allergan, Pfizer, MSD, Heidelberg, Zeiss Meditec</td>
<td>CellMed, Alzenau</td>
<td>Allergan, Pfizer, MSD, Heidelberg Engineering</td>
<td>Heidelberg Engineering</td>
<td>Zeiss Meditec</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Fingeret, M.</td>
<td>Alcon, Pfizer, Optovue, Heidelberg Engineering</td>
<td>None</td>
<td>Allergan, Zeiss</td>
<td>None</td>
<td>Heidelberg Engineering, Optovue, Carl Zeiss</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Flanagan, J.G.</td>
<td>None</td>
<td>None</td>
<td>Heidelberg, Optovue</td>
<td>None</td>
<td>Heidelberg, Optovue</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Fortune, B.A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Freedman, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Friedman, D.S.</td>
<td>Alcon-sponsored travel to meeting in Australia</td>
<td>None</td>
<td>Pfizer, NicOx Promedior</td>
<td>Pfizer</td>
<td>Pfizer, Alcon</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Fujimoto, J.</td>
<td>Royalty from intellectual property owned by MIT &amp; licensed to Carl Zeiss Meditec</td>
<td>None</td>
<td>Optovue</td>
<td>None</td>
<td>None</td>
<td>Optovue</td>
<td>No</td>
</tr>
<tr>
<td>Gandolfi, S.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan</td>
<td>Alcon, Allergan, Merck, Pfizer</td>
<td>Alcon, Allergan, Bausch &amp; Lomb., Sifi</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Garway Heath, D.</td>
<td>Allergan, Carl Zeiss Meditec, Heidelberg, Pfizer</td>
<td>None</td>
<td>Allergan, Carl Zeiss Meditec, Pfizer</td>
<td>None</td>
<td>Carl Zeiss Meditec, Heidelberg, Optovue, Pfizer, Reichert, Zeimer</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Gazzard, G.</td>
<td>Allergan</td>
<td>None</td>
<td>Allergan, Pfizer, MSD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Get, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Gedde, S.J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>George, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Pfizer, Vistakon</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Geyer, O.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Giaconi, J.A.A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Company 1</td>
<td>Company 2</td>
<td>Company 3</td>
<td>Company 4</td>
<td>Company 5</td>
<td>Company 6</td>
<td>Company 7</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Goldberg, I.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, Pfizer</td>
<td>Alcon, Allergan, Pfizer, Ellex</td>
<td>Alcon</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Gomez Goyeneche, F.</td>
<td>None</td>
<td>None</td>
<td>Allergan, Alcon</td>
<td>Allergan, Alcon</td>
<td>Allergan, Pfizer, Sophia</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Gong, H.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Goni, F.J.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, Pfizer</td>
<td>Lectures for Alcon, Allergan, Pfizer, Genzyme</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Graham, S.</td>
<td>None</td>
<td>Objectivision Pty Ltd Australia</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Greenfield, D.S.</td>
<td>Allergan, Alcon, Pfizer, Optovue, Topcon</td>
<td>None</td>
<td>Allergan, Alcon, Pfizer, Optovue, Topcon</td>
<td>None</td>
<td>Allergan, Pfizer, Optovue, Carl Zeiss Meditec, Heidelberg</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Grehn, F.</td>
<td>None</td>
<td>None</td>
<td>Allergan</td>
<td>None</td>
<td>MSD, Pfizer, Santen</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Greve, L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Grigera, D.E.</td>
<td>None</td>
<td>None</td>
<td>Allergan</td>
<td>Allergan</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gross, P.B.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Grosskreutz, C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Grus, F.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gupta, N.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Harris, A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hartleben, C.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Harwerth, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hauser, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>He, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Healey, P.R.</td>
<td>Allergan, Alcon</td>
<td>None</td>
<td>Pfizer</td>
<td>None</td>
<td>Alcon, Allergan</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Heijl, A.</td>
<td>Carl Zeiss Meditec, Allergan</td>
<td>Carl Zeiss Meditec</td>
<td>Alcon, Allergan, Pfizer, Carl Zeiss Meditec</td>
<td>None</td>
<td>Carl Zeiss Meditec, Allergan, Santen</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Helal, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Herndon, Jr, L.W.</td>
<td>Alcon, Allergan, ISTA, Optonol, iScience, Reichert, Pfizer</td>
<td>None</td>
<td>Alcon, ISTA</td>
<td>Alcon, Allergan, Optonol, iScience, Reichert, ISTA, Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Salary, Royalty, Honoraria</td>
<td>Patent Holder/Receipt of intellectual property</td>
<td>Advisory Board/Consulting</td>
<td>Speakers’ Bureau</td>
<td>Supported/contracted research</td>
<td>Ownership interest (stocks, stock options, etc)</td>
<td>Off Label or unapproved treatment/device discussion</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Heuer, D.K.</td>
<td>Alcon, Allergan, Pfizer, Sirion Therapeutics</td>
<td>None</td>
<td>Allergan, Pfizer, Danube, NicOx</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>Danube</td>
<td>No</td>
</tr>
<tr>
<td>Higginbotham, E.J.</td>
<td>Pfizer, Alcon, Allergan</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Hitchings, R.A.</td>
<td>Alcon, Allergan, Merck, Pfizer</td>
<td>None</td>
<td>Alcon, Allergan, Merck, Pfizer, Santen</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ho, Ch.L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Hoffmann, E.M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Hollo, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, Pfizer, Santen</td>
<td>None</td>
<td>Alcon, Allergan</td>
<td>None</td>
</tr>
<tr>
<td>Hommer, A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Honjo, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Hutchinson, B.T.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Irkec, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ishida, K.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Iwase, A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Jampel, H.D.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Allergan</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Jofre-Bonnet, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>John, S.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Johnson, Ch.A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Allergan, Ophthalmic Research Associates, Boeringer Ingelhein, Pfizer, Welch Allyn</td>
<td>None</td>
<td>Allergan, Welch Allyn</td>
<td>None</td>
</tr>
<tr>
<td>Jonas, J.B.</td>
<td>Allergan, Pfizer, MSD, Zeiss Meditec</td>
<td>CaliMed AG</td>
<td>Allergan, Pfizer, MSD, Zeiss Meditec</td>
<td>Heidelberg</td>
<td>Heidelberg, Zeiss Meditec</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Jonasson, F.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Junemann, A.G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Kagemann, L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Kahook, M.</td>
<td>Alcon</td>
<td>None</td>
<td>Alcon, Allergan, VRT</td>
<td>None</td>
<td>Alcon, Genentech</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Kashiwagi, K</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>--------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Kass, M.A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Katz, L.J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Kaufman, P.L.</td>
<td>Inspire, Pfizer, Alcon, Santen, Allergan, B&amp;L, Cyto kinetics, QLT, Danube, Cascade</td>
<td>None</td>
<td>Inspire, Alcon, Santen, Allergan, Bausch &amp; Lomb, Cyto kinetics, QLT, Danube, Cara, Cascade</td>
<td>None</td>
<td>Inspire, Santen, Danube, Cara, Nu-Lens, Lens AR, Inc. (aka Frey Research LLC)</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Kaushik, S.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca, Promedior, GSK</td>
<td>None</td>
<td>Yes Mitomycin C (Kyowa); 5 Fluorouracil</td>
<td></td>
</tr>
<tr>
<td>Khaw, P.</td>
<td>None</td>
<td>None</td>
<td>Allergan, Astra-Zeneca, Aquesys, Bausch &amp; Lomb, Merck, Pfizer, Promedior</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca, Promedior, GSK</td>
<td>None</td>
</tr>
<tr>
<td>Konstas, A.G.</td>
<td>Alcon, Allergan, Merck</td>
<td>None</td>
<td>Alcon, Allergan, Merck</td>
<td>Alcon, Allergan, Merck, Pfizer</td>
<td>Alcon, Allergan, Merck, Pfizer</td>
<td>None</td>
<td>Yes Brimonidine (Alcon)</td>
</tr>
<tr>
<td>Kook, M.S.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Krupin, T.</td>
<td>Alcon, Allergan, Merck, Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Allergan</td>
<td>None</td>
<td>Yes Brimonidine (Alcon)</td>
</tr>
<tr>
<td>Kumar, R.S.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Kuwayama, Y.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Kowa, Pfizer, Santen, Senju</td>
<td>Alcon, Kowa, Pfizer, Santen, Senju, Banyu, Otsuka, Elex</td>
<td>Alcon</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Kymes, S.</td>
<td>None</td>
<td>None</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lachkar, Y.</td>
<td>None</td>
<td>None</td>
<td>Allergan, Pfizer, Alcon, MSD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lam, D.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lambrou, G.N.</td>
<td>Novartis</td>
<td>None</td>
<td>Fovea Pharmaceuticals</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Langer, R.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Latina, M.</td>
<td>Lumenis</td>
<td>Lumenis</td>
<td>Lumenis</td>
<td>Lumenis</td>
<td>Lumenis</td>
<td>Lumenis</td>
<td>No</td>
</tr>
<tr>
<td>Lemij, H.G.</td>
<td>None</td>
<td>None</td>
<td>Pfizer</td>
<td>None</td>
<td>Pfizer, Carl Zeiss, Meditec</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lerner, F.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Alcon, MSD, Pfizer, Sidus</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Leuenberger, E.U.</td>
<td>None</td>
<td>None</td>
<td>Allergan</td>
<td>Pfizer</td>
<td>Alcon</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Salary, Royalty, Honoraria</td>
<td>Patent Holder/Receipt of intellectual property</td>
<td>Advisory Board/Consulting</td>
<td>Speakers' Bureau</td>
<td>Supported/contracted research</td>
<td>Ownership interest (stocks, stock options, etc)</td>
<td>Off Label or unapproved treatment/device discussion</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>Leung, C.K.S.</td>
<td>Heidelberg, Topcon, Carl Zeiss Meditec</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Optovue, Carl Zeiss Meditec</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Levin, L.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Yes Canaloplansthy (iScience); Laser/Biolight (Trabectome/NeoMedix)</td>
<td>No</td>
</tr>
<tr>
<td>Lewis, R.A.</td>
<td>None</td>
<td>Alcon, i-Science, Transcend, Aquesys, Ivantis, QLT, Aeric</td>
<td>Allergan, Pfizer, Zeiss</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>Liang, Y.B.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Liebmann, J.M.</td>
<td>None</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>Topcon, Carl Zeiss Meditec, Optovue, Heidelberg Eng.</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lim, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lin, S.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lindsell, B.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lindsey, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Pfizer, Othera, Allergan</td>
<td>No</td>
</tr>
<tr>
<td>Liu, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Loon, C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Lu, D-W.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Mackey, D.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Pfizer Australia</td>
<td>No</td>
</tr>
<tr>
<td>Mandal, A.K.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Mani, B.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Manni, G.L.</td>
<td>Alcon</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Yes Azarga (Alcon)</td>
</tr>
<tr>
<td>Mansberger, S.L.M.</td>
<td>Allergan</td>
<td>None</td>
<td>Heidelberg, Santen</td>
<td>None</td>
<td>Alcon</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Marchini, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Martin, K.R.G.</td>
<td>MSD, Allergan, Alcon, Pfizer</td>
<td>None</td>
<td>Allergan, Alcon, Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Mattox, C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Maul, E.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>McAllistar,</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliations</td>
<td>Grants</td>
<td>Research</td>
<td>Contracted</td>
<td>Clinical</td>
<td>Disclosures</td>
<td>Notes</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------</td>
<td>--------</td>
<td>----------</td>
<td>------------</td>
<td>----------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>McLaren, G.D.</td>
<td>MSD, Pfizer, Alcon, Allergan</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Medeiros, F.</td>
<td>Pfizer, Allergan, Alcon, Carl Zeiss, Reichert</td>
<td>None</td>
<td>Pfizer, Allergan, Alcon</td>
<td>Pfizer, Allergan</td>
<td>Carl Zeiss Meditec</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Melamed, S.</td>
<td>Solx, Allergan, Ellex</td>
<td>None</td>
<td>Allergan</td>
<td>None</td>
<td>Alcon, Allergan, Merck</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Michelson, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Migdal, C.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, Merck, Pfizer, Santen</td>
<td>Alcon, Allergan, Merck, Pfizer, Santen</td>
<td>Alcon, Allergan, Danube Pharmaceuticals</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Miglior, S.*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mikelberg, F.S.*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mills, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Minckler, D.S.</td>
<td>None</td>
<td>None</td>
<td>Neomedix</td>
<td>Alcon, Allergan, Merck Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Molteno, A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Molteno Ophthalmics Ltd. w/ spouse Tes Molteno</td>
<td>Yes Avastin (Roche)</td>
</tr>
<tr>
<td>Morgan, J.</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>Alcon, Pfizer</td>
<td>None</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Mosaed, S.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Murthy, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Nardi, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Solx Gold-shunt (FDA approved study)</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Netland, P.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Solx (Gold Micro Shunt Phase III trials)</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Nickells, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Nicolela, M.T.</td>
<td>None</td>
<td>None</td>
<td>Pfizer, Allergan, Alcon</td>
<td>Alcon, Allergan, Heidelberg Eng.</td>
<td>Alcon</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Nolan, W.</td>
<td>Alcon, Allergan, Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Obstbaum, S.A.*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Okeke, C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Palmberg, P.</td>
<td>None</td>
<td>None</td>
<td>Pfizer</td>
<td>None</td>
<td>Abbott (tube vs trab support to our coordinating center)</td>
<td>None</td>
<td>Yes Mitomycin C - BMS</td>
</tr>
<tr>
<td>Pang, C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Salary, Royalty, Honoraria</td>
<td>Patent Holder/Receipt of intellectual property</td>
<td>Advisory Board/Consulting</td>
<td>Speakers’ Bureau</td>
<td>Supported/contracted research</td>
<td>Ownership interest (stocks, stock options, etc)</td>
<td>Off Label or unapproved treatment/device discussion</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Parikh, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Park, K.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Parrish, R.</td>
<td>None</td>
<td>None</td>
<td>Bausch &amp; Lomb, Pfizer, Glaukos, Alimera, Danube</td>
<td>None</td>
<td>None</td>
<td>Vitreoretinal Technologies, Inc, Sirion, InnFocus</td>
<td>No</td>
</tr>
<tr>
<td>Pasquale, L.</td>
<td>Alcon, Allergan</td>
<td>None</td>
<td>Innovation Factory</td>
<td>Alcon</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Perez Grossman, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Peters, D.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Pfeiffer, N.</td>
<td>None</td>
<td>None</td>
<td>Alcon, MSD, Pfizer, Santen, Allergan, Novartis</td>
<td>Alcon, MSD, Pfizer, Santen, Allergan, Novartis</td>
<td>Alcon, MSD, Pfizer, Santen, Allergan, Novartis, Heidelberg</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Pillunat, L.</td>
<td>Allergan, Santen, Merck</td>
<td>None</td>
<td>Allergan, Santen</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Piltz-Seymour, J.R.*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Porciatti, V.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Prum, B.E.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Alcon</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Quigley, H.</td>
<td>None</td>
<td>None</td>
<td>Pfizer</td>
<td>None</td>
<td>Alcon, Pfizer</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Racette, L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Radcliffe, N.</td>
<td>None</td>
<td>None</td>
<td>Allergan</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ramakrishnan, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ramli, N.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ramulu, P.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Alcon</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Realini, T.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ren, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Rhee, D.</td>
<td>None</td>
<td>None</td>
<td>Santen</td>
<td>Alcon, Allergan</td>
<td>Pfizer</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ritch, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>RojanaPongpun, P.</td>
<td>None</td>
<td>None</td>
<td>Alcon</td>
<td>Alcon, Allergan</td>
<td>Allergan</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Rossetti, L.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan</td>
<td>Alcon, Allergan</td>
<td>Pfizer</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Sahel, J.</td>
<td>Fovea Pharma, Vene Jignal</td>
<td>Novartis</td>
<td>Allergan, Genesinal, Servier</td>
<td>None</td>
<td>Fovea Pharma, Servier</td>
<td>Fovea Pharma</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Company 1</td>
<td>Company 2</td>
<td>Company 3</td>
<td>Company 4</td>
<td>Company 5</td>
<td>Company 6</td>
<td>Company 7</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Sakai, H.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sakata, L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sample, P.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Samuelson, T.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, AMO, AqueSys, Glaukos, iScience, Ivantis, Pfizer, QLT, Santen</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Yes iStent (Glaukos)</td>
</tr>
<tr>
<td>Schlotzer, U.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Schmetterer, L.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Schuman, J.</td>
<td>Alcon, Optovue, Carl Zeiss Meditec, Merck</td>
<td>Bioptigen, Carl Zeiss Meditec</td>
<td>Vindico, SLACK</td>
<td>None</td>
<td>Inspire Pharmaceuticals, SOLX, Carl Zeiss Meditec</td>
<td>None</td>
<td>Yes Optical coherence tomography (Zeiss, Bioptigen, Heidelberg, OPKO, Optopol, Topcon, Optovue); Confocal scanning laser ophthalmoscope (Heidelberg Engineering, GmbH); Scanning laser polarimeter (Carl Zeiss Meditec)</td>
</tr>
<tr>
<td>Schwartz, M.*</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>Pfizer</td>
<td>Allergan, Pfizer</td>
<td>Pfizer</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Schwartz, G.</td>
<td>None</td>
<td>None</td>
<td>Allergan Bausch &amp; Lomb, Inspire, Ioptima, Cobalt</td>
<td>None</td>
<td>BioVascular Inc, iScience, Optonol</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Seah, S.</td>
<td>None</td>
<td>None</td>
<td>OPKO Instrumentation</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Shaarawy, T.*</td>
<td>None</td>
<td>None</td>
<td>Bausch &amp; Lomb, iScience, iTherapeutix</td>
<td>None</td>
<td>Alcon, Allergan</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Sherwood, M.</td>
<td>Alcon, Elsevier</td>
<td>None</td>
<td>Allergan Bausch &amp; Lomb, Inspire, Ioptima, Cobalt</td>
<td>None</td>
<td>BioVascular Inc, iScience, Optonol</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Shields, B.</td>
<td>None</td>
<td>None</td>
<td>OPKO Instrumentation</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Shingleton, B.</td>
<td>None</td>
<td>None</td>
<td>Bausch &amp; Lomb, iScience, iTherapeutix</td>
<td>None</td>
<td>Alcon, Allergan</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Sihota, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Pfizer</td>
<td>None</td>
</tr>
<tr>
<td>Singh, K.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, Santen, Bausch &amp; Lomb, Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Salary, Royalty,</td>
<td>Ownership interest</td>
<td>Patents, Royalty,</td>
<td>Supported/contracted research</td>
<td>Advisory Board/Consulting</td>
<td>Speakers’ Bureau</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------------</td>
<td>--------------------</td>
<td>-------------------</td>
<td>-------------------------------</td>
<td>--------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Sit, A.</td>
<td>Allergan, Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>So, K.F.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Spaeth, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Spiegel, D.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Stamper, R.L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Stegmann, R.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Stroulakis, N.G</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Sugiyama, K.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Susanna, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Tamm, E.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Tania, A.P.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Tanigawa, H.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Tejwani, S.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Tzeel, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Thom, C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Thanos, S.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Thomas, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Thaeye, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Tomidokoro, A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Tomita, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

- **Off Label or unapproved treatment/device discussion**: No
- **Ownership interest**: None
- **Patents, Royalty, Honoraria**: None, Allergan, Pfizer, Merck, Alcon, Allergan, Pfizer
- **Supported/contracted research**: None, None
- **Advisory Board/Consulting**: None
- **Speakers’ Bureau**: None
<table>
<thead>
<tr>
<th>Name</th>
<th>Company(s)</th>
<th>Position(s)</th>
<th>Funding(s)</th>
<th>Industry(s)</th>
<th>Publications</th>
<th>Conflict of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topouzis, F.</td>
<td>Alcon, Pfizer</td>
<td>None</td>
<td>Pfizer</td>
<td>None</td>
<td>Alcon, Pfizer</td>
<td>No</td>
</tr>
<tr>
<td>Toris, C.</td>
<td>Alcon, Allergan</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, Pfizer, Santen, Alimera, Denali Vision</td>
<td>No</td>
</tr>
<tr>
<td>Trope, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Tsai, J.C.</td>
<td>None</td>
<td>None</td>
<td>Allergan, Merck, Pfizer</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Tuulonen, A.</td>
<td>Allergan, Alcon, Pfizer, Merck</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Varma, R.</td>
<td>None</td>
<td>None</td>
<td>Alcon, Allergan, Genentech, Pfizer, AqueSys, Laboratorios Sophia, Bausch &amp; Lomb</td>
<td>None</td>
<td>Allergan, AqueSys, Genentech, Optovue, Pfizer</td>
<td>AqueSys</td>
</tr>
<tr>
<td>Venkatesh, R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Ventura, L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Verbin-Levkovitch, H.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Vijaya, L.</td>
<td>Pfizer</td>
<td>None</td>
<td>Merck</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Viswanathan, A.</td>
<td>Alcon, Allergan, Bausch &amp; Lomb, Merck, Novartis, Pfizer</td>
<td>None</td>
<td>Allergan</td>
<td>None</td>
<td>Allergan, Pfizer</td>
<td>No</td>
</tr>
<tr>
<td>Vizzeri, G.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Vold, S.D.</td>
<td>None</td>
<td>None</td>
<td>ISTA</td>
<td>None</td>
<td>Allergan, Alcon</td>
<td>No</td>
</tr>
<tr>
<td>Walton, D.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Wand, M.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Wang, N.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Wang, L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Wang, T.H.*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wax, M.B.</td>
<td>Panoptica Inc</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Panoptica, Inc. No</td>
</tr>
<tr>
<td>Weinreb, R.N.</td>
<td>Allergan, Alcon, Merck, Pfizer</td>
<td>None</td>
<td>Allergan, Alcon, Merck, Pfizer, Optovue, Topcon, Carl Zeiss Meditec</td>
<td>None</td>
<td>Novartis, Heidelberg Engineering</td>
<td>No</td>
</tr>
<tr>
<td>Wells, T.</td>
<td>Alcon, Allergan</td>
<td>None</td>
<td>Allergan, Allergan</td>
<td>None</td>
<td>Alcon</td>
<td>No</td>
</tr>
<tr>
<td>Wheeler, L.</td>
<td>Allergan Employee</td>
<td>None</td>
<td>Allergan, Allergan, Pfizer</td>
<td>None</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Wiggs, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Name</td>
<td>Salary, Royalty, Honoraria</td>
<td>Patent Holder/Receipt of intellectual property</td>
<td>Advisory Board/Consulting</td>
<td>Speakers’ Bureau</td>
<td>Supported/contracted research</td>
<td>Ownership interest (stocks, stock options, etc)</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>-----------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Wilson, M.R.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Wollstein, G.</td>
<td>None</td>
<td>Bioptigen</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Carl Zeiss Meditec, Optovue</td>
</tr>
<tr>
<td>Wong, T.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Wright, D.J.</td>
<td>Pfizer, Allergan</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Yamamoto, T.</td>
<td>Otsuka, Pfizer, Alcon, Santen, Senjo, Merck</td>
<td>None</td>
<td>Otsuka, Pfizer, Alcon</td>
<td>None</td>
<td>None</td>
<td>Pfizer, Alcon</td>
</tr>
<tr>
<td>Yücel, Y.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Allergan</td>
</tr>
<tr>
<td>Zalta, A.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Zangwill, L.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Heidelberg Engineering, Carl Zeiss Meditec, Optovue (equipment)</td>
<td>None</td>
</tr>
<tr>
<td>Zeyen, T.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Zhang, C.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Zhao, J.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
Abou-el-Enin A., 2
AbouSedera K., 2
Agulto M.B.A., 24
Ahmed I., 38; 43
Alhara M., 18; 29
Al Sayyad F., 6
Allingham R.R., 41; 42
Alvarado J., 23; 28
Alward W., 25; 41; 42
Ancker E., 2; 2
Andersson S., 33
Aquino M., 35
Aquino N., 35
Araie M., 5; 22; 29; 30; 36; 39
Artes P., 4
Arvind H., 33
Asawaphureekorn S., 35
Ashaye A., 33
Aung T., 19; 24; 27
Azuara Blanco A., 17
Babkova B., 8
Baerveldt G., 24
Bagdoniene R., 9
Barkana Y., 8
Barton K., 24; 37; 41
Baskaran M., 4
Baudouin Ch., 24; 30
Beck A.D., 42
Bel Meki M., 6
Bellows R., 23
Ben Amor K., 2; 22; 32
Bengtsson B., 16
Benysek V., 8
Betkova J., 7
Bhattacharjia S., 42
Blondeau P., 4
Bloom P., 37
Blumenthal E.M., 14; 37
Boehm A., 35
Borras T., 15; 22
Bourne R., 33
Bowed C., 22
Brandt J., 17; 22; 23; 25
Brooks A., 36
Brown R.H., 38; 40
Burgoyne C.F., 10
Burk R., 35
Butkien A., 9
Buys Y., 4; 4; 37
Calkins D., 39
Campbell R., 4
Cantor L.B., 23
Carassa R., 27; 35; 37
Casiraghi J., 3
Chacon C., 3
Chakrabart K., 14; 41; 42
Chauhan B., 4; 29; 35
Chen T.C., 35
Chew P.T.K., 27; 36
Christensen S.R., 24
Cohen R., 3
Coleman A.L., 17; 23; 31
Condon G.P., 20; 38; 40
Congdon N., 23; 31; 32; 38
Cordeiro M.F., 15; 36
Costa V.P., 17; 27; 41
Cutlere D., 8
Cotroni P., 13
Craig J., 30; 42
Crandall A.S., 38; 40; 43
Crowston J.G., 10; 15; 18; 29; 30
Cvenkel B., 7
Dada T., 4; 36
Dahan E., 9; 24
Damji K., 4
de Moraes C.G.V., 16
DeMoraes G., 10
Diestelhorst M., 36
Dios J.A., 3
Drexler W., 15
Dubra A., 10
Duncan O., 22
Duncan R., 18
El Hamzawy H., 7
El-Sayyad F., 23; 43
Epstein D.L., 25
Fan B., 22
Fang S.K., 35
Fantes F., 3
Fechtner R., 26; 30; 35
Feiman R.L., 23
Feuer W.J., 23
Fichtl M., 7
Fingeret M., 35; 42
Flanagan J.G., 42
Forgacova V., 7
Fortune B.A., 22
Freedman J., 24
Friedman D.S., 10; 11; 14; 17; 22; 27; 33
Frysk Z., 8
Fucik M., 8
Fujimoto J., 15
Gaddie B., 6
Galgauskas S., 9
Gandolfi S., 36
Garway Heath D., 6; 16; 19; 35
Gazzard G., 22; 35
Ge J., 18
Gedde S.J., 10; 37; 42
George R., 4
Geria M., 3
Geyer O., 28
Giaconi J.A.A., 42
Gohar S., 7
Goldberg I., 12; 24; 25; 28; 30
World Glaucoma Congress, July 8-11, 2009

Organized by The Hippocrates Glaucoma Foundation

Goldenfeld M., 8
Gomez Goyeneche F., 22
Gong H., 22
Goni F.J., 5; 26
Graham S., 22
Greenfield D.S., 11; 15; 16; 29; 31
Grehn F., 11; 24; 40
Greve E., 11; 12; 13
Grigera D.E., 26; 41
Gross P.B., 25
Grosskreutz C., 33
Grus F., 36
Gupta N., 19; 36; 39
Hamouda L., 2
Harris A., 29; 36
Hartleben C., 36
Hanwerth R., 42
Hauser M., 33
He M., 24; 30
Healev P.R., 17; 21; 22
Heijl A., 16; 16; 35; 43
Helal M., 6; 42
Herman M., 8
Herndon Jr L.W., 22; 26; 27; 38
Heuer D.K., 35
Higginbotham E.J., 33
Hitchings R.A., 29
Ho Ch.L., 22; 35
Hoffmann E.M., 14
Holló G., 7; 36
Hommer A., 5; 36
Honjo M., 36
Hornova J., 7
Hutchinson B.T., 42
Irkec M., 25; 42
Ishida K., 37
Iwase A., 42
Jampel H.D., 31
Janulevičienė I., 9
Jirkova B., 8
John S., 18; 36; 39
Johnson C.A., 16; 19; 42
Jonas J.B., 23; 29; 37
Jonasson F., 20
Jordão da Silva M., 3
Jünenemann A.G.M., 21
Jurecka T., 7
Kagemann E., 27
Kagemann L., 36
Kahook M., 30; 37
Karhanova M., 8
Kashiwagi K., 5; 18
Kass M.A., 16; 43
Katz L.J., 23; 28
Kaufman P., 32; 39
Kaushik S., 4; 25
Khaw P., 22; 24; 35; 38
Kheleq el-Saadani A., 2
Kim C.-Y., 10
Kim T.W., 9
Konstas A.G., 20; 40
Kook M.S., 14
Krupin T., 12; 31
Kubena K., 7
Kubena T., 7
Kumar R.S., 25
Kurimoto Y., 6
Kurtz S., 8
Kuwayama Y., 23
Kuzmienė L., 9
Kymes S.M., 20; 33
Lachkar Y., 35
Lam D., 12; 26; 27; 38; 40; 43
Lambrou G.N., 12; 24
Langer R., 13
Latina M., 23
Lemij H.G., 14; 19; 29; 35
Lerner F., 25; 43
Lenenberger E., 23
Leung C.K.S., 14; 16; 35; 36
Levin L., 32
Lewis R.A., 28
Lewis T., 6
Li B., 24
Li J., 6; 23
Lim M., 36
Lin S., 19; 37
LindseIl B., 24
Lindsey J., 15; 32; 39
Liscak R., 8
Lischinsky I., 3
Liu C.J.L., 6
Liu J., 6; 23
Loon C., 33
Lu D.-W., 5; 24
Lynch J., 3
Lynne-Williams S., 42
Mackey D., 42
Mandal A.K., 4; 22; 35
Mani B., 42
Mansberger S.L.M., 17; 23
Marchini G., 36
Maresova K., 8
Marey H., 2
Martin K., 19; 36
Martin K.R.G., 15; 30; 33
Mattox C., 23; 36
Maul E., 3; 22; 31; 32
Maynart Tavares L., 3
McAllister J., 23
McLaren G.D., 23
Medeiros F.A., 6; 10; 19; 21; 29
Melamed S., 8; 23; 27; 30
Merton R., 13
Michelson G., 36
Migdal C., 5; 18; 23; 25
Miglior S., 17; 23; 35
Mikelberg F.S., 37
Mills R., 42
Minckler D.S., 37
Mlcak P., 8; 8
Molteno A., 24
Moon J.-I., 9
Morgan J., 18
Mosaed S., 28
Murthy G., 25
Nahum P., 3
Nangia V., 4
Nardi M., 28
140
Nassar M., 2
Nesher R., 8; 9
Netland P., 27; 35; 42
Nickells R., 39
Nicolela M.T., 4; 14; 23
Nolan W., 24
Novacek L., 8
Novotna J., 8
Obstbaum S.A., 20
Okeke C., 33
Omi A., 3
Ouertani A., 2
Palmberg P., 3; 20; 27; 28
Pandav S.S., 4
Pang C., 41; 42
Parikh R., 4; 4; 23
Park K., 35
Park K.H., 10
Parrish R., 41
Pasquale L.R., 11; 12; 29; 33; 41
Pasta J., 8
Pavlickova N., 7
Perez Grossman R., 3; 41
Peskova H., 7
Peters D., 28
Peyret A., 3
Pfeiffer N., 19; 30
Pillunat L., 23
Piltz-Seymour J.R., 37
Porciatti V., 22
Pracharova Z., 8
Prazenicova M., 8
Prum B.E., 35
Quigley H., 15; 18; 22; 32; 40
Racette L., 19
Racemiel R., 8
Radcliffe M., 33
Rafuse P., 4
Rahman el-Sebaei A., 2
Ramakrishnan R., 4; 23
Raml N., 26
Ramula Y., 31
Ramulu P., 41
Realini T., 26
Rehak J., 8
Ren R., 17; 21
Rhee D., 38
Ritch R., 12; 20; 24; 32
RojanaPongpun P., 17; 24
Rossetti L., 23
Ruzickova E., 7
Sahel J., 18
Sakai H., 5; 35
Sakata L., 27
Sample P., 14
Samuelson T., 26; 38; 40
Schützler-Schrehardt U., 20
Schmetterer L., 36
Schuman J., 11; 12; 14; 15; 35; 36
Schwartz G., 20; 36
Schwartz M., 32; 36
Sedki A., 2
Seong G.J., 9
Shaarawy T., 5; 11; 28; 31; 32; 35; 40
Shah M., 4
Shantha B., 4
Sherwood M., 24; 43
Shields B., 37
Singleton B., 40; 43
Sickakova S., 7
Sihota R., 4; 32; 41
Simicak J., 8
Singh K., 11; 12; 13; 23; 41
Siraultiene R., 9
Sit A., 6; 15; 21; 23; 34; 39
Skorkovska K., 7
Skorkovska S., 7
Skuta G.L., 26; 35
So K.F., 32
Spaeth G., 31
Speiczenie S., 9
Spiegel D., 28
Stamper R.L., 42
Standefor J., 31
Strnad P., 8
Strouthidis N.G., 21
Sugiyama K., 16; 31
Sung K.R., 10
Susanna Jr R., 11; 12; 13; 17; 26; 37; 43
Suzuki E., 3
Svacinova J., 8
Tamm E., 39; 39
Tanihara H., 27; 35; 39
Tanna P., 31
Tejwani S., 25
Tetz M., 38
Tezel G., 18; 32
Tham C.Y, 24; 26; 27
Thanos S., 33
Thomas R., 20; 25; 31
Thygesen J., 5; 24; 26; 27; 35
Tomidokoro A., 23; 36
Tomita G., 10; 42
Topouzis F., 17
Toris C., 39
Trope G., 24
Tsai J., 20; 36
Tuulonen A., 20; 20
Twa M., 6
Varma R., 31
Venkatesh R., 25
Ventura L., 32; 32
Verbin-Levkovitch H., 32; 33
Vijaya L., 4; 35
Viswanathan A., 30; 31
Vizzeri G., 33
Vlalci O., 8
Vladyka V., 8
Vlkova E., 8
Vold S.D., 43
Vomacka J., 8
Vyasa P., 4
Vyborny P., 7; 8
Wagdi F., 2
Walton D., 35
Wand M., 23

www.worldglaucoma.org

141
World Glaucoma Congress, July 8-11, 2009

Wang L., 24
Wang N., 24; 31; 32
Wang T.-H., 24
Wax M.B., 32; 36
Weinreb R.N., 6; 10; 12; 15; 21; 29; 30
Wells T., 21; 28
Wheeler L., 36; 39
Wiggs J., 41; 42
Wilson R., 17; 23; 33
Wollstein G., 8; 9; 35
Wong H.T., 10
Wong T., 37
Wright D.J., 24
Wu K.-Y., 5
Yamamoto T., 5; 17
Yaqub M., 6
Yu Y., 15
Zalish M., 8
Zalta A., 42
Zampachova E., 7
Zangwill L., 16; 35; 35
Zanutigh V., 3
Zhang C., 32
Zhao J., 24

Organized by The Hippocrates Glaucoma Foundation
See you at WGC-2011!